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Horizonte 
 
O sonho é ver as formas invisíveis 
Da distância imprecisa, e, com sensíveis 
Movimentos da esperança e da vontade, 
Buscar na linha fria do horizonte 
A árvore, a praia, a flor, a ave, a fonte - 
Os beijos merecidos da Verdade. 
 
Fernando Pessoa, Mensagem 
 
 
 
 
 
 
 
 
 
 
   
  
 
 
 
 
The brain is wider than the sky 
 
The brain is wider than the sky,  
For, put them side by side,  
The one the other will include  
With ease, and you beside.  
   
The brain is deeper than the sea,         
For, hold them, blue to blue,  
The one the other will absorb,  
As sponges, buckets do.  
   
The brain is just the weight of God, 
For, lift them, pound for pound,          
And they will differ, if they do,  
As syllable from sound.  
 
Emily Dickinson, Complete Poems 
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Abstract 
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by 
a progressive decline in both motor and cognitive functions. Nevertheless, 
in stark contrast to the nigrostriatal pathology underlying the motor 
aspects of the disorder, the brain areas involved and the 
pathophysiological mechanisms underlying cognitive deficits are not fully 
understood. An important hallmark of PD is the abnormal accumulation 
of misfolded alpha-synuclein (aSyn)-positive cytoplasmic inclusions 
termed Lewy bodies (LBs), which occurs early in the disease process and 
spreads to various brain regions including those related to memory, such 
as the hippocampus and cortex. 
PD’s current therapeutic options consist primarily of dopamine 
replacement strategies that only provide a symptomatic relief of motor 
symptoms, without affecting cognitive impairment or disease progression.  
Adenosine A2A receptors (A2AR) emerged as promising non-dopaminergic 
targets for the treatment of PD. Anti-parkinsonian actions are achieved 
through the blockade of this receptor, whose expression and function 
become aberrant throughout aging and in age-related pathologies, 
including the early stages of PD. Although A2AR were originally identified 
based on their ability to improve PD motor features, they have also been 
recognized for their beneficial effects on cognition. Moreover, several 
studies have brought into discussion the potential neuroprotective effect 
of A2AR antagonists, with epidemiological studies suggesting an inverse 
correlation between caffeine consumption, an A2AR antagonist, and the 
risk of developing PD. Furthermore, A2AR deregulation was proposed to 
play an important role in aSyn-mediated neurotoxicity, since aSyn-
induced damage to striatal neurons was clearly reduced in A2AR KO mice.  
xx 
However, the extent to which A2AR are involved in PD and aSyn-
associated toxicity, the underlying protective molecular mechanisms, or 
the impact on cognitive-associated brain areas are largely unknown; 
however current data suggest the involvement of mechanisms beyond 
A2AR-D2R interactions and of brain areas other than the basal ganglia. 
This thesis compiles the major findings from my experimental 
work on the pathological mechanisms underlying PD-associated 
neurotoxicity and cognitive deficits, and on the ability of A2AR to 
modulate aSyn-mediated synaptic dysfunction, aggregation, and neuronal 
death, all of which are key hallmarks in PD and other synucleinopathies. 
We report for the first time that, pharmacological A2AR blockade 
or genetic deletion (A2AR KO mice) fully prevents the aSyn-mediated 
toxic effects on synaptic plasticity, recorded as long-term potentiation 
(LTP) in the Schaffer collaterals. This neuroprotective effect afforded by 
A2AR inhibition is due to the reestablishment of glutamate NMDA 
receptors (NMDAR) signaling. Furthermore, we also show the ability of 
A2AR to modulate the latter stages of aSyn-toxicity, using neuroblastoma 
SH-SY5Y cells overexpressing aSyn and rat primary neuronal cultures 
exposed to aSyn oligomers for longer periods. Selective A2AR antagonists 
are able to prevent both exogenous and endogenous aSyn-associated cell 
death. Interestingly, A2AR blockade also decreases the number of cells 
displaying aSyn aggregates, raising the possibility that the well-
documented effects of A2AR antagonists can involve the control of aSyn 
aggregation process, thereby preventing the associated neurotoxicity. 
We then proposed to explore the mechanisms and potential players 
involved in aSyn-associated synaptic toxicity and further confirm the 
instrumental role of A2AR on aSyn pathological processes in vivo. We now 
identify the cellular prion protein (PrPC) as a key mediator of aSyn-
associated synaptic dysfunction. We show that the toxic effects of aSyn 
oligomers on synaptic function are fully prevented by PrPC blockade or 
xxi 
deletion, via an NMDAR-dependent mechanism, which we previously 
reported to be involved in A2AR neuroprotection. Extracellular aSyn 
oligomers form a complex with PrPC at the postsynaptic density, inducing 
the phosphorylation of intracellular Fyn kinase via the metabotropic 
glutamate receptor 5 (mGluR5). aSyn engagement of PrPC/mGluR5/Fyn 
signaling causes NMDAR activation and, consequently, dysregulation of 
Ca2+ homeostasis. 
Lastly, we show that the in vivo blockade of A2AR, known to 
impede mGluR5-evoked phosphorylation of NMDAR, rescues learning 
and memory deficits, evaluated in the Morris Water Maze and the Y Maze 
task, and reestablishes synaptic plasticity impairments acompaning early 
cognitive deficits in a mouse model of PD. 
Overall, our findings provide novel and compelling insights into 
the early mechanisms preceding PD neurodegeneration and identify A2AR 
and PrPC as key mediators of aSyn pathology. Furthermore, our results 
suggest that A2AR represent an important therapeutic target for the 
development of effective drugs for the treatment of cognitive deficits in 
PD and other disorders associated with the accumulation of aSyn, thus 
having immediate implications for clinical practice. 
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Resumo 
A doença de Parkinson (PD) é uma doença neurodegenerativa 
caracterizada pelo declínio progressivo das funções motora e cognitiva. 
Contudo, ao contrário dos sintomas motores, que se sabe estarem 
associados a uma patologia nigroestriatal, as áreas cerebrais envolvidas e 
os mecanismos fisiopatológicos subjacentes aos défices cognitivos não 
são conhecidos. Outra importante manifestação anatomopatológica da PD 
é a acumulação de inclusões citoplasmáticas de alfa-sinucleína (aSyn), 
denominadas de corpos de Lewy (LBs). Os LBs estão presentes mesmo 
nas fases iniciais da PD e, propagam-se por várias regiões cerebrais ao 
longo da progressão da doença, nomeadamente regiões associadas à 
memória e aprendizagem, como o hipocampo e o córtex. 
As opções terapêuticas atuais para PD consistem principalmente 
em estratégias de reposição de dopamina, que apenas proporcionam uma 
melhora dos sintomas motores, não alterando os défices cognitivos nem a 
progressão da doença. Os recetores de adenosina A2A (A2AR) surgiram 
como importantes alvos terapêuticos não dopaminérgicos para o 
tratamento da PD. As ações anti-parkinsónicas são alcançadas através do 
bloqueio destes recetores, cuja expressão e função se torna aberrante com 
o envelhecimento e em patologias associadas, como a PD. Embora o 
interesse inicial dos A2AR como alvo terapêutico tenha surgido com base 
na sua capacidade de melhorar os sintomas motores da PD, estes recetores 
são também reconhecidos pelos seus efeitos benéficos na função 
cognitiva. Para além disso, vários estudos demonstraram um potencial 
efeito neuroprotetor dos antagonistas dos A2AR, com estudos 
epidemiológicos sugerindo uma correlação inversa entre o consumo de 
cafeína, um antagonista dos A2AR, e o risco de se desenvolver a PD. 
Adicionalmente, outro estudo demonstrou que a neurotoxicidade induzida 
xxiv 
pela aSyn em neurónios estriatais é prevenida em ratinhos com uma 
deleção no gene que codifica para os A2AR. Contudo, o papel dos A2AR 
na PD, mais precisamente na toxicidade induzida pela aSyn, os 
mecanismos moleculares protetores subjacentes ao seu bloqueio e o seu 
impacto em áreas cerebrais associadas à função cognitiva, não são ainda 
conhecidos. Esta tese compila as principais descobertas da nossa 
investigação sobre os mecanismos patológicos subjacentes à 
neurotoxicidade e aos défices cognitivos associados à PD, e à capacidade 
dos A2AR em modular estes eventos. 
No nosso primeiro estudo demonstramos pela primeira vez que, 
tanto bloqueio farmacológico dos A2AR como a deleção do gene que 
codifica para os A2AR (ratinhos A2AR KO), previne a toxicidade sinática 
induzida por oligómeros de aSyn, medida através da potenciação de longa 
duração (LTP). Este efeito neuroprotetor é devido ao restabelecimento da 
sinalização mediada pelos recetores de glutamato NMDA (NMDAR). 
Adicionalmente, mostramos a capacidade dos A2AR em modular os 
últimos estágios da toxicidade mediada pela aSyn, usando um modelo 
celular que sobreexpressa aSyn, e culturas primárias de neurónios 
expostas a oligomeros de aSyn. Os antagonistas seletivos dos A2AR 
preveniram a morte celular e neuronal induzida tanto pela aSyn endógena 
como pelos oligomeros de aSyn adicionados exogenamente.  
Curiosamente, o bloqueio dos A2AR também teve implicações na 
agregação de aSyn, diminuindo a percentagem de células com agregados. 
Estes resultados sugerem que o efeito protetor dos antagonistas dos A2AR, 
descrito já em vários estudos, possa envolver o controle do processo de 
agregação da aSyn, prevenindo assim a neurotoxicidade associada a esta 
proteína. 
De seguida, fomos investigar os mecanismos e potenciais 
mediadores envolvidos na toxicidade sináptica associada à aSyn. 
Identificamos a proteína priónica (PrPC), na forma celular, como um 
xxv 
mediador chave na disfunção sináptica induzida pela aSyn. 
Demonstramos que os efeitos tóxicos dos oligómeros na função sináptica 
são totalmente prevenidos aquando do bloqueio ou deleção da PrPC. Este 
efeito ocorre através de um mecanismo dependente dos NMDAR, à 
semelhança da neuroprotecção associada ao bloqueio dos A2AR. 
Adicionalmente, demonstramos que os oligómeros de aSyn formam um 
complexo com a PrPC ao nível da densidade pós-sináptica, levando a uma 
ativação do recetor de glutamato metabotrópico 5 (mGluR5) que induz a 
fosforilação da quinase Fyn. A ativação da via de sinalização 
PrPC/mGluR5/Fyn leva à fosforilação da subunidade NR2B dos NMDAR 
e, consequentemente, a uma desregulação na homeostasia de Ca2+. 
Concluímos os nossos estudos mostrando que o bloqueio in vivo 
dos A2AR, conhecido por prevenir a fosforilação dos NMDAR evocada 
pelos mGluR5, reestabelece os déficits cognitivos, avaliados através dos 
testes comportamentais Morris Water Maze e Y-Maze, e danos na 
plasticidade sináptica observados num modelo de ratinho da PD.  
Em suma, as nossas descobertas fornecem dados importantes sobre 
os mecanismos que precedem a neurodegeneração na PD e identificam os 
A2AR e a PrP
C como mediadores cruciais na toxicidade associada à aSyn. 
Para além disso, os nossos resultados sugerem que os A2AR representam 
um importante alvo terapêutico para o desenvolvimento de fármacos 
eficazes para o tratamento dos déficits cognitivos associados à PD e outras 
sinucleinopatías.
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State of the art 
Over the past decades, the average life expectancy has increased globally, 
reaching a worldwide average of about 71.4 years in 2015 and around 80 
years in developed countries (World Health Organization, 2016). This 
advance has been achieved especially due to improvements in sanitation, 
medical improvements, rising living standards, and a decline in child 
mortality. Considering the demographics of the world population, between 
2000 and 2050 the proportion of people over 60 years will double from 
about 11% to 22%, which, in absolute terms, means an increase from 605 
million to 2 billion people (Jin et al., 2014). Although the increasing life 
expectancy generally reflects positive human development, new 
challenges are arising, especially in the health sector due to aging-related 
diseases such as neurodegenerative diseases. 
Neurodegenerative diseases, such as Parkinson’s disease (PD), are 
devastating progressive conditions and a major healthcare challenge 
worldwide, disabling millions. Although there are palliative treatments, 
currently, there is no cure or effective disease-modifying therapy for any 
of these disorders.  
Hence, major efforts must be directed toward the identification of 
the molecular players responsible for disease onset and a better 
understanding of the pathological mechanisms involved, in order to open 
the gates to novel and more effective therapies.  
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Parkinson’s disease 
Parkinson´s Disease as a Systemic Disease 
200 years have gone since James Parkinson´s wrote a monograph entitled 
An Essay on the Shaking Palsy (Goetz, 2011; Parkinson, 2002), in which 
he detailed  the symptoms of paralysis agitans, a condition he had 
observed among six of his patients and that 60 years later would be named 
after him – (Charcot et al., 1887): 
 
“Involuntary tremulous motion with lessened muscular power, in 
parts not in action and even when supported; with a propensity to 
bend the trunk forward, and to pass from a walking to a running 
pace” 
 
The essay focused mainly on the motor features of PD and, in fact, 
PD was originally considered as a movement disease characterized mainly 
by its motor symptoms (MS), such as bradykinesia or slowness of 
movement, resting tremor, rigidity, and postural and gait instability (Fahn, 
2003; Lees et al., 2009). Based on this, PD was often considered to involve 
a simple pathological process comprising the selective loss of 
dopaminergic neurons from the substantia nigra pars compacta (SNc), a 
small region in the mesencephalon. These dopaminergic neurons innervate 
the basal ganglia, and their selective degeneration and consequent 
reduction of striatal dopamine (DA) concentration, directly alter the 
activity of the cortico-striato-pallido-thalamocortical pathways controlling 
motor behaviour and action selection (Fig. 1.1; Wichmann and DeLong, 
2003). 
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Figure 1.1. Schematic diagram of the direct and indirect pathways of the 
basal ganglia motor circuits in healthy and PD states. Red arrows indicate 
inhibitory projections, and blue arrows indicate excitatory projections. The 
changes in the thickness of the arrows in the PD state indicate the proposed 
increase (larger arrow) or decrease (thinner arrow) in firing rate activity of 
specific connections. The dashed arrows used to label the dopaminergic 
projection from the SNc to the putamen in PD indicate a partial lesion of that 
system in this condition. Note that many connections have been purposefully 
omitted from this diagram. GPe, globus pallidus, external segment; GPi, 
globus pallidus internus; SNc, substantia nigra pars compacta; STN, 
subthalamic nucleus. 
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Recently, there has been a shift in the conceptualization of the 
disease, and PD is now recognized as a systemic disorder affecting several 
distinct neuronal populations of the central and peripheral nervous system 
(CNS; PNS), which leads to a high range of clinical features. Even though 
MS have historically been identified as the most relevant aspect of the 
disease (Parkinson, 2002), accumulating clinical evidence reveals a broad 
spectrum of non-motor symptoms (NMS) associated with PD. 
Furthermore, it is increasingly clear that, at least some of these non-
parkinsonian features, can predate the onset of the classical motor signs, 
by years and even decades (Berg et al., 2015; Chaudhuri et al., 2006).  
NMS occurring in PD cover a wide variety of manifestations, 
including autonomic dysfunction (gastrointestinal and cardiovascular 
dysfunction with orthostatic hypotension), sensory disturbances (olfactory 
deficits, also known as hyposmia, and vision problems), pain, sleep 
disorders, neuropsychiatric problems (depression and anxiety) and 
cognitive impairment (Figure 1.2; Chaudhuri and Schapira, 2009; Hawkes 
et al., 2010; Lim et al., 2009; Savica et al., 2010; Schapira and Tolosa, 
2010; Tolosa et al., 2009). Cognitive impairment is an important feature 
of PD with a spectrum of deficits ranging from none to severe dementia. 
The intermediate zone between normal cognition and dementia has been 
termed mild cognitive impairment (MCI; Dalrymple-Alford et al., 2011; 
Litvan et al., 2012). These cognitive symptoms involve abnormalities in 
spatial performance and memory deficits, with both short- and long-term 
memory being affected. Alterations in organization, planning, regulation 
of goal-directed behaviours, information retrieval and attention are widely 
observed in PD patients and are key events triggering the manifestations 
of PD-associated cognitive decline (Aarsland et al., 2003; Chahine et al., 
2016; Jellinger, 2017). Epidemiological studies show that 18.9% to 38.2% 
of PD patients develop MCI in the early stages of the disorder (Litvan et 
al., 2011, 2012; Williams-Gray et al., 2007), and up to 50% of those with 
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PD develop dementia after 10 years, increasing to over 80% after 20 years 
(Bosboom et al., 2004; Hely et al., 2008; Williams-Gray et al., 2007, 
2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Schematic diagram of NMS in PD. PD NMS reflect deficits in 
various functions of the CNS and autonomic nervous system (ANS). 
Multisystem involvement develops to varying levels of severity and in a 
variable sequence in different patients. 1Bronner et al., 2015; Sakakibara et al., 
2016; Winge, 2015; 2Pfeiffer, 2016; 3Zhu et al., 2016; 4Zweig et al., 2016; 
5Albers et al., 2017; 6Goldman, 2016; 7Sung and Nicholas, 2013; 8Valkovic et 
al., 2015. 
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Characterization of NMS is potentially valuable for PD early 
identification since the current diagnosis of PD requires multiple MS to be 
established, and while subtle motor signs may be present, a clinical 
diagnosis cannot be made until they become more definite. Nonetheless, 
at the time the diagnosis is made, PD has progressed over an estimated 
period of 10 to 15 years and a loss of 50 to 60% of the nigral DA neurons 
already occurred (Fig. 1.3). This limits all the current potential therapeutic 
interventions, especially those aiming at neuroprotection. 
Based on this problematic, the Movement Disorders Society 
(MDS) has recently established a task force to redefine clinical PD 
considering the new insights of the disease (Berg et al., 2015, 2015; 
Postuma et al., 2015). MDS proposed that early PD should be divided into 
three stages (Fig. 1.3):  
 
(I) Preclinical PD – the neurodegenerative processes have already 
started, but there are no evident symptoms or signs (defined by 
disease biomarkers when available); 
(II) Prodromal PD – presence of early symptoms and signs, but are 
still insufﬁcient to deﬁne the disease; 
(III) Clinical PD – the diagnostic criteria for PD are fulfilled based 
on the presence of classical MS. 
 
 Nevertheless, there is no validated early diagnostic biomarkers of 
PD. Although non-specific, precursor NMS such as constipation, 
depression, mild cognitive impairments, hyposmia, or rapid eye movement 
(REM) sleep disorder (RBD) characterize a population in which future 
biomarkers for the diagnosis of prodromal PD should be tested (Miller and 
O’Callaghan, 2015). This would be of great value and allow (1) to 
intervene at the onset or in an early phase of the disease and (2) to monitor 
the progress of therapeutic interventions that may slow or stop PD course. 
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Figure 1.3. Graphical illustration of PD progression. The yellow line 
represents the continuous degeneration of the dopaminergic neurons of the SN. 
People at risk of PD progress to a preclinical phase before the prodromal 
phase, in which nonmotor symptoms and slight motor signs can occur, and 
finally the clinical phase. The prodromal phase with early neurodegenerative 
changes occurs years or even decades before the clinical diagnosis of PD can 
be made. 
 
Overall, the shift in focus from the classic MS to NMS has, 
therefore, followed the strong evidence that: (1) several NMS begin with 
an earlier pre-motor prodrome; (2) at the time MS appear, approximately 
50 to 60% of dopaminergic neurons have already been lost, and; (3) under 
chronic dopaminergic treatment the progression of MS stabilizes in most 
people with long-term disease; however, NMS, such as cognitive 
impairments, are not affected by dopamine replacement therapies and 
continue to develop throughout the course of the disease, accumulating 
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greater disability. In fact, several studies show that cognitive impairments 
and clinically evident dementia severely affect patient’s global health, and 
 their behavioral manifestations have disruptive effects on familial 
and social dynamics, which may result in nursing home placement and, 
finally, cause a severe negative impact on patient quality of life and 
caregivers burden (Aarsland et al., 2007, 2008; Levy et al., 2002; Marras 
et al., 2008). This evidence reveals a strong need for studies on the 
pathological mechanisms of the NMS in order to understand the 
pathological process of the disorder and, consequently, find the urgently 
required biomarkers and therapeutic strategies to tackle PD-associated 
cognitive dysfunction and dementia. 
 
Epidemiology of Parkinson’s Disease 
Epidemiological data regarding the prevalence, number of cases, 
incidence, and number of newly diagnosed cases of PD are of interest for 
their potential to identify risk factors and improve understanding of the 
disease’s natural history. These data have also been increasingly used to 
guide effective planning of medical services. Although several studies 
report data on the epidemiology of PD, methodological differences 
between studies make a direct comparison of prevalence and incidence 
estimates difficult. 
PD is, at present, the second most common neurodegenerative 
disorder in the elderly population, after Alzheimer´s disease (AD; Dorsey 
et al., 2007), with a generally accepted prevalence ranging from 35.8 to 
12.500 per 100.000 inhabitants. Age is the greatest risk factor for the 
development of PD, with a nearly exponential increase in incidence, and 
consequently prevalence, after 55 years of age (Driver et al., 2009; 
Pringsheim et al., 2014). This trend has important public health 
implications; with an aging population and rising life expectancy 
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worldwide, the number of people with PD is expected to increase by more 
than 50% by 2030 (Dorsey et al., 2007).  
PD seems more frequent in Europe, North America, and Australia, 
with a prevalence of 1601, compared with individuals from Asia, where 
the prevalence is 646 (per 100.000). PD is also more prevalent in males 
(1729 per 100.000, >65 years) than in females (1644 per 100.000; Moisan 
et al., 2016; Riedel et al., 2016). The annual incidence estimates range 
from 1,5 to 346 per 100.000 inhabitants (von Campenhausen et al., 2005; 
Muangpaisan et al., 2009; Zou et al., 2015). It is important to note that 
incidence studies may be underestimated since they are affected by under-
diagnosing of PD, especially among the most elderly. 
 
Aetiology of Parkinson’s Disease 
Despite the many decades of research, our understanding of the aetiology 
of PD, like many other human neurodegenerative disorders, is still very 
scarce due to the difficulty to infer an active sequence of events, often 
expressed over prolonged periods of time. Current theories suggest a 
combination of genetic predispositions, complemented potentially by 
epigenetic, and environmental factors to be involved in PD aetiology (Fig. 
1.4; Delamarre and Meissner, 2017; Wirdefeldt et al., 2011).  
 
Genetics. Over the past 2 decades, there has been an explosion of research 
on the genetics of PD. Although most cases of PD are thought to be 
sporadic (> 90%), genetics likely plays a significant role (Lill, 2016). 
Family members of affected patients have a 2- to 3-fold increased risk to 
develop the disease, compared to subjects in the general population 
(Savica et al., 2016; Sveinbjörnsdottir et al., 2000). Rare familial forms of 
PD with both autosomal dominant and recessive inheritance have been 
described. Several genes have been associated with monogenic forms of 
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the disease, with SNCA (encoding for alpha-synuclein; Polymeropoulos et 
al., 1997), LRRK2 (leucine-rich repeat kinase 2; PARK8; Paisán-Ruíz et 
al., 2004; Zimprich et al., 2004), VPS35 (vacuolar protein sorting 35; 
Vilariño-Güell et al., 2011; Zimprich et al., 2011), CHCHD2 (coiled-coil-
helix-coiled-coil-helix domain containing 2; Jansen et al., 2015), DCTN1 
(p150Glued subunit of dynactin; Araki et al., 2014), and EIF4G1 genes 
(eukaryotic translation initiation factor 4-γ1; Chartier-Harlin et al., 2011), 
causing autosomal dominant forms of PD, and PINK1 (PTEN-induced 
putative kinase 1; PARK5; Bonifati et al., 2005), DJ-1 (Daisuke-Junko-1; 
PARK7), parkin (PARK2; Djarmati et al., 2004), ATP13A2 (ATPase type 
13A2; PARK9; Ramirez et al., 2006), PLA2G6 (Paisan-Ruiz et al., 2009), 
and FBX07 genes (F-box only protein 7; PARK15; Di Fonzo et al., 2009) 
associated with recessive transmission. 
In addition to monogenic forms of PD, which, as mentioned, only 
account for a small proportion of all PD cases, advances in genomics and 
bioinformatics have uncovered additional genetic risk factors for PD. In 
the past decade, 900 genetic association studies, such as genome-wide 
association studies (GWAS), have identified more than 30 loci associated 
with the modulation of PD risk (Nalls et al., 2014). Of note, most of the 
GWAS hits appear to be driven by non-coding variation and are thus likely 
associated with the regulation of gene expression (Nalls et al., 2014). 
Heterozygous glucocerebrosidase gene (GBA) mutations, responsible for 
the most frequent lysosomal storage disorder, Gaucher disease, were 
shown to increase the risk of developing PD more than 5-fold (Lees et al., 
2009). One of the strongest associations with the disease is alpha-synuclein 
(aSyn), a small protein preferentially found at presynaptic termini and in 
the nucleus (Maroteaux and Scheller, 1991).  There are pathogenic 
missense mutations and multiplication mutations in SNCA gene encoding 
for aSyn. Thus, not only a mutant protein, but also both differences in 
SNCA expression and, consequently, wild-type (wt) aSyn protein levels 
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have been shown to play a critical role in PD susceptibility, as 
demonstrated in families with SNCA triplications and duplications (Kalia 
and Lang, 2015; Miller et al., 2004; Mutez et al., 2011). The role of aSyn 
in PD will be further dissected. 
 
Epigenetics. Epigenetic modifications provide phenotypic plasticity, 
allowing adaptation to a change in the environment without modifying the 
genotype. Based on this, recent studies showed that several regulatory 
mechanisms such as DNA methylation of promoter regions, histone 
modifications, and RNA-based mechanisms are involved in PD-related 
gene expression (Ammal Kaidery et al., 2013; Labbé et al., 2016). 
Epigenetic methylation of the SNCA locus, which is associated with a 
decrease in gene expression, was shown to be reduced in 
DNA from sporadic PD patients SN, putamen and cortex (Jowaed et al., 
2010), pointing toward a yet unappreciated epigenetic regulation of SNCA 
expression in PD. In accordance, post-mortem analysis of PD patients 
brains also revealed a significantly decrease in SNCA methylation in the 
SN (Matsumoto et al., 2010). Similarly, sporadic PD patients have been 
shown to have differential expression of various miRNA probes, including 
miR-34b/c, which has been associated with the development of 
mitochondrial dysfunction (Margis et al., 2011; Miñones-Moyano et al., 
2011). 
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Figure 1.4. Schematic overview of the interplay of genetic, 
environmental and epigenetic domains possibly underlying Parkinson’s 
disease (PD) pathophysiology. Results of epidemiological studies have 
revealed various environmental exposures that increase (in white) or 
decrease (in blue) the risk of developing PD. Findings of genome-wide 
association studies have identified genetic risk factors, which are 
polymorphisms within certain genes that influence risk for developing PD. 
Epigenetic modification, which alters the functionality of a locus or 
chromosome without changing the underlying DNA sequence, may account 
for some of the fundamental differences in expression patterns between PD 
patients and controls. Examples of relevant risk factors in each domain are 
listed. 
  
Introduction 
15 
 
Environment. Occupational, lifestyle and environmental factors, possibly 
in interaction with each other or with susceptibility genes, also play an 
important part in influencing the general risk of developing PD (Fig. 1.4). 
Epidemiologic studies have shown an increased risk of PD with pesticide 
exposure, prior head injury, rural living, β-blocker use, agricultural 
occupation, and wood preservative use. Among specific toxins that may 
contribute to PD are 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) and other isoquinoline derivatives, organophosphate, pesticides, 
and possibly mitochondrial toxins such as rotenone. Several neurotoxins 
not only produce a PD phenotype being used in many PD animal models 
of the disease, but can also affect different epigenetic mechanisms, such as 
methylation, demethylation, hyperacetylation, and deacetylation of certain 
genomic regions (Labbé et al., 2016). Moreover, an interesting inverse 
relationship has been reported between PD and coffee drinking, tobacco 
smoking, non-steroidal anti-inflammatory drug use, calcium channel 
blocker use, or alcohol consumption (Noyce et al., 2012). 
The risk of developing PD is clearly multifactorial, but the 
elaborate interplay between the several factors is just beginning to be 
deciphered. A further understanding of PD risk factors and their 
interactions is expected to have broad implications for the elucidation of 
the disease pathogenic mechanisms, identification of biomarkers, and new 
therapeutic interventions. 
 
Lewy Body Pathology and Cognitive Deficits 
Almost 100 years after Parkinson had published his findings, the German 
neurologist Friedrich Lewy identified intracytoplasmic neuronal protein 
deposits in the brain of PD patients, which later became known as Lewy 
bodies (LBs; Lewy, F. H., 1912). However, the biochemical nature of the 
deposits remained unknown until 1997, when Maria Spillantini and 
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colleagues found that their main component was the presynaptic protein 
aSyn (Spillantini et al., 1997). These aSyn deposits can also be found in 
neuronal processes (Lewy neurites - LN) as well as in astrocytes and 
oligodendroglial cells of PD patients (Kalia and Lang, 2016; Spillantini et 
al., 1997). In addition, LB brain pathology is also found in other two 
neurodegenerative disorders, dementia with LBs (DLB) and multiple 
system atrophy (MSA), which are now collectively termed as 
synucleinopathies (Baba et al., 1998; Wakabayashi et al., 1998a). Despite 
the fact that all these disorders have aSyn-containing inclusions deposited 
in the brain, the cell types and brain structures that are affected can vary 
between them. This leads to different clinical manifestations, which are the 
basis for the differential diagnosis. However, these disorders also share 
several symptoms such as chronic and progressive decline in motor, 
cognitive, behavioral, and autonomic functions (Halliday et al., 2011). 
Recently, a new definition and diagnostic criteria for clinical PD was 
published (Postuma et al., 2015). Under the light of these new criteria, 
early dementia is no longer considered an exclusion criterion for PD, 
eliminating the distinction between PD and DLB. As so, DLB can be now 
classified as a PD subtype if all other criteria for PD are met (Kalia and 
Lang, 2016). 
In contrast to MS, which are thought to reflect neuronal loss within 
the SN (Fig. 1.1), little is known about the functional networks underlying 
NMS in PD, although the depletion of striatal DA has also been associated 
with it (Green et al., 2002). Besides the dopaminergic transmission 
abnormalities, several studies indicate that the accumulation of LBs and 
LNs (Spillantini et al., 1997) is not restricted to the SN, but can also be 
found in extranigral regions, such as cortex, amygdala, locus coeruleus, 
reticular formation, vagus nuclei, and the hippocampus, as well as outside 
of the brain, namely in the spinal cord and PNS (Beach et al., 2010; Del 
Tredici et al., 2010; Forno, 1987). As mentioned, several 
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neuropsychological symptoms, such as cognitive impairments and 
dementia, have a relatively poor response to dopaminergic therapy, 
suggesting that dysfunction of these extranigral neuronal populations and 
possibly LB pathology underlie, or at least contribute to, the appearance of 
these symptoms (Chaudhuri et al., 2006).  
According to the Braak theory, LB pathology progresses in a 
stereotyped pattern over the course of PD, starting in the olfactory mucosa 
and enteric nervous system (ENS), traveling into the brain via vagal and 
olfactory nerves, and progressing to particular structures in a caudal-to-
rostral predictable direction within the brain. This pattern begins in the 
dorsal motor nucleus of the glossopharyngeal and vagal nerves and 
olfactory bulb (stage one), ascending to the pontine tegmentum (stage 
two), midbrain, basal forebrain and limbic system (stage three), 
mesocortex and allocortex (stage four), and finally invading the neocortex 
at the latest stages of the disease (stage five and six; Braak et al., 2003, 
2004). The presence of LBs occur early in the disease process and is 
accompanied by progressive neuronal dysfunction and eventually death of 
affected neuronal populations (Braak and Del Tredici, 2008). Moreover, 
the proposed temporal and spatial progression seems to explain the clinical 
course of PD. Evidence for an association between LB pathology and NMS 
is most convincing for cognitive impairments in PD. Post-mortem studies 
have shown a strong correlation between cognitive impairments, including 
dementia, and subcortical and cortical LB formation, including the 
transentorhinal and entorhinal cortices, hippocampus, other limbic cortex 
regions, and neocortex (Beach et al., 2009; Braak et al., 2005; Caviness et 
al., 2011; Irwin et al., 2012; Kempster et al., 2010; Kövari et al., 2003). 
Accordingly, a recent clinical study also reported a correlation between LB 
and several NMS, including cognitive impairments, in LRRK2-related PD 
(Kalia et al., 2015). 
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Structural brain imaging allows in vivo determination of regional 
neurodegeneration. PD studies, using a range of imaging analyses, have 
reported an association between regional brain volumes, namely parietal-
temporal cortex, prefrontal cortex, hippocampus and amygdala, and 
cognitive decline (Ibarretxe-Bilbao et al., 2008; Lyoo et al., 2010; Song et 
al., 2011). In fact, many PD patients present an Alzheimer's disease (AD) 
pattern of brain atrophy together with neuropathological changes in the 
hippocampus (Apaydin et al., 2002; Compta et al., 2011; Farlow and 
Cummings, 2008; Kang, 2016; Weintraub et al., 2012). Interestingly, a 
mice model of PD overexpressing human wt aSyn, the main component of 
the LB, develop neuronal degeneration not only in the SN but also in the 
hippocampus, as well as reduced hippocampal neurogenesis, leading to 
progressive motor decline and cognitive impairment (Nuber et al., 2008). 
Consistently, hippocampal and parietal lobes atrophy has also been 
suggested to predict a more rapid future cognitive decline (Weintraub et 
al., 2012). These findings support the involvement of the hippocampus 
with cognitive impairment and long-term decline in PD. 
 
aSyn, a key player in Parkinson’s Disease  
A major breakthrough in PD pathogenesis was made when, in 1997, a 
mutation in SNCA was identified in an Italian family and in three unrelated 
families of Greek origin with autosomal dominant PD (Polymeropoulos et 
al., 1997). It was of considerable importance that the pathology was 
essentially identical to that observed in sporadic PD; the presence of LBs 
and neuronal degeneration was then confirmed in many regions of the 
brain, including the SN and locus coeruleus, in the Italian family (Golbe et 
al., 1990). In the same year, several immunohistochemical studies 
described fibrillar aggregates of aSyn as the major protein component of 
LBs in PD and also in DLB and MSA (Arima et al., 1998; Baba et al., 
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1998; Galvin et al., 2001; Irizarry et al., 1998; Spillantini and Goedert, 
2000; Spillantini et al., 1997; Takeda et al., 1998; Wakabayashi et al., 
1997, 1998b; Waxman and Giasson, 2009). This suggested, for the first 
time, that aSyn was not only involved in the aetiology of PD but also 
underlaid LB formation in this condition and in other synucleinopathies. 
Since then, many research efforts have been concentrated on aSyn. To 
date, six missense mutations (A30P, E46K, A53T, A53E, H50Q, G51D) 
in the SNCA gene have been shown to be associated with autosomal 
dominant forms of the disease (Fig. 1.5; Appel-Cresswell et al., 2013; 
Krüger et al., 1998; Lesage et al., 2013; Pasanen et al., 2014; 
Polymeropoulos et al., 1997; Zarranz et al., 2004).  
 
 
 
 
 
 
Figure 1.5. Schematic representation of the different domains of aSyn. 
aSyn is divided into three overlapping regions, namely an N-terminal repeat 
region (aa 1–95), a central hydrophobic NAC region (aa 61–95), and an acidic 
C-terminus (aa 96–140). The repeat region contains six conserved repeat 
motifs (white boxes) and is believed to be involved in aSyn interactions; the 
NAC domain is required for the aggregation of aSyn, whereas the acidic tail 
in the C-terminus is critical for binding of various ions and proteins. All six 
PD-related mutations are located within the amphipathic region in the N-
terminus of the protein. 
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The next landmark studies linking SNCA to PD, identified 
triplications (Singleton et al., 2003) and duplications (Chartier-Harlin et 
al., 2004; Ibáñez et al., 2004) of the SNCA locus in separate families with 
an autosomal dominant inheritance pattern, which was later associated 
with an increase in total aSyn levels (Miller et al., 2004). Several studies 
show that the simple increase in the expression levels of the wt protein is 
sufficient to cause neurodegeneration and that such increase may underlie 
the pathogenesis of sporadic PD. Besides, SNCA dosage correlates with 
earlier onset, faster progression, and more severe disease presentation 
(Konno et al., 2016; Ross et al., 2008). Nevertheless, the exact cause of 
aSyn abnormal accumulation, neuronal death and disease progression 
related to its overexpression remains largely unknown (Imai et al., 2001; 
Janicki and Monteiro, 1999; Ko et al., 2008; Morishima et al., 2001; Saha 
et al., 2000; Shimura et al., 2001; Wu et al., 2000). 
When a specific genetic defect is identified in rare familial cases, 
it is almost a reflex reaction to look at the same gene in the sporadic 
disease, with the hope of identifying polymorphisms that may be linked to 
the disease in association studies. In fact, the contribution of aSyn in 
sporadic forms of the disease was further strengthened by GWAS showing 
that polymorphic variations in non-coding regions of the SNCA locus 
represent a major risk factor for sporadic PD pathogenesis (Edwards et al., 
2010; Satake et al., 2009; Simón-Sánchez et al., 2009). Specific variations, 
including a dinucleotide repeat sequence REP1 within the SNCA promoter, 
rs356168 in intron 4, and rs356210 in the 3′ UTR region, have all been 
proposed to influence both SNCA expression and disease risk (Fuchs et al., 
2008; Maraganore et al., 2006; Soldner et al., 2016). These studies, support 
a role for aSyn in the aetiology of both familial and sporadic forms of this 
disease and extend the relevance of this protein to a larger cohort of 
patients (Hamza et al., 2010; Satake et al., 2009; Simón-Sánchez et al., 
2009).  
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aSyn is a ubiquitous protein highly expressed in the brain. This 
protein is abundant in neurons, especially enriched in presynaptic 
terminals (Goedert, 1999; Lavedan, 1998) and, although its exact function 
is unknown, it is thought to be involved in synaptic function and plasticity, 
processes highly influenced by aging. It is prominently expressed in the 
cortex and hippocampus, brain regions with a high synaptic plasticity 
potential (Maroteaux and Scheller, 1991). It has also been postulated that 
aSyn regulates the size of the presynaptic vesicular pool (Murphy et al., 
2000), neurotransmitter release and processes associated with the 
organization and regulation of synaptic vesicles (Kahle et al., 2000; Perez 
et al., 2002). Delayed developmental expression of aSyn compared to 
synaptophysin, suggests its role in maintenance rather than formation of 
synapses (Murphy et al., 2000; Withers et al., 1997).  
aSyn is a 140-amino acid soluble protein that is frequently divided 
into three overlapping regions: the N-terminal repeat region of about 100 
amino acids containing six 11-residue repeats some of which display 
amphipathic properties; the hydrophobic NAC region from amino acids 
61–95; and the acidic C-terminal region (George et al., 1995; Lundvig et 
al., 2005). aSyn displays a high degree of structural plasticity that is 
governed by its environment. Under normal physiological conditions, 
aSyn is intrinsically unfolded in solution, which means that in the purified 
form at neutral pH it lacks an ordered secondary or tertiary structure. Upon 
binding to phospholipid membranes or synthetic vesicles containing acidic 
phospholipids, its N-terminal repeat region acquires a α-helical structure 
that is not prone to aggregation (Bartels et al., 2011; Deleersnijder et al., 
2013). However, aSyn exhibits a propensity to misfold into protofibrils 
and higher-order oligomers following changes in pH and ionic strength, 
increases in molecular crowding, and interactions with lipid membranes as 
well as secondary modification such as DA adduction, nitrosylation, and 
phosphorylation (Conway, 2001; Conway et al., 1998, 2000; Ding et al., 
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2002; Fink, 2006; Hashimoto et al., 1999; Kowall et al., 2000; Perrin, 
2001; Sharon et al., 2003; Shtilerman et al., 2002; Tsigelny et al., 2008; 
Vila et al., 2000; Volles and Lansbury, 2002; Volles et al., 2001). It is 
speculated that distinct strains of pathological aSyn likely exist in 
neurodegenerative disease brains and may underlie the tremendous 
heterogeneity of synucleinopathies. aSyn aggregates first into multiple 
soluble oligomeric species, ranging from dimers to more than a 70-
monomers assembly (Cremades et al., 2012),  that can be stabilized by β-
sheet-like interactions. This β-sheet-like structure can readily polymerize 
into higher molecular weight insoluble amyloid-like fibrils that are the 
main components of the LBs and LNs (Fig. 1.6; Braak et al., 1999; 
Spillantini et al., 1998). The mechanism by which aSyn incites 
pathogenesis is multifarious but commonly proposed to be due to a toxic 
gain-of-function due to its structural conversion (Lundvig et al., 2005). 
Why and how this presynaptic protein deposits aberrantly in neurons 
remain elusive although the NAC region appears pivotal for forming these 
aggregates (Giasson et al., 2001).  
Furthermore, which of the aSyn species are the major culprits in 
PD is still a matter of debate, with attention shifting from fibrils to soluble 
amyloid oligomers as key players in the disease process. In fact, a growing 
number of studies show that oligomers have a higher cytotoxicity 
compared to the fibrillar form of the proteins (Demuro et al., 2005; Fink, 
2006; Kayed et al., 2003; Lambert et al., 1998; Roher et al., 1996; Volles 
and Lansbury, 2003), suggesting that soluble amyloid oligomers may be 
the cause of cellular toxicity instead of the fibrillar aggregates (Bemporad 
and Chiti, 2012; Caughey and Lansbury, 2003; Danzer et al., 2007; Ding 
et al., 2002; Diógenes et al., 2012; Fink, 2006; Goldberg and Lansbury, 
2000; Haass and Selkoe, 2007; Lashuel et al., 2002a; Volles and Lansbury, 
2003; Winner et al., 2011). Some studies indicate that fibrillar aggregates 
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could simply be a storage mechanism and or even be protective (Quist et 
al., 2005). 
Nevertheless, despite the intensive efforts to characterize aSyn is 
role in PD and its potential as a target for neuroprotective therapies, there 
are still more questions than answers as to whether and how aSyn plays a 
direct causative role in PD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. A simplified representation of the protein aggregation 
process. Monomers can self-associate and form fibrillar structures via 
intermediate oligomeric aggregates (A and B from Takahashi and 
Wakabayashi, 2005).  
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Current Concepts on Parkinson’s Disease Pathogenic 
Mechanisms  
All the epidemiological findings, pathological observations and genetics 
discoveries already described above, resulted in substantial advances in the 
understanding of the pathophysiology of PD. Nevertheless, the underlying 
mechanisms and precise molecular players involved in neuronal 
dysfunction and degeneration remain unclear. Numerous and distinct 
hypothesis concerning cellular imbalances have been implicated in PD 
pathogenesis including post-translational modifications, impaired protein 
degradation machinery, formation of pore-like structures with perforation 
of membranes, mitochondrial malfunction, bioenergetics, dopamine 
synthesis, Golgi apparatus and transport, as well as oxidative stress, 
chronic endoplasmic reticulum (ER) stress, transcriptional deregulation, 
glutamate receptor dysfunction, and neuroinflammation (Dauer and 
Przedborski, 2003; Kalia et al., 2013; Wales et al., 2013). Below are 
discussed some of the main hypothesis. Note that the molecular events here 
mentioned are not mutually exclusive, and some of them can even co-
operate to induce PD pathology. 
 
Prion-disease-like mechanisms. PD is a protein-misfolding disorder, 
sharing fundamental biological properties with other neurodegenerative 
diseases, including AD, HD, motor neuron diseases and prion diseases. In 
fact, a particular focus of research suggests a link between prion proteins 
and small protein aggregates or assemblies - namely oligomers, ribbons, 
and fibrils - in neurodegenerative diseases. Laboratory studies have 
demonstrated that small aSyn aggregates may not only cause neuronal 
death at the site of expression and formation but, may also propagate the 
neurogenerative process via a “prion-like” spreading. Prions are composed 
of the scrapie prion protein (PrPsc), a misfolded form of the endogenous 
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cellular PrP (PrPC), and underlie disorders such as Creutzfeldt-Jakob 
disease, bovine spongiform encephalopathy, and scrapie (Prusiner, 1998). 
The conversion of alpha helical PrPC to the β-sheet rich PrPsc confers an 
infectivity that is the defining feature of a prion (Pan et al., 1993). Though 
the precise molecular mechanisms underlying the propagation of the prion 
protein are unknown, it is universally accepted that PrPsc acts as a template 
upon which native PrPC is refolded into PrPsc. Based on this idea, the 
question whether aSyn-pathology arise as a function of a “prion-like” 
mechanism, arouse (Costanzo and Zurzolo, 2013; Marques and Outeiro, 
2012). This hypothesis was brought forward when post-mortem autopsy of 
a PD patient brain tissue revealed that engrafted nigral neurons also 
develop LB pathology, suggesting that the healthy transplanted tissue 
could be transformed by the host tissue (Kordower et al., 2008; Li et al., 
2008). Animal studies have also shown the spread of aSyn from the 
periphery to the brain, after intramuscular, gastric or intravenous injection 
(Peelaerts et al., 2015; Reichmann et al., 2016). In addition, pathological 
studies on PD patients suggest that PD pathology progresses from the ENS 
and the olfactory bulb into the CNS. Preliminary evidence that these 
findings are relevant to PD has come from epidemiological studies 
demonstrating a lower risk of developing PD in people who underwent 
truncal vagotomy (Liu et al., 2017a; Svensson et al., 2015). These findings 
do not directly demonstrate the spread of aSyn but suggest that an intact 
vagus nerve, which may act as a conduit from the gut to the brain, increases 
the risk of PD. The current and disputed hypothesis of a “prion-like” 
dissemination of aSyn is now being studied by many PD research groups 
and suggests that the spreading of aSyn pathology is due to the cell-to-cell 
transmission of a pathogenic form of aSyn. This process involves: (1) the 
release of aSyn from a cell; (2) aSyn uptake by neighboring nerve cells; 
and (3) subsequently induction of LB pathology in the recipient cell, 
probably caused by a seeding and self-propagation effect of the 
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endogenous aSyn, promoting oligomerization and fibrillization of 
surrounding monomeric aSyn (Costanzo and Zurzolo, 2013). 
 
Membrane disruption and pore formation. One conceivable and vastly 
studied pathway to cell-to-cell transmission and consequent disruption of 
cellular homeostasis and toxicity is the permeabilization of cellular 
membranes (Gallegos et al., 2015; Iljina et al., 2016; Stöckl et al., 2013). 
It is known that misfolded amyloid proteins may form pore-like structures 
and elicit channel activity in the membrane (Dobson, 2003). Amyloid ion 
channels allow ionic exchange across the plasma membrane and thus 
disrupt the cellular ionic homeostasis. Such ionic exchange ultimately 
leads to cellular Ca2+ loading, which is a common property of 
amyloidogenic cellular pathophysiology and neurodegeneration and will 
be further discussed. In accordance, several studies by different groups 
have demonstrated that one of the pathological properties of aSyn is due 
to the ability of its oligomers to form pores which change membrane 
permeability (Tsigelny et al. 2012). The first reports on membrane 
permeabilization by pore-like annular shaped aSyn oligomers came in the 
early 2000s by Lansbury group (Lashuel et al., 2002b; Volles and 
Lansbury, 2002). Many studies came after, showing that aSyn oligomeric 
species are able to interact and interfere with lipid cellular membranes, 
increasing membrane conductance and forming ion permeable pore-like 
structures (Feng et al., 2010; Kim et al., 2009; Kostka et al., 2008; Quist 
et al., 2005; van Rooijen et al., 2010, 2010; Schmidt et al., 2012; Tsigelny 
et al., 2008, 2012; Volles and Lansbury, 2002; Zakharov et al., 2007). It 
has also been reported that mutant A53T and A30P aSyn causes higher 
membrane permeability and induces the formation of pores in SH-SY5Y 
cells plasma membrane, which allows Ca2+ influx, and therefore plays an 
important role in cell degeneration (Furukawa et al., 2006). More recently, 
this hypothesis was tested in neuronal membranes exposed directly to 
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extracellular aSyn oligomers. Using a variation of the patch-clamp 
technique, Pacheco and colleagues showed that aSyn oligomers rapidly 
associate with hippocampal membranes in a punctate fashion and form 
“pore-like structures”, resulting in increased membrane conductance and 
Ca2+ influx (Pacheco et al., 2015). This amyloid pore formation was shown 
to be dependent on two membrane lipids, ganglioside and cholesterol, that 
physically interact with amyloid proteins through specific structural motifs 
(Di Scala et al., 2016a). However, some of these studies were conducted 
using fairly high concentrations of aSyn, in the µM range, which exceeds 
largely the physiopathological range of concentration found in 
cerebrospinal fluid (CSF) of PD patients (Parnetti et al., 2016). 
Furthermore, another hypothesis suggests that aSyn oligomers to not 
necessary form pore-like structures but instead, increase membrane 
permeability by thinning of the hydrophobic core of the lipid bilayer. In 
this case, the incorporation of the oligomers between tightly packed lipids 
would facilitate the diffusion of small molecules across the membrane 
(Bemporad and Chiti, 2012; Stöckl et al., 2013). Plus, the existence of 
these “pore-like structures” was never observed in living animals.  
 
Calcium dysregulation. Ca2+ is the most pleiotropic ion and is able to 
trigger the majority of intracellular pathways in all cell types in response 
to external or internal stimuli. In the brain, and especially in neurons, Ca2+ 
plays a fundamental role in synaptic transmission, plasticity, transport, and 
neuron-neuron and neuron-glia signaling (Carafoli, 2002). Any alterations 
of the physiological Ca2+ signal in neurons or astrocytes lead to changes in 
signal transduction and cell death. Ca2+ dysregulation has been extensively 
reported in aSyn models of PD as one of the key factors which trigger 
neuronal dysfunction and degeneration in PD (Brini et al., 2014; Fedrizzi 
and Carafoli, 2011). Additionally, there are a number of ways in which 
aSyn and Ca2+ might be linked. On one hand, overexpression of 
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intracellular aSyn in neuroblastoma cell models has been associated with 
alterations in basal and depolarising-stimulus-evoked Ca2+ signals. 
Accordingly, several studies have shown an increase in basal intracellular 
Ca2+ levels after exposing neurons or astrocytes to exogenous aSyn 
oligomers (Danzer et al., 2007), with no changes with monomeric or 
fibrillar forms, confirming a species-specific effect. However, a recente 
study by Angelova and colleagues, suggests that the application of the 
unfolded monomeric form of aSyn can also induce an increase in Ca2+ 
levels but with no changes in channel formation as it was observed for the 
oligomers. Moreover, only Ca2+ increase induced by aSyn oligomers is 
associated with cell death (Angelova et al., 2016). Overall these findings 
confirm that aSyn interacts with membranes to affect Ca2+ signaling and 
the oligomeric β-sheet-rich aSyn species ultimately lead to Ca2+-dependent 
cell death. On the other hand, high levels of intracellular Ca2+ can promote 
the intracellular oligomerization and aggregation of aSyn. Thus, there is a 
complex loop in which aSyn expression and abnormal aggregation might 
initially promote Ca2+ dysregulation, which might, in turn, promote further 
aggregation (Follett et al., 2013; Nath et al., 2011). Moreover, 
epidemiological studies suggest that the use of Ca2+ channel blockers are 
associated with a reduced risk of PD (Noyce et al., 2012). The ability of 
Ca2+ channel blockers to reduce oxidative stress in neurons that are 
susceptible to death in PD has also been proposed to explain these 
observations. Indeed, previous studies suggest that SN neurons are 
particularly prone to higher levels of basal mitochondrial oxidative stress 
due to an increasing in intracellular Ca2+ (Surmeier and Schumacker, 
2013). Therefore, Ca2+ channel blockers might protect neurons by 
decreasing concentrations of reactive oxygen species (ROS). 
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Oxidative stress. The maintenance of redox homeostasis is critical for the 
proper function of redox-sensitive signaling proteins in neuron cells as 
well as for neuronal survival (Apel and Hirt, 2004; Chinta and Andersen, 
2008; Scialò et al., 2017). Oxidative stress is caused by an imbalance in 
the redox state of the cell, either by overproduction of ROS or by 
dysfunction of the endogenous antioxidant systems (Dias et al., 2013). The 
role of oxidative stress is increasingly recognized in neurological and 
neurodegenerative disorders (Gandhi and Abramov, 2012; Halliwell, 
2006), with a large body of evidence from post-mortem studies implicating 
oxidative stress in the pathology of PD (Gaki and Papavassiliou, 2014). In 
the brain, the primary sites of ROS generation include mitochondria in the 
neurons and glia. The production of these free radicals has been reported 
to be exacerbated in PD. This can occur due to neuroinflammation, 
dopamine degradation, mitochondrial dysfunction, aging, glutathione 
(GSH) depletion, and high levels of iron or Ca2+ (Liu et al., 2017b). In vitro 
studies reported that aSyn oligomers, but not fibrils or monomers, are able 
to induce oxidative stress, resulting in a decreased level of GSH in neurons 
and astrocytes. Importantly triplication of aSyn also demonstrated a 
reduction in GSH in human neurons derived from induced pluripotent stem 
cells (Deas et al., 2016). However, aSyn was also reported to directly 
activate GSH peroxidase in order to prevent oxidative stress (Koo et al., 
2013). Another more controversial hypothesis, attempting to link oxidative 
stress to the susceptibility of SNc neurons to cell death in PD propose that 
excessive cytotoxic free radicals result from oxidation of cytosolic 
dopamine and its metabolites or from an overload of free iron within the 
SNc (Greenamyre and Hastings, 2004; Jellinger, 2013; Sian-Hülsmann et 
al., 2011). Understanding ROS-related mechanisms in PD progression can 
provide important insights into possible treatments that alleviate PD 
symptoms.  
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Mitochondrial dysfunction. The implication of mitochondrial 
dysfunction in PD pathology has been shown for a long time, both in PD 
toxic models (rotenone and MPTP) and, more recently, in familial cases of 
the disease (Burchell et al., 2010a, 2010b; Schapira et al., 1990; Yan et al., 
2013). These studies report that soluble, prefibrillar aSyn oligomers, but 
not monomeric or fibrillar aSyn, inhibit mitochondrial complex I, promote 
Ca2+-induced mitochondrial swelling and depolarization, and enhance 
cytochrome c release (Banerjee et al., 2010; Luth et al., 2014; Reeve et al., 
2015; Sherer et al., 2002). Importantly, cells with triplication of aSyn also 
demonstrated mitochondrial dysfunction (Mak et al., 2011; Sarafian et al., 
2013). The role of aSyn in mitophagy, mitochondrial fission/fusion and 
protein trafficking to this organelle has also been suggested (Gottschalk et 
al., 2014; Mullin and Schapira, 2013). In addition, activation of 
mitochondrial permeability transition pore (mPTP), a protein that is known 
to be involved in mitochondrial swelling and damage, was shown to be 
associated with neurodegeneration in a transgenic (Tg) human aSyn mouse 
model (Martin et al., 2014).  And, interestingly, impaired mitochondrial 
function, resulting from exposure to toxins, promoted aSyn aggregation 
(Betarbet et al., 2000; Song et al., 2004). Thus, it is not clear whether toxic 
aSyn leads to mitochondrial dysfunction or mitochondrial dysfunction 
causes the formation of pathological forms of the protein, but a synergistic 
interaction between aSyn and this organelle is likely to play an important 
role in neurodegeneration (Nakamura, 2013). 
Overall, aSyn oligomers can induce toxic Ca2+ signaling, which, in 
turn, activates enzymatic ROS production and the combination of 
oxidative stress and Ca2+ overload affects mitochondria, which can trigger 
the cell death cascade. Various neuroprotective strategies have been 
identified to diminish mitochondrial oxidative stress within dopaminergic 
neurons. 
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Neuroinflammation. When microglial cell activation was first 
characterized in the brain of patients with parkinsonian symptoms almost 
30 years ago, the hypothesis that neuroinflammation could be involved in 
the pathophysiology of PD gain attention (McGeer et al., 1988). Since 
then, in vitro, in vivo and post-mortem studies suggesting that 
neuroinflammatory mechanisms contribute to the cascade of events which 
lead to neuronal death and disease progression, emerged. Consistent with 
this idea, anti-inflammatory drugs, namely non-steroidal anti-
inflammatory drugs, were shown to have a protective effect both in animal 
models and in epidemiological studies (Bassani et al., 2015; Noyce et al., 
2012). Despite neuroinflammatory processes being found to also 
contribute to many other neurodegenerative disorders, such as AD, 
Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and 
progressive supranuclear palsy, neuroinflammation does not seem to be 
merely a consequence of neurodegeneration.  
Available data support the importance of non-cell-autonomous 
pathological mechanisms occurring within areas of neurodegeneration in 
PD. Most of these mechanisms are mediated by activated microglia, 
astrocytes, and peripheral immune cells. Astrocytes and microglia are both 
involved in clearance of extracellular debris, which might aid in the 
survival of neurons. Furthermore, activated microglia can release trophic 
factors, such as brain-derived neurotrophic factor (BDNF) and glial cell 
line-derived neurotrophic factor (GDNF), but can also release harmful 
reactive oxygen and nitrogen species and pro-inflammatory cytokines 
(Hirsch and Hunot, 2009). This cellular response might eventually lead to 
dopaminergic cell death and, hence, disease progression. Although much 
evidence from preclinical studies suggests a deleterious role of immune-
associated mechanisms in PD, there is still some scepticism regarding this 
topic, especially due to the overall inability of animal models that can 
accurately predict the outcomes of trials that test neuroprotection in 
The Role of A2AR on aSyn Toxicity 
 
32 
 
humans (Dragunow, 2008). Thus, the ultimate goal of translating our basic 
understanding of the neuroinflammatory network into therapeutic 
interventions is still distant and a more vigorous investigation into 
immune-associated changes in PD is needed.  
Although remarkable insights into the pathogenesis of PD have 
emerged in recent years, many questions remain unanswered and the 
relative contributions of the different possible mechanisms of PD-
pathology are unknown. Considerable challenges need to be explored in 
order to reconcile the diverse and sometimes contradictory range of 
studies. Further studies are needed to examine the factors that control the 
cell-to-cell transfer of aSyn, the impact of inflammation, oxidative stress, 
mitochondrial dysfunction, membrane disruption, and Ca2+ dysregulation 
on the accumulation of misfolded proteins, synaptic impairment and 
neuronal degeneration. Hopefully, insight from future studies will translate 
into an improved molecular understanding of aSyn pathology and 
ultimately lead to novel and effective therapeutic strategies that interfere 
with key steps in the pathogenic mechanism, thereby altering the disease 
progression. 
 
Therapeutic Avenues in Parkinson’s Disease 
Currently, the pharmacological and non-pharmacological treatments 
approved for PD only offer symptomatic relief for patients. As these 
treatments are not able to arrest or reverse the progression of the disease, 
PD remains incurable. 
 
Dopaminergic therapies for PD. The motor symptoms can be managed 
with several different drugs that either boost the levels of DA in the CNS 
or mimic its effects. In 1967 a revolutionary therapeutic breakthrough was 
made by George Cotzias with the introduction of high dosage levodopa 
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therapy, a DA precursor also known as L-Dopa (Fig. 1.7; Cotzias et al., 
1969; Hornykiewicz, 2010). And despite the advances in PD research, 
levodopa continues to be the gold standard for the treatment of PD 
nowadays. It is often the first line treatment for patients over 55 years of 
age and it is typically administered along with carbidopa, a peripheral 
decarboxylase inhibitor which blocks peripheral conversion of levodopa 
to DA, thus allowing dose reduction and also minimizing its peripheral 
adverse effects. This regime is usually effective for 5 years at delaying PD 
MS. Yet, chronic levodopa treatment is associated with shortened duration 
of the effect (“wearing off” phenomenon), the development of motor 
complications (referred as the long-term levodopa syndrome; Barbeau, 
1976), including motor fluctuations (“on-off” effects) and dyskinesias, 
nausea, hallucinations, orthostatic hypotension and sleep disturbances 
(Schapira, 2005; Schapira et al., 2006), that can themselves be disabling. 
For patients under 55 years of age, a DA receptor agonist (e.g., 
pramipexole, ropinirole, rotigotine, apomorphine), is typically the first line 
treatment (Fahn, 2015; Fahn et al., 2004). These drugs are used as the 
initial choice for dopaminergic therapy, as they delay the need for 
levodopa, and also as an add-on therapy to levodopa in patients who 
develop motor complications, since it allows a reduction in levodopa dose. 
However, most patients who begin treatment with DA receptor agonists 
will eventually need to add levodopa within a few years. DA receptor 
agonists are often most effective in addressing mild-to-moderate MS, and 
are less prone to induce dyskinesia and motor fluctuations, yet they can 
cause more behavioral disturbances, such as hallucinations, nausea, 
postural hypotension, somnolence, compulsive gambling, shopping, eating 
and hypersexuality (Alonso Cánovas et al., 2014; Constantinescu, 2008; 
Factor, 2001).  
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Other commonly prescribed drugs for PD MS reduce DA 
metabolism via selective monoamine oxidase-B (MAO-B) inhibition (e.g., 
selegiline, rasagiline, and the recently approved safinamide) or catechol-
o-methyl-transferase (COMT) inhibition (e.g., entacapone, tolcapone, 
opicapone) (Fig. 1.7; Choy, 2017; Connolly and Lang, 2014; Rizek et al., 
2016). 
NMS invariably do not respond to dopaminergic medication and 
are probably the major current challenge faced in the clinical management 
of PD. Therefore, attention is now being focused on developing new 
therapeutic interventions that target not only dopaminergic signaling but 
also non-dopaminergic pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Dopamine synthesis and activity in neurons. DA is synthesized 
from L-aromatic amino acid (L-Dopa or levodopa) by Dopa decarboxylase. 
DA is then either used, broken down by catechol-O-methyltransferase 
(COMT) or monoamine oxidase-B (MAO-B) enzymes, or further transformed 
into noradrenaline by the rate-limiting enzyme dopamine β-hydroxylase. In 
red, the inhibitors of the corresponding enzymes. 
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Non-dopaminergic approaches. Non-dopaminergic drug treatments for 
PD can have two different aims: (1) Targeting motor function. Within the 
basal ganglia, the main neurotransmission pathways are primarily 
controlled by gamma-aminobutyric acid (GABA) and glutamate 
transmission. These pathways have a large range of other neurotransmitter 
receptors on their surface that are potential targets for drug manipulation 
of motor function (Fig. 1.8). Possible targets include 5-hydroxytryptamine 
(5-HT; serotonin) receptors, noradrenergic receptors, histamine receptors, 
nicotinic and muscarinic cholinergic receptors, ionotropic and 
metabotropic glutamate receptors, and adenosine receptors. (2) Targeting 
NMS. Outside of the basal ganglia, the pathology of PD affects many other 
brain nuclei (e.g. locus coeruleus, raphe nuclei, and dorsal motor nucleus 
of the vagus) and their target structures (e.g. amygdala, hippocampus, and 
cortex) and a range of neuromodulators and neurotransmitters other than 
dopamine (e.g. 5-HT, noradrenaline, acetylcholine, GABA, glutamate, and 
adenosine). These rational provide a focus for using non-dopaminergic 
drugs to manipulate both the motor and non-motor features of PD. 
 Non-dopaminergic approaches for the treatment of PD MS have 
been exploited to a limited degree through the use of amantadine and 
anticholinergic drugs. Anticholinergics are an alternative and 
complementary approach to dopaminergic treatments used to restore the 
balance between cholinergic and dopaminergic inputs on the basal ganglia. 
Anticholinergic drugs (e.g. trihexyphenidyl, benztropine) are effective for 
patients with a tremor-predominant phenotype (Singh et al., 2007). The 
side-effect profile of muscarinic antagonists has limited their use in PD, 
but there is now interest in pursuing subtype selective M4 antagonists as a 
means of affecting the basal ganglia without causing cognitive 
impairment, blurred vision, dry mouth, or urinary retention.  
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Figure 1.8. Simplified diagram of the neurologic pathways in healthy and 
PD states, and the major sites of action of drugs used for the treatment of 
motor features. Dopaminergic afferents from the SNc, glutaminergic 
afferents from the motor cortex, and cholinergic striatal interneurons all 
converge to exert effects on the activity of GABAergic neurons, which are the 
main efferent neurons of the striatum. Dopaminergic neurons exert inhibitory 
effects on GABAergic neurons, whereas cholinergic and glutaminergic 
neurons produce excitatory effects. The loss of dopaminergic neurons in PD 
results in a decreased dopamine inhibition, via D2 receptors, leading to an 
abnormally high output by GABAergic efferents. This increased inhibitory 
output causes increased inhibition of the thalamus, as well as reduced 
excitatory input to the motor cortex.  
 
Amantadine is an anti-influenza agent which was serendipitously 
found to be useful in PD. Amantadine modulates the release of DA from 
DA terminals in the striatum, possesses anticholinergic properties and 
blocks glutamate N-methyl-D-aspartic acid receptor (NMDAR). It may be 
effective in managing MS in mildly affected patients with early disease 
and in reducing motor fluctuations in patients with advanced disease 
(Hubsher et al., 2012). If dyskinesia occurs as PD progresses, amantadine 
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can also target this particular symptom. However, the use of amantadine 
has been limited by its side-effects profile, these include insomnia, leg 
swelling and/or skin discolouration (termed livedo reticularis), blurred 
vision, nausea, dizziness or lightheadedness, and hallucinations. 
It is now appreciated that PD is associated with widespread 
pathology affecting additional neuronal fields and neurotransmitter 
systems, including the anterior olfactory structures, dorsal motor nucleus 
of the vagus, caudal raphé nuclei, locus coeruleus, hippocampus, cerebral 
cortex, and the ANS. Accordingly, continuous studies have shown that the 
mechanism of PD involves not only dopaminergic but also non-
dopaminergic mechanisms involving adenosinergic, cholinergic, 
adrenergic, serotoninergic, glutamatergic, histaminic and iron chelator 
pathways (Blandini et al., 1996; Buddhala et al., 2015; Huot et al., 2017; 
Schiffmann et al., 2007). This widespread pathology is on the basis of PD 
NMS but, unlike most MS, have often limited treatment options or 
response (Chaudhuri et al., 2006). Despite the available treatments that can 
effectively control or improve disability of some of the NMS, namely 
depression, psychosis, autonomic dysfunction, sleep disorders and fatigue 
(Kalia and Lang, 2015; Seppi et al., 2011), the current pharmacological 
therapies for PD cognitive impairments, including dementia, can only ease 
the symptoms and their benefits are often marginal and non-sustained. 
These include rivastigmine, donepezil, and galantamine, all acting by 
increasing cholinergic neurotransmission in the CNS. Additionally, no 
medications are currently available to treat MCI (Gratwicke et al., 2015; 
Svenningsson et al., 2012; Szeto and Lewis, 2016). Consequently, there is 
an urgent need to develop approaches to treatment that are non-
dopaminergic in nature. 
Adenosine A2A receptor (A2AR) antagonists represent a novel and 
promising class of non-dopaminergic drugs currently under evaluation for 
the treatment of PD patients. The interest on targeting A2AR in the realm 
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of PD first arose based on a study using adenosine receptors antagonists in 
an hemiparkinsonian rat model (Fuxe and Ungerstedt, 1974) and on the 
potency of methylxanthines, such as caffeine, in enhancing levodopa 
action (Fredholm et al., 1976). Since then, and based on the ability of 
purinergic signaling, namely A2AR, to fine-tune DA actions in the striatum, 
A2AR became a focus for treating PD MS. However, the role of central 
A2AR is now viewed as much broader than just controlling D2 receptor 
function. Their physiological functions, mechanisms of action, 
involvement in PD pathology and their potential role as therapeutic targets 
for both MS and NMS in PD, as well as neuroprotective agents will be 
further discussed. 
 
Potential neuroprotective agents. Another major therapeutic challenge 
for PD is the development of disease-modifying treatments to slow or 
prevent the progression of neurodegeneration. Neuroprotection is proving 
a difficult issue, with several anti-parkinsonian therapeutics that look 
highly effective in preclinical animal studies turning out to be ineffective 
in clinical trials. This has occurred with MAO-B inhibitors, glutamate 
antagonists, enhancers of mitochondrial function, inhibitors of apoptotic 
mechanisms, trophic factors, DA agonists, amongst others (Morelli et al., 
2009). New approaches are emerging based on epidemiological data, 
associating several factors with a reduced risk of developing PD. Although 
some are still controversial, others are already in clinical trials. Examples 
of these factors are cigarette smoking (with a nicotine patch in phase II 
trial), the use of nonsteroidal anti-inflammatory drugs, anti-hypertensive 
agents as Ca2+ channel blockers (with isradipine in phase III trial), diabetes 
(with the anti-diabetic drug exenatide in phase II trial) and caffeine intake 
(with the adenosine A2AR antagonist istradefylline currently approved in 
Japan).  
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Among other agents that are currently being investigated as 
potential neuroprotective agents are phytochemicals such as 
isorhynchophylline, resveratrol, trehalose, ginseng, ginkgo biloba, 
saponins, chronic lithium therapy, cannabis, L-carnitine, estrogen, and 
NMDAR antagonists (Huang and Adachi, 2016; Mythri et al., 2012; Singh 
et al., 2007; Sun et al., 2015). Some features that make them good drug 
candidates are their low cytotoxicity. Since oxidative stress is believed to 
be involved in the pathogenesis of PD, several compounds with proven 
antioxidant properties, namely melatonin, selenium, uric acid, vitamins A, 
C, and E and Coenzyme Q10 (CoQ10) are now being investigated as 
potential neuroprotective agents for PD (Sarkar et al., 2016; Yang et al., 
2016).  
Although numerous theories have been proposed and many 
promising neuroprotective agents have been tested in the clinical trials, 
none of them was established as a neuroprotective agent. Thus, further 
research is necessary to develop such an agent in order to mitigate PD 
pathology. 
 
Non-pharmacological treatments. Surgical therapies may be considered 
during the progression of PD, especially if symptoms cannot be adequately 
controlled by pharmacological agents. Similar to the available PD drugs, 
surgical options offer only symptomatic benefit. While pallidotomy and 
thalamotomy can still be done in certain situations, they have largely been 
replaced by deep brain stimulation (DBS). DBS of the STN and GPi can 
be more effective at managing MS in patients with advanced, medication-
refractory PD (Deuschl et al., 2006). Besides, it provides an additional 
benefit for tremor, rigidity, and bradykinesia; although gait and balance 
are unlikely to improve, and cognition may be worsened (Fasano et al., 
2012). Newer drug delivery systems for PD are increasingly more focused 
on site-specific delivery of pharmaceuticals. A non-pharmacological 
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technology currently on clinical trials is a PD vaccine that showed 
extremely positive results in an animal model of PD (Masliah et al., 2005). 
The rationale behind PD vaccine is that immunization with aSyn 
stimulates the immune system to target the toxic form of aSyn promoting 
its degradation (Romero-Ramos et al., 2014). Human trials on the 
proposed vaccine, affilope, are currently in phase I. Another promising 
non-pharmacological treatment for PD under investigation is gene therapy 
which corrects genetic abnormalities contributing to disease pathogenesis 
at the molecular level. This approach involves either the introduction of a 
replacement allele into cells to compensate for the loss of gene function or 
the silencing of a dominant mutant allele that is pathologic to cells. Since 
PD is mainly idiopathic and thus not involving one specific genetic target, 
PD gene therapy also focuses on pathways of cell repair and 
neuroprotection. Three main approaches are under discussion: (1) 
induction of DA production, (2) neuronal protection in the SNc, and (3) 
GABA-mediated inhibition of the STN (Choong et al., 2016; Simonato et 
al., 2013). The clinical delivery of adeno-associated virus encoding human 
aromatic L-amino acid decarboxylase (AAV2-hAADC), by gene therapy, 
is now in phase I of clinical trials. This strategy is based on the loss of the 
enzyme AADC as the dopaminergic neurons die, resulting in a reduction 
in the conversion of levodopa into DA. Gene therapy to replace AADC 
should provide significant clinical benefit to PD patients by potentially 
reducing the required levodopa dose level and dyskinesias associated with 
high levodopa administration (Mittermeyer et al., 2012). Another 
promising approach for PD treatment is the transplantation of DA-
producing neurons to replace those degenerated during the disease 
pathogenesis. Regenerative-medicine aims at developing autologous stem 
cell-derived therapies, with studies demonstrating that mature cells can be 
coaxed back into stem cells. The potential source for regenerative 
medicine is the human pluripotent stem cells (hPSCs) which include 
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human embryonic stem cells (hESCs), human induced pluripotent stem 
cells (hiPSCs), human neural cells and mesenchymal cells. After 
transplantation into humans, the neuronal progenitors will eventually 
derive into DA neurons and rescue the symptoms underlying dopaminergic 
neuronal loss (Dhivya and Balachandar, 2017). 
 
Overall, currently available pharmacological and non-
pharmacological therapies are unable to arrest, nor reverse the advance of 
this relentlessly progressive and severely debilitating condition. 
Furthermore, as NMS are a significant determinant of PD patient’s quality 
of life, it is essential that any intervention in PD pathogenesis to slow the 
disease targets not only dopaminergic signalling but also non-
dopaminergic pathways. Lastly, the discrepancy between encouraging 
preclinical data and failure to translate the results into therapies is likely to 
be related primarily to our incomplete understanding of the pathogenic 
mechanisms underlying PD. 
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Adenosine A2A Receptors as Targets in Parkinson’s Disease 
 
Adenosine Physiology  
Adenosine is a naturally occurring purine ribonucleoside (Fig. 1.9) with 
the primary and evolutionary conserved function of maintaining a 
bioenergetic equilibrium. It is distributed ubiquitously throughout the body 
and is directly involved in key processes sustaining cellular viability and 
adaptability, such as energy charge (via ATP/ADP), redox control (via 
NADH), epigenetic control (via the methyl donor SAH), and formation of 
DNA and RNA (since adenosine contains adenine as its nucleobase). 
Moreover, all cells have an intracellular metabolism based on adenosine, 
using this molecule as a paracrine signal to coordinate physiological 
processes, especially in excitable tissues as the heart and the brain, acting 
both as a homeostatic transcellular messenger, and as a neuromodulator. 
The latter is of particular interest within the CNS, where it is involved in 
the regulation of local neuronal excitability and in a variety of important 
synaptic processes and signaling pathways. It is considered a 
neuromodulator rather than a neurotransmitter since it is not stored nor 
released in synaptic vesicles, as a classical neurotransmitter, and it does 
not have direct effects on synaptic transmission, but rather plays an 
important fine-tuning influence on other neurotransmitters and thus 
modulating neuronal communication.  
Adenosine affects neuronal activity through multiple mechanisms: 
(1) presynaptically by controlling neurotransmitter release and 
maintaining the inhibitory tone; (2) postsynaptically by modulating the 
activity of neurotransmitter receptors and other neuromodulators and 
hyperpolarizing or depolarizing neurons; and (3) nonsynaptically mainly 
via regulatory effects on glial cells (Boison et al., 2010; Daré et al., 2007; 
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Fredholm et al., 2005; Ribeiro and Sebastião, 2010; Sebastião and Ribeiro, 
2009).  
 Because adenosine acts as a fine-tuner of synaptic transmission, it 
has a key role in the homeostatic control of the nervous system activity. 
When this homeostasis is disrupted, there is an abnormal neuronal 
communication that can lead to several pathologies of the CNS. Based on 
this, adenosine has been studied in a wide range of diseases, namely sleep 
disorders, epilepsy, panic disorder, anxiety, schizophrenia, AD and PD. A 
promising therapeutic strategy to reestablish neuronal homeostasis in these 
pathological conditions, is to modulate neurotransmitter receptors or 
transporters, via adenosine and adenosine receptors (Lopes et al., 2011). 
 
 
 
 
 
 
 
 
Figure 1.9. Chemical structure of adenosine. Adenosine is a nucleoside, 
composed of an adenine molecule attached to a ribose sugar molecule 
(ribofuranose) through a β-N9-glycosidic bond. 
 
Adenosine Synthesis and Metabolism 
It is well established that adenosine can be formed in the CNS either intra 
or extracellularly (Fig. 1.10). In the cell, adenosine is an intermediate for 
the synthesis of nucleic acids and adenosine-5’-triphosphate (ATP), and 
may be formed through: (1) dephosphorylation of cytosolic adenosine 
triphosphate (ATP), or (2) breakdown of adenosine monophosphate 
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(cAMP) by phosphodiesterase (PDE), both followed by the hydrolysis of 
5’-adenosine monophosphate (AMP), catalyzed by cytosolic 5’-
nucleotidase. Another intracellular source of adenosine may be (3) the 
hydrolysis of S-adenosyl-homocysteine (SAH), by SAH hydrolase 
(SAHH), an enzyme present in brain areas such as the neocortex, 
hippocampus, and cerebellum (Latini and Pedata, 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10. Schematic representation of adenosine production, 
metabolism, and transport. Adenosine can be synthesized intra and 
extracellularly by nucleotidase enzymes activity. Bidirectional specific 
transporters, namely equilibrative nucleoside transporters (ENT) or 
concentrative nucleoside transporters (CNT) regulate the extracellular 
concentration of adenosine. Abbreviations are as follow: AMP, 5’-adenosine 
monophosphate; SAH, S-adenosyl-homocysteine; SAHH, S-adenosyl-
homocysteine hydrolase; AC, adenylate cyclase; XO, xanthine oxidase; 5’NT, 
5'-nucleotidase; ADA, adenosine deaminase; ADK, adenosine kinase; AMPK, 
AMP-activated protein kinase; HCY, homocysteine; CD39, cluster of 
differentiation 39; CD73, cluster of differentiation73; PDE, 
phosphodiesterase. 
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 The synthesized intracellular adenosine can then (4) be transported, 
as such, to the extracellular medium by facilitated diffusion through 
bidirectional nucleoside transporters (NT). This can occur after an increase 
in the intracellular levels of adenosine (e.g., during ischemia, hypoxia, and 
seizures) or a reversal of sodium gradient and allows the regulation of 
adenosine extracellular concentrations. There are two main categories of 
nucleoside transporters: the equilibrative NT (ENT), which carry both 
purine and pyrimidine nucleosides across cell membranes in both 
directions and following their concentration gradient; and the 
concentrative NT (CNT), that mediate influx of nucleosides via the 
transmembrane sodium gradient. In the CNS the ENT appear to dominate 
(Thorn and Jarvis, 1996; Young et al., 2013) while CNT, despite operating 
at the blood brain barrier, are only found at low levels in the brain. 
Extracellular adenosine can also appear through (5) the rapid extracellular 
conversion of locally released adenine nucleotides (especially  ATP) to 
ADP and then AMP, via the ectonucleotidase pathway (Zimmermann and 
Braun, 1999), and (6) the breakdown of cAMP and direct formation of 
AMP, via ecto-PDE pathway (Fig. 1.10). Adenosine is then formed from 
AMP by the action of ecto-5’-nucleotidase CD73, a glycolipid-anchored 
protein thought to be the only relevant enzyme which generates 
extracellular adenosine in the brain (Lovatt et al., 2012). The pathways (4) 
and (5) above are the predominant ones and the relative importance of each 
of them depends on the metabolic state of the cells and, in the case of 
neuronal cells, their excitability status. Thus, high-frequency neuronal 
firing and astrocytic stimulation lead to the predominance of the pathway 
(5) for extracellular adenosine formation (Dunwiddie and Masino, 2001; 
Fredholm et al., 2005; Latini and Pedata, 2001). Furthermore, the 
formation of adenosine is dependent on the availability of oxygen and 
energetic compounds as well as on the rate of synthesis and degradation of 
ATP, released from both neuronal and glial cells. In fact, it is the release 
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of ATP from astrocytes, either vesicular (Pascual et al., 2005) or via 
secretion through hemichannels, that is the major source of synaptic 
adenosine (Kang et al., 2008; Kawamura et al., 2010). Because ATP is 
continuously released as a neurotransmitter in the brain, adenosine is 
continuously produced within the extracellular space. This process of 
extracellular adenosine formation is very fast and occurs within seconds 
(Dunwiddie et al., 1997). In basal conditions, adenosine concentrations are 
normally kept in the range of 30-300 nM (Dunwiddie et al., 1997), by a 
steady-state expression of adenosine kinase (ADK). At these 
concentrations, adenosine exerts a tonic inhibitory effect on synaptic 
transmission. 
The bioavailability of adenosine is thought to oscillate with 
neuronal activity and depends upon its metabolization. Extracellular 
adenosine is primarily inactivated by uptake across the neuronal cell 
membrane, followed by either intracellular phosphorylation to AMP by 
ADK or, to a lesser degree, irreversible deamination to inosine, by 
adenosine deaminase (ADA). Inosine can then be degraded to 
hypoxanthine, xanthine, and ultimately uric acid by xanthine oxidase (XO) 
(Morelli et al., 2010). ADK is a part of the cycle between adenosine and 
AMP, which sustains the concentration gradient that allows adenosine 
uptake into cells by ENT. However, conditions prompting an increase in 
intracellular adenosine will reverse transport direction, leading to release 
of adenosine into the extracellular space (Gu et al., 1995). Once present in 
the extracellular space, adenosine may diffuse far away and influence its 
receptors (Abbracchio and Burnstock, 1998; Abbracchio et al., 2009; 
Burnstock et al., 2011; Fredholm et al., 2001, 2011; Ribeiro et al., 2002). 
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Adenosine Receptors and Signaling Pathways 
Currently, four subtypes of adenosine receptors have been cloned and 
characterized: the high affinity A1R and A2AR (Ka values of 70 and 150 
nM, respectively), and A2BR and A3R which  exhibit a lower affinity 
for adenosine (Ka values of 5100 and 6500 nM, respectively; 
Dunwiddie and Masino, 2001; Ralevic and Burnstock, 1998; Tucker 
and Linden, 1993). Interestingly, human A3R show higher affinity for 
adenosine but have a low density in most tissues (Fredholm et al., 2001; 
Ribeiro et al., 2002).  
 Adenosine receptors are all metabotropic G-protein coupled 
receptors (GPCR). Classically A1R and A3R are coupled to AC 
inhibitory G proteins (Gi/Go), whereas A2AR and A2BR are coupled to 
AC excitatory G proteins (Gs/Golf) (Fig.1.11; Fredholm et al., 2001). To 
note that all adenosine receptors are pleiotropic receptors, meaning that 
they can potentially couple to different G proteins and to different 
transducing systems, according to their degree of activation and their 
particular cellular and subcellular localization (Cunha, 2005). The main 
adenosine-mediated intracellular signaling pathway involves the 
formation of cAMP, with A1R and A3R stimulation causing, via Gi and 
Go proteins, AC inhibition, which leads to reduced protein kinase A 
(PKA) activity and cAMP response element binding protein (CREB) 
phosphorylation.  On the other hand, stimulation of A2AR and A2BR 
activates AC, via Gs/Golf proteins, resulting in the activation of PKA, 
which in turn phosphorylates CREB. However, A2AR have also been 
reported to couple to Gq proteins, resulting in protein kinase C (PKC) 
activation (Lopes et al., 1999a). Having adenosine receptors, namely 
A1R and A2AR, opposite effects, the question how the cell senses the 
need of the system and decide which receptor should preferentially be 
activated, arises. Data suggests that at lower frequencies stimulation 
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and thus low extracellular adenosine concentrations, inhibitory A1R are 
predominantly activated. On the contrary, at higher frequencies 
stimulation and high levels of extracellular adenosine, excitatory A2AR 
are preferentially activated (Correia-de-Sá and Ribeiro, 1996). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11. Simplified schematic representation of G-protein coupled 
adenosine receptors. Adenosine A1R and A3R are usually coupled to Gi/0 
proteins, decreasing the activity of adenylate cyclase (AC). A2AR and A2BR 
receptors are usually coupled to Gs/olf, activating AC and consequently PKA, 
which in turn phosphorylates CREB. Additionally, A3R, A2BR and A2AR may 
couple to Gq/11 proteins, activating the PLC pathway. Only selected 
mechanisms and pathways are shown. 
 
Another crucial point for understanding adenosine’s differential 
modulation in the brain, is the distribution of adenosine receptors. In the 
brain, the adenosine high-affinity receptors, A1R and A2AR, represent the 
most relevant receptors for adenosine-meditated effects (Fredholm et al., 
2005). Adenosine A1R are the most highly conserved receptor subtype 
between species, most abundant (it is the second most abundant 
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metabotropic receptor in the brain), and widely distributed, being highly 
expressed in cortex, cerebellum, and hippocampus (Reppert et al., 1991). 
Adenosine A2AR, although also widespread in the brain, display high 
expression levels in neurons of the dorsal and ventral striatum 
(GABAergic striatopallidal medium spiny neurons and cholinergic 
interneurons), nucleus accumbens in the basal forebrain, and olfactory 
tubercle (Jarvis and Williams, 1989; Rosin et al., 1998). A2AR are also 
found in the neocortex and hippocampus albeit with a considerably lower 
density (Cunha et al., 1994a; Kirk and Richardson, 1995; Sebastião and 
Ribeiro, 1996). A2AR are thought to play an essential role in the regulation 
of locomotion, sleep, anxiety, memory, and cognition. A2BR are also 
widely distributed in the brain but at low levels (Feoktistov and Biaggioni, 
1997), and, because they are low affinity receptors, functional studies 
suggest that they may only be relevant in pathological conditions, when 
the extracellular adenosine levels are increased. The A3R are expressed at 
an intermediate level in the human cerebellum and hippocampus and at 
lower levels in other brain regions (Dixon et al., 1996; Fredholm et al., 
2000; Ribeiro et al., 2002).  
Both A1R and A2AR are mostly located at synapses, in particular 
glutamatergic excitatory synapses, although both receptors are also found 
in GABAergic, cholinergic, dopaminergic, serotoninergic and 
noradrenergic synapses (Cunha, 2016). In the hippocampus, the effects of 
adenosine under physiological conditions are mostly mediated by A1R 
activation and consequent inhibition of glutamate release. Adenosine has, 
therefore, a tonic inhibitory effect on hippocampal synaptic transmission 
(Sebastião et al., 1990). Interestingly, despite the low expression and 
density of A2AR in the hippocampus, these receptors play an important role 
in the modulation of synaptic transmission. Different effects resulting from 
A2AR activation were observed, in both neurons and astrocytes (Sebastião 
and Ribeiro, 2009). The first evidence of A2AR mediated effects on the 
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hippocampus revealed a presynaptic modulatory effect of A2AR upon A1R 
inhibitory actions, resulting in a facilitatory effect on synaptic transmission 
(Cunha et al., 1994b; O’Kane and Stone, 1998). In neurons, other 
presynaptic effects were observed later in the modulation of release or 
uptake of different neurotransmitters, such as glutamate (Lopes et al., 
2002), GABA (Cristóvão-Ferreira et al., 2009; Cunha and Ribeiro, 2000) 
or acetylcholine (Cunha et al., 1994b). Postsynaptically, A2AR are 
implicated in the modulation of AMPA mediated currents (Dias et al., 
2012), and also have been shown to colocalize with mGluR5 and mediate 
NMDAR signaling (Sarantis et al., 2015; Tebano et al., 2005). 
Additionaly, postsynaptic activation of A2AR was also implicated in the 
downstream activation of CREB in the hippocampus (Li et al., 2015). 
Evidence also expand A2AR modulatory actions to growth factors 
and neuropeptides (Cunha-Reis et al., 2007; Diógenes et al., 2004; Flajolet 
et al., 2008; Gomes et al., 2009; Sebastião et al., 2000). In particular, a 
crosstalk between A2AR and the neurotrophin receptor TrkB was been 
described, with important implications for BDNF effects (Assaife-Lopes 
et al., 2014; Diógenes et al., 2004, 2007; Tebano et al., 2008). A2AR are 
also found in astrocytes and microglia, where they control Na+/K+-
ATPase, glutamate release (Nishizaki et al., 2002), and GABA uptake 
(Cristóvão-Ferreira et al., 2013), as well as the production of pro-
inﬂammatory cytokines. All these effects potentially contribute to the 
selective A2AR-mediated control of synaptic plasticity (Cunha, 2016). 
 
The Role of Adenosine and Adenosine Receptors in Pathology 
Brain insults can trigger a large outflow of adenosine and ATP, as a danger 
signal. Under pathological conditions as ischemia, epilepsy, hypoxia, and 
excitotoxicity, and also during aging, there is a decrease in the energy 
charge which leads to an increase of intracellular levels of adenosine that 
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can than diffuse out of the cell. In these conditions, extracellular adenosine 
concentrations can rise as much as 10-fold (Dale and Frenguelli, 2009; 
Fredholm et al., 2000; Latini and Pedata, 2001; Wei et al., 2011) and 
activate A1R, which work as a hurdle for damage initiation and signal the 
noxious stimuli to neighboring cells (Cunha, 2005). A1R play a key role in 
neuroprotection by decreasing glutamate release and hyperpolarizing 
neurons. In fact, studies show that the A1R activation at the onset of 
neuronal injury, attenuates brain damage, whereas its blockade 
exacerbates damage in adult animals. 
Interestingly, although adenosine is involved in relevant 
physiological roles and neuroprotection, it may also contribute to neuronal 
damage and cell death. In chronic pathological conditions, elevated levels 
of adenosine will preferentially act on A2AR rather than on A1R. 
Consequently, there will be a reduction in the A1R-mediated inhibition of 
neurotransmitter release and synaptic transmission (Fernandez et al., 1996) 
and an increase in the A2AR-mediated facilitation of neurotransmission 
(Fredholm, 1997) which will lead to an adenosinergic inhibitory tonus and 
the appearance of a stimulatory one. This chronic state where A2AR are 
preferentially activated can lead to an alteration in the levels of adenosine 
receptors. In fact, several studies suggest both changes in adenosine and 
adenosine receptors expression levels in different chronic noxious brain 
conditions and upon aging. In these situations there is an increase in basal 
adenosine levels and a down-regulation of A1R signaling and expression 
in the cerebral cortex, hippocampus and cerebellum (Cheng et al., 2000; 
Cunha et al., 1995; Pagonopoulou and Angelatou, 1992; Sebastião and 
Ribeiro, 2000), and G-protein coupling of A1R are increased (Cunha, 
2001). On the contrary, A2AR expression levels are increased, namely in 
the cortex and hippocampus (Cunha et al., 1995). Changes in adenosine 
receptor levels not only impact on the overall effects of adenosine but may 
also have consequences on the signaling pathways operated by these 
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receptors. The actions mediated by the activation of adenosine receptors 
are related to the capacity to modulate neurotransmitters release, synaptic 
transmission, and plasticity, as well as, to modulate other receptors and 
molecules, such as neurotrophins, DA receptors, cannabinoid receptors, 
NMDAR, and mGluR5 receptors (Ferré and Sebastião, 2016; Ribeiro and 
Sebastião, 2010; Sarantis et al., 2015; Sebastião and Ribeiro, 2009; Tebano 
et al., 2005, 2008). Moreover, the unbalance of A1R and A2AR levels has 
been associated with changes in the transduction mechanisms associated 
with these receptors (Lopes et al., 1999b). In aged rats, A2AR dependent 
activation of glutamate release becomes more pronounced and shifts from 
a PKC mediated signaling to PKA/cAMP/CREB dependent effects (Li et 
al., 2015; Lopes et al., 1999b, 2002; Rebola et al., 2003), leading to 
intracellular Ca2+ increase and hippocampal-dependent cognitive deficits 
(Batalha et al., 2016). In young adult animals this effect is dependent on 
A1R activation, however, when A1R are blocked in old animals, no 
changes are observed, revealing that these effects are no longer being 
mediated by A1R (Lopes et al., 1999b). Conversely, A2AR blockade, either 
with caffeine or selective A2AR antagonists (SCH 58261, KW-6002 or 
MSX-3), affords neuroprotection in models of epilepsy, depression, AD 
and PD (Arendash et al., 2006; Cunha et al., 2008; Dall’Igna et al., 2007; 
Laurent et al., 2014; Viana da Silva et al., 2016), prevents hippocampal-
dependent memory deficits and LTP impairments in aged animals (Costa 
et al., 2008; Prediger et al., 2005), and markedly reduce cerebral ischemic 
damage in animal models of focal and global ischemia. Furthermore, 
knocking-out A2AR rescues stress and AD-related synaptic dysfunction 
(Kaster et al., 2015; Laurent et al., 2014).  
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Therapeutic Potential of A2AR in Parkinson’s Disease 
The interest in de adenosine system mostly stems from the recognition that 
its main function is to assist in maintaining homeostasis in biological 
systems. In pathological conditions, this adenosinergic system is often 
impaired. Hence, it can be considered a system of choice to manipulate 
brain circuits in order to restore their proper function. As mentioned 
before, several studies show an overactivation and overexpression of A2AR 
in aging and in different deleterious brain conditions such as PD, as so, the 
blockade of these receptors has been proposed to be therapeutically useful 
in these situations (Cunha et al., 1995; Diógenes et al., 2007; Lopes et al., 
1999a). Moreover, epidemiological studies show an inverse relation 
between the consumption of caffeine and the risk of developing PD and 
memory disruption during aging, AD and PD (Arendash and Cao, 2010; 
Ascherio et al., 2001; Eskelinen et al., 2009; Flaten et al., 2014; Maia and 
de Mendonça, 2002; Ritchie et al., 2007). More recently, polymorphisms 
in the human A2AR gene (ADORA2A) have been linked to a reduced risk 
of PD (Popat et al., 2011). As such, adenosine A2AR emerged as a potential 
target for the treatment of PD, and several lines of research focusing on the 
different properties and roles of A2AR arose, namely: (1) the role of A2AR 
in the control of neurodegeneration in several noxious brain conditions and 
neurodegenerative disorders; (2) their role in controlling dopamine D2 
signaling and consequently motor function; and (3) the A2AR effects on 
memory and cognition. These three lines of evidence are discussed below. 
 
A2AR and neuroprotection. One of the major limitations of the current 
pharmacological treatment of PD is represented by its substantial 
ineffectiveness in halting neuronal degeneration. According to the 
classical view of neuronal damage as resulting from glutamate 
excitotoxicity (Mattson, 2003), it has been emphasized that the blockade 
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of A2AR may potentially represent a valuable approach in counteracting 
neurodegeneration in PD. In fact, A2AR pharmacological blockade or 
genetic deletion has been associated with neuroprotective effects in several 
animal models of PD, namely toxin-induced models, MPTP,  6-
hydroxydopamine (6-OHDA), and rotenone models (Bové et al., 2005; 
Chen et al., 2001a; Ikeda et al., 2002; Pierri et al., 2005; Schwarzschild et 
al., 2003; de Souza et al., 2017). These studies demonstrate that A2AR is 
involved in the degeneration of the dopaminergic neurons projecting from 
SN onto the striatum. In alignment, A2AR have also been proposed to play 
an instrumental role in aSyn-mediated neurodegeneration. In this study, 
aSyn-induced damage to striatal neurons was clearly reduced in A2AR KO 
mice (Kachroo and Schwarzschild, 2012). 
Despite the neuroprotection elicited by A2AR antagonists clearly 
manifested in different PD animal models, the neuronal mechanism 
underlying this effect, or the impact to other brain areas, namely cognitive 
associated areas, have not yet been ascertained. Possible mechanisms 
underlying neuroprotection include the normalization of glutamatergic 
synapses by A2AR blockade. This is due to a combined ability of A2AR to 
facilitate the release of glutamate and the activation of NMDAR. 
Furthermore, A2AR also control glia function and brain metabolic 
adaptation, two other emerging mechanisms to understand PD 
pathogenesis. In addition, neuroprotection also depends on the ability of 
A2AR to control mitochondria-induced apoptosis. Thus, A2AR might not 
only control the trigger of neuronal dysfunction of brain circuits (e.g. 
glutamate excitotoxicity) but also their main system of amplification (e.g. 
neuroinflammation and metabolic imbalance) as well as their main effector 
system (e.g. apoptotic-induced neuronal damage). Therefore, A2AR are 
now conceived as a normalizing device promoting adequate adaptive 
responses in neuronal circuits. This makes A2AR particularly attractive to 
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manage early synaptic dysfunction in PD and cognitive-associated deficits, 
considered one of the most disabling symptoms of PD. 
To date, no clinical studies have demonstrate A2AR neuroprotective 
effects. However, as previously mentioned, epidemiological studies 
consistently show a lower risk of developing PD in individuals that 
regularly consume caffeine throughout their lifetime (Ascherio et al., 
2001). A randomized controlled trial also demonstrated that treating PD 
patients with caffeine improved objective motor measures (Postuma et al., 
2012). Beneficial effects prompted by caffeine have been largely attributed 
to A2AR antagonism at dosages equivalent to 3-5 mg/kg. 
In sum, direct evidence of neuroprotection mediated by A2AR 
antagonist in experimental animal models, as well as data from 
epidemiological studies, provide new insights into the study of the 
antiparkinsonian potential of the drugs. Yet, the ability of A2AR to impact 
on brain tissue damage is still a matter of a hot debate and whether A2AR 
antagonists can be considered as neuroprotective or not, still needs further 
clarification and a direct evidence in humans. 
 
A2AR as targets for PD motor symptoms. Probably the most exhaustive 
documentation of the use of A2AR antagonists in PD, namely in PD motor 
symptoms, was prompted by the particularly high abundance of A2AR in 
the basal ganglia (Fredholm et al., 2005; Schiffmann et al., 2007). In this 
particular case, targeting adenosine A2AR first arose based on its tight 
physical and functional interaction with dopamine D2 receptors in the 
striatum. In fact, one of the main actions of A2AR is the control of 
dopaminergic signaling, which plays a key role in striatal signal processing 
and thus in motor control (Schiffmann et al., 2007). A2AR and D2 receptors 
have opposing effects on cAMP production in cells, such that activation of 
A2AR inhibits dopamine D2 receptor signaling. Conversely adenosine 
A2AR antagonists have been shown to enhance D2 dependent signalling 
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(Shook and Jackson, 2011). These drugs provide benefit by inhibiting the 
overactive striatopallidal pathway (Hauser and Schwarzschild, 2005). In 
accordance, several studies show that A2AR blockade improves motor 
function in different rodent and primate models of PD (Armentero et al., 
2011; Morelli et al., 2009; Pinna, 2014) and tends to attenuate dyskinesia 
(Cunha, 2016; Xiao et al., 2006). Nevertheless, the role of central A2AR is 
now viewed as much broader than just controlling D2 receptor function. It 
is now clear that A2AR can control motor function in the absence of 
dopaminergic signaling (Chen et al., 2001b; Shiozaki et al., 1999). This 
indicates that striatal A2AR work through dopamine-independent 
mechanisms to impact on brain function. The concept of dopamine-
independent effects of A2AR function is particularly relevant in the case of 
extra-striatal A2AR, where dopaminergic signaling is far less intense 
(Bastia et al., 2005; Huang et al., 2006; Xiao et al., 2006). Studies 
identified a critical role of A2AR in extra-striatal neurons in providing a 
prominent excitatory effect on psychomotor activity (Shen et al., 2008). 
These extra-striatal receptors were shown to be located in glutamatergic 
synapses, including striatal glutamatergic terminals, and control both the 
release of glutamate as well as NMDAR (Lopes et al., 2002; Marchi et al., 
2002; Rebola et al., 2005a, 2008). Thus, a major role of A2AR is to 
normalize the functioning of glutamatergic synapses which dysfunction 
seems a common feature of many chronic brain diseases. This view comes 
in line with the robust neuroprotection afforded by A2AR blockade 
previously discussed.  
 
A2AR and cognitive function. Consumption of coffee is well documented 
to increase alertness and there is a trend to consider that caffeine improves 
performance and cognition, especially in situations of cognitive 
impairment (Chen et al., 2007; Cunha, 2005; Sawyer et al., 1982; 
Takahashi et al., 2008). Several data show that caffeine and selective 
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adenosine A2AR antagonists can improve memory performance in rodents 
evaluated through different tasks. The effects of A2AR on memory are 
further substantiated by the ability of A2AR to impact working memory 
(Chen, 2014) and reference memory performance (Cunha and Agostinho, 
2010). In fact, in experimental models of aging, chronic stress, early stages 
of Huntington’s disease, deficit hyperactivity disorder (ADHD), diabetic 
encephalopathy, early life convulsions, AD, and PD, pharmacological or 
genetic blockade of A2AR impedes memory deterioration and can enhance 
cognitive function (Bara-Jimenez et al., 2003; Batalha et al., 2013; Canas 
et al., 2009; Dall’Igna et al., 2007; Kaster et al., 2015; Laurent et al., 2016; 
Li et al., 2015; Lopes et al., 2011; Prediger et al., 2005).  
Importantly, this ability of A2AR blockade to improve both motor 
and cognitive functions in animal models of neurological disorders, was 
shown to correlate with neuroprotection not only in the SNc and striatal 
areas but also in extra-striatal brain regions. Consequently, A2AR activity 
in brain may achieve the modulation of cognitive function, particularly 
those associated with degenerative disorders, through its control of 
neuronal death in extra-striatal brain areas.  
 
Clinical testing of adenosine A2AR-based therapies. In recent years, 
there has been a wide array of adenosine-based therapies testes in both 
preclinical and clinical research for multiple diseases. Clinical trials in PD 
patients showed that the selective A2AR antagonist KW-6002, also known 
as istradefylline, reduces the OFF time and potentiates motor improvement 
when co-administered with low doses of L-DOPA (levodopa) (Kadowaki 
Horita et al., 2013; Kondo et al., 2015; LeWitt et al., 2008; Mizuno et al., 
2010; Pinna, 2014; Uchida et al., 2014). The proposed advantage of this 
strategy is a reduction in the required dose of L-DOPA, with concomitant 
reductions in the associated side effects, consisting mainly of dyskinesias 
and progressive cognitive impairment  (Armentero et al., 2011). Likewise, 
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other A2AR antagonists, namely tozadenant and preladenant, also 
ameliorate the off time and dyskinesia in PD patients under L-DOPA 
therapy (Factor et al., 2013; Hauser et al., 2014, 2015). Table 1 outlines 
examples of recent clinically tested adenosine A2AR-based therapies, their 
mechanisms of action, and the success of the trial. 
Although several successes have been reported (Atack et al., 2014; 
Kadowaki Horita et al., 2013; Kondo et al., 2015; Pinna, 2014; Pugliese et 
al., 2009; Uchida et al., 2014; Yuzlenko and Kieć-Kononowicz, 2006), 
many drugs have failed in clinical trials. At this moment, no clinical trial 
on adenosine-based therapy is ongoing, but istradefylline is already 
approved in Japan as an adjunctive treatment for PD (Dungo and Deeks, 
2013; Kondo et al., 2015; Mizuno et al., 2010; Uchida et al., 2014). 
Nevertheless, the introduction of A2AR antagonists in clinics as anti-
parkinsonian agents is hoped to bolster our knowledge on the role of A2AR 
in PD pathology, and consequently open new windows to tackle motor 
dysfunction and, more importantly, cognitive deficits, which represent 
now one of the major unmet needs in PD.  
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Table 1. Name, mechanism of action (MOA), use in clinical trials and 
respective references (Ref) of adenosine A2AR antagonists. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 (Postuma et al., 2012); 2, 3, 4, 5 (Armentero et al., 2011; Dungo and Deeks, 2013; 
Mizuno et al., 2010; Rauck et al., 2015); 6, 7 (Hattori et al., 2016; Hauser et al., 2015); 
8, 9, 10 (Hauser et al., 2014; Lane et al., 2012; Moeller et al., 2012)  
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Aim 
Research conducted in the last two decades provided important advances 
into molecular players and pathways involved in PD and other 
synucleinopathies, but still, there is much to understand and discover. The 
precise mechanisms involved in PD progression, the molecular basis of 
cognitive deficits, and the pathological role of its major culprit, aSyn, are 
unclear.  
Novel approaches to PD therapy are sought, and adenosine A2AR 
emerged as a attractive target for the treatment of both motor and non-
motor symptoms. However, the precise molecular mechanisms underlying 
potential neuroprotection and the effects of A2AR on early cognitive 
impairments driven by aSyn, remain unknown. 
In this context, the work described in this thesis aimed to explore 
the pathological underpinnings of aSyn-associated synaptic dysfunction 
and neuronal death and gain insight into the novel concept of a crosstalk 
between aSyn and A2AR, specifically focusing on the early stages of the 
disease and cognitive-associated brain areas. In order to accomplish this 
general aim, three specific tasks were designed: 
I. Explore the ability of A2AR to modulate aSyn-mediated 
synaptic dysfunction, oligomerization and aggregation, and 
lastly, neuronal death.  
II. To clarify the molecular pathways involved in aSyn-driven 
toxicity and identify novel key molecular players here 
involved. 
III. To assess whether the in vivo pharmacological blockade of 
A2AR constitutes a valid strategy for treating early synaptic 
impairments and cognitive deficits, using an aSyn mice model.  
 
  
 
  
  
   
 
 
 
 
 
 
 
 
Chapter II 
Adenosine A2A Receptors Modulate aSyn 
Aggregation and Toxicity 
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Abstract 
Abnormal accumulation of aggregated alpha-synuclein (aSyn) is a 
hallmark of sporadic and familial Parkinson's disease (PD) and related 
synucleinopathies. Recent studies suggest a neuroprotective role of 
adenosine A2A receptor (A2AR) antagonists in PD. Nevertheless, the 
precise molecular mechanisms underlying this neuroprotection remain 
unclear. 
We assessed the impact of A2AR blockade or genetic deletion 
(A2AR KO) on synaptic plasticity and neuronal cell death induced by aSyn 
oligomers. We found that impairment of LTP associated with aSyn 
exposure was rescued in A2AR KO mice or upon A2AR blockade, through 
a NMDA receptor-dependent mechanism. The mechanisms underlying 
these effects were evaluated in SH-SY5Y cells overexpressing aSyn and 
rat primary cortical cultures exposed to aSyn. Cell death in both conditions 
was prevented by selective A2AR antagonists. Interestingly, blockade of 
these receptors did not interfere with aSyn oligomerization, but, instead, 
reduced the percentage of cells displaying aSyn inclusions. 
Altogether, our data raise the possibility that the well-documented 
effects of A2AR antagonists involve the control of the latter stages of aSyn 
aggregation, thereby preventing the associated neurotoxicity. These 
findings suggest that A2AR represent an important target for the 
development of effective drugs for the treatment of PD and related 
synucleinopathies. 
 
Keywords: α-Synuclein, adenosine A2A receptors, hippocampus, 
neuroprotection, Parkinson’s disease. 
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Introduction 
Parkinson’s disease (PD) is a progressive and chronic neurodegenerative 
disorder characterized by the loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNc), which underlies the classical motor 
symptoms of the disease (Jankovic, 2008). Another important 
neuropathological hallmark of the disease is the presence of intraneuronal 
inclusions known as Lewy bodies (LB) and Lewy neurites (LN; Braak et 
al., 2003). These deposits occur early in the disease process and are 
accompanied by progressive neuronal dysfunction and, eventually, the 
death of the afflicted neuronal populations (Braak and Del Tredici, 2008). 
Behavioral and cognitive deficits are concomitant with these pathological 
changes (Turner, 2002). In fact, the accumulation of LB and LN is not 
restricted to the SN but is extended to several brain areas including those 
related to memory, such as the hippocampus and cortex (Braak et al., 2004; 
Mattila et al., 2000; Spillantini et al., 1997). Moreover, recent post-mortem 
studies in PD patient brains suggest a correlation between cognitive 
deficits or dementia and the accumulation of cortical LB (Braak et al., 
2005; Caviness et al., 2011; Kövari et al., 2003). These inclusions are 
mainly composed of fibrillar aggregates of aSyn, a neuronal presynaptic 
protein associated with both familial and sporadic forms of PD (Hamza et 
al., 2010; Satake et al., 2009; Simón-Sánchez et al., 2009). 
Recently, adenosine A2A receptors (A2AR) emerged as an attractive 
non-dopaminergic target for the treatment of motor and non-motor 
symptoms (MS; NMS) of PD. Anti-parkinsonian actions are achieved 
through the blockade of this receptor, whose expression and function 
become aberrant throughout aging and in age-related pathologies, 
including the early stages of PD (Lopes et al., 1999a; Varani et al., 2010; 
Villar-Menéndez et al., 2014). This strategy was also proven beneficial in 
other diseases associated with neuronal dysfunction, such as epilepsy, 
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acute and chronic stress and Alzheimer’s disease (AD; Batalha et al., 2013; 
Canas et al., 2009; Cunha, 2005; Laurent et al., 2014a). In addition, 
epidemiological studies show an inverse correlation between the 
consumption of caffeine, an A2AR antagonist, and the risk of developing 
PD (Ascherio et al., 2001). 
Furthermore, A2AR deregulation was suggested to play an important 
role in aSyn mediated neurotoxicity, since aSyn induced damage to striatal 
neurons was clearly reduced in A2AR KO mice (Kachroo and 
Schwarzschild, 2012). However, the extent to which A2AR are involved in 
aSyn-associated toxicity, the underlying protective molecular 
mechanisms, or the impact on other brain areas are still unknown. 
Therefore, the purpose of this study was to gain insight into the novel 
concept of a crosstalk between aSyn and A2AR and to explore the ability 
of A2AR to modulate aSyn-mediated synaptic dysfunction, formation of 
inclusions, and neuronal death. To test these hypotheses, we first assessed 
the functional outcomes of the pharmacological blockade or genetic 
deletion of A2AR on rodent hippocampal slices exposed to extracellular 
aSyn oligomers. Then, we set out to determine how A2AR affect aSyn-
mediated cell death, and more importantly, whether modulation of A2AR 
function impacts on aSyn aggregation and oligomerization.  
Here, we show for the first time that selective adenosine A2AR 
antagonists rescue both exogenous and endogenous aSyn-associated cell 
death. In addition, we found that A2AR modulation alters the formation of 
aSyn inclusions in cultured cells. Furthermore, the toxic effects of aSyn 
oligomers on synaptic function are fully prevented by A2AR blockade or 
deletion, through a mechanism dependent on NMDA receptor (NMDAR). 
These findings suggest that A2AR represent an important target for the 
development of effective drugs for the treatment of PD and related 
synucleinopathies. 
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Results 
A2AR blockade rescues neuronal cell death induced by 
exogenous aSyn oligomers  
First, we compared the effect of different aSyn species on rat primary 
hippocampal cultures. Cells were incubated with either monomeric or 
oligomeric aSyn preparations for different time periods. The confirmation 
of the biochemical properties of the different species was performed by 
SDS-PAGE/immunoblot analysis, revealing that monomers migrated with 
a typical molecular weight of ~15 kDa (monomeric molecular weight of 
aSyn) while oligomeric forms migrated with an apparent molecular weight 
of >30 kDa and <180 kDa (Fig. 2.1d). We found no significant 
cytotoxicity in cells treated with either aSyn species (500 nM) for 90 min, 
as assessed by PI and Syto-13 staining. Conversely, we found that after 24 
h of exposure there was a robust increase in neuronal cell death upon 
incubation with aSyn oligomers (cell viability CTR = 68.7 ± 4.6%; cell 
viability aSyn olig, 24h = 35.5 ± 3.1%; n = 4; P < 0.001; Fig. 2.1a, b), while 
monomeric species had no effect on cell viability.  
We next investigated whether adenosine A2AR could attenuate the 
neurotoxic effects induced by exposure to aSyn oligomers. The blockade 
of A2AR, using the selective antagonists SCH 58261 (50 nM) or ZM 
241385 (50 nM), significantly reduced neuronal cell death induced by 
aSyn oligomers, resulting in levels similar to control (cell viability SCH 58261 
+ aSyn olig, 24h = 70.6 ± 4.3%; cell viability ZM 241385+ aSyn olig, 24h = 69.7 ± 3.2%, 
n = 4; P < 0.001 vs. CTR; Fig. 2.1a, c).  
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Figure 2.1. Neuronal death induced by extracellular aSyn oligomers is 
prevented by A2AR blockade. (a) Representative images of hippocampal 
cultures labeled with propidium iodide (PI) and Syto-13 in (i) control 
conditions (CTR), (ii) after 24 h incubation with aSyn monomers (aSyn mon, 
500 nM), (iii) or with aSyn oligomers (aSyn olig, 500 nM) alone or in the 
presence of the selective A2AR antagonists, (iv) SCH 58261 (50 nM) or (v) 
ZM 241385 (50 nM). Scale bar: 50 µm. (b) Cell viability upon incubation with 
extracellular aSyn mon or olig. Only 24 h incubation with aSyn olig leads to 
a decrease in cell viability compared to CTR. (c) Rescue of cell viability after 
exposure to aSyn olig for 24 h by the selective A2AR antagonists, SCH 58261 
(50 nM) or ZM 241385 (50 nM). (d) SDS-PAGE separation of the different 
aSyn species (monomers and oligomers). Monomers migrate with monomeric 
molecular weight (15 kDa) whereas aSyn oligomers display SDS-resistant 
high molecular weight species. P < 0.001. Cell viability is presented as the 
percentage of living cells compared to the number of total cells counted. All 
values are mean ± SEM of 4 independent experiments. 
 
 
 
a 
b c d 
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Pharmacological or genetic blockade of A2AR prevents LTP 
impairment induced by aSyn oligomers 
We have previously demonstrated that aSyn oligomers, but not monomers 
or fibers, impair synaptic plasticity and increase basal synaptic 
transmission through NMDAR activation (Diógenes et al., 2012). Thus, 
we next set out to investigate the role of A2AR on this impairment of 
synaptic function. For this, we pre-incubated rat hippocampal slices with 
aSyn oligomers together with the selective A2AR antagonist SCH 58260 
(50 nM, 110 min; Fig. 2.2a), and induced LTP in Schaffer-collaterals/CA1 
pyramid glutamatergic synapses by theta burst stimulation. The LTP 
amplitude was significantly reduced in slices pre-incubated with aSyn 
oligomers (500 nM, 90 min) when compared to control slices (LTPCTR = 
58.1 ± 7.4%; LTPaSyn olig = 7.7 ± 2.3%; n = 9; P < 0.001; Fig. 2.2b, d). 
When A2AR were blocked by SCH 58261, the LTP magnitude was 
reestablished to control values (LTPSCH 58261+ aSyn olig = 50.6 ± 13.0%; n = 
5; P < 0.01 vs. LTPaSyn olig; Fig. 2.2b, d). SCH 58261 alone did not affect 
LTP magnitude (LTP SCH 58261 = 52.5 ± 10.6%; n = 5; P < 0.05 vs. LTPCTR; 
Fig. 2.2b, c). 
To assess the role of A2AR on NMDAR mediated effects, we 
evaluated the effect of the NMDAR antagonist APV (50 μM) on basal 
synaptic transmission. As expected, APV did not modify the fEPSP slope 
in control slices (Fig. 2.2f). In contrast, the acute application of APV 
induced a progressive reduction of the fEPSP in aSyn oligomer-treated 
slices (fEPSPCTR = 100.0 ± 1.2%; fEPSPaSyn olig = 87.6 ± 2.1%; n = 6-7; P 
< 0.001; Fig. 2.2e,f), in agreement with the previously reported impact of 
oligomeric aSyn on NMDAR (Diógenes et al., 2012). Interestingly, when 
slices were pre-incubated with SCH 58261 together with aSyn oligomers, 
the effect of the NMDAR antagonist was prevented (fEPSPSCH 58261+ aSyn 
olig = 94.8 ± 1.0%; n = 4; P < 0.05 vs. fEPSPaSyn olig; Fig. 2.2e, f). 
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Accordingly, we observed an increase in NMDAR subunit 2B 
(NMDAR2B; 137.9 ± 9.4%; n = 3; P < .005 vs CTR; Fig. 2.2h) in slices 
exposed to aSyn, but not in NMDAR subunit 1 (NMDAR1). This increase 
was prevented by co-incubation with SCH 58261 (95.1 ± 11.9%; n = 3; P 
< .005 vs CTR; Fig. 2.2h). SCH 58261 alone did not alter NMDAR2B. 
In order to evaluate whether A2AR blockade also rescued baseline 
synaptic efficiency, input/output (I/O) curves were recorded. Slices pre-
incubated with aSyn oligomers alone showed a shift to the left in the I/O 
curve, as previously described (Diógenes et al., 2012). SCH 58261 co-
incubation did not change this aSyn-induced effect (Fig. 2.2g).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. A2AR blockade rescues LTP impairment induced by 
extracellular aSyn oligomers. (a) Schematic representation of hippocampal 
slices incubation protocol. (b) Representative traces (1) prior and (2) after LTP 
induction, composed of the stimulus artifact followed by the presynaptic 
volley and the fEPSP. (C) Changes in fEPSP slope upon LTP induced by 
theta-burst stimulation from hippocampal rat slices (CTR: control; aSyn olig: 
a c d 
b 
e 
h 
f g 
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after pre-incubation with aSyn oligomers, 500 nM, 90 min; aSyn olig + SCH 
58261: after incubation with aSyn oligomers in the presence of the A2AR 
antagonist, SCH 58261, 50 nM, 110 min). SCH 58261 rescued LTP 
impairment induced by aSyn oligomers. P < 0.01. (d) LTP magnitude after 
theta-burst stimulation (change in fEPSP slope at 50–60 min). (e) Effect of 
NMDAR antagonist APV (50 µM, 30 min) superfusion on basal fEPSP slope. 
SCH 58261 prevented the effect of aSyn oligomers on NMDAR contribution 
to basal synaptic transmission. P < 0.05. (f) Quantification of the effects 
observed in (e) (change in slope between baseline and the last 10 min of APV 
application). (g) Input/Output (I/O) curves corresponding to fEPSP slope 
evoked by different stimulation intensities (60 – 300 µA). Slices co-incubated 
with aSyn olig and SCH 58261 displayed higher Emax values when compared 
with control slices, similar to what was observed with aSyn olig alone. (h) Co-
immunoprecipitation of PSD-95 in hippocampal slices. NMDAR2B are 
enriched in aSyn olig pre-incubated slices while co-incubation with SCH 
58261 reestablished NMDAR2B subunit levels. NMDAR1 levels were not 
changed in any condition. Values were normalized to PSD-95. IgG was used 
as a negative control (Neg CTR). P < 0.05. All values are mean ± SEM of 3-
9 independent experiments. 
 
We then assessed the synaptotoxic effects of aSyn oligomers on 
hippocampal slices from A2AR KO mice. Remarkably, aSyn oligomers 
(500 nM, 90 min) failed to impair LTP in A2AR KO mice (LTPCTR = 34.3 
± 6.9%; LTPaSyn olig = 31.2 ± 4.2%; n = 3; P < 0.05; Fig. 3D-E), in contrast 
to the significant effect in WT mice (LTPCTR = 64.43 ± 14.2%, n = 4; 
LTPaSyn olig = 10.9 ± 12.9%; n = 3; P < 0.05; Fig. 2.3a, b). As observed in 
rat hippocampal slices, aSyn oligomers also increased basal synaptic 
excitability, as observed by the shift to the left of the I/O curve, both in 
WT and A2AR KO mice (Fig. 2.3c, f). 
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Figure 2.3. A
2A
R deletion fully prevents LTP impairment induced by 
extracellular aSyn oligomers. (a) Changes in fEPSP slope induced by theta-
burst stimulation recorded from WT mice hippocampal slices in control 
conditions (CTR) or in the presence of aSyn oligomers (aSyn olig, 500 mM, 
90 min). (b) Changes in fEPSP slope induced by theta-burst stimulation 
recorded from global A
2A
R KO mouse hippocampal slices in control 
conditions or in the presence of aSyn oligomers (aSyn olig). Genetic deletion 
of A2AR prevented LTP impairment induced by aSyn olig in WT mice slices. 
(c) Plot of the LTP magnitude (change in fEPSP slope at 50–60 min 
comparing to baseline) from (a). (d) Plot of the LTP magnitude from 
experiments shown in (b). (e) I/O curves from WT hippocampal slices, 
corresponding to fEPSP slope evoked by various stimulation intensities (400 
a 
b 
d 
e 
c f 
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–700 µA) in control conditions and upon pre-incubation with aSyn oligomers. 
(f) I/O curves from A2AR KO hippocampal slices obtained by the same method 
as in (e). aSyn oligomers have a comparable effect both in WT or in A2AR KO 
mice. All values are mean ± SEM of 3-4 independent experiments. 
 
A2AR blockade rescues cell death induced by endogenous 
aSyn  
To evaluate the role of A2AR on the toxicity induced by intracellular aSyn, 
we used an established Dox-inducible (tet-off) neuroblastoma cell model 
that we verified to express A2AR (Supplementary Fig. 2.1a).  Maximal 
aSyn expression was reached at 12 days after Dox removal 
(Supplementary Fig. 2.1b) and, at this time point, we found a significant 
decrease in cell viability compared to control cells in the presence of Dox 
(+Dox) (cell viability+Dox CTR = 91.6 ± 1.5 %; cell viability–Dox CTR = 68.7 
± 1.6%; n = 8-9; P < 0.001; Fig.  2.4a, b); the A2AR mRNA or protein 
levels were not altered (Supplementary Fig. 2.1c, d). This toxicity was 
completely prevented by a 24 h treatment with the selective A2AR 
antagonists, SCH 58261 or ZM 241385 (cell viability–Dox+SCH 58261 = 87.1 
± 5.1%; cell viability-Dox+ZM 241385 = 84.8 ± 5.5%; n = 4-7; P < 0.01 vs. 
+Dox CTR; Fig. 2.4a, b). Furthermore, activation of A2AR with the 
selective A2AR agonist CGS 21680 (30 nM) in control cells in the presence 
of Dox, resulted in cytotoxicity, mimicking aSyn overexpression (-Dox 
CTR) (Fig. 2.4c). Importantly, these effects were not due to changes in 
aSyn levels induced by the different treatments (Supplementary Fig. 
2.1e). 
Next, we investigated if NMDAR were involved in this effect. When 
NMDAR were blocked by APV alone, the toxicity induced by 
overexpression of aSyn (-Dox; Fig. 2.4a, c) was completely rescued (cell 
viability-Dox+APV = 92.5 ± 1.7%; n = 4; P < 0.001 vs. -Dox CTR). This effect 
is the same of that observed upon A2AR blockade. Consistently, blockade 
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of NMDAR also prevented toxicity induced by direct A2AR activation with 
CGS 21680 (Fig. 2.4a, c).  
 
 
 
Figure 2.4. A2AR blockade rescues SH-SY5Y cell toxicity induced by 
increased levels of endogenous aSyn. (a) Representative images of 12 days 
in vitro (DIV) tet-off SH-SY5Y cells labeled with PI and Syto-13 (i) in the 
presence (ii) or absence of doxycycline (Dox; 2 µg/mL) and (iii-vi) under 
different treatments. Scale bar: 50 µm. (b) Cell viability with different cell 
treatments. The overexpression of aSyn, induced by the absence of Dox (-
Dox), lead to a decrease in the number of viable cells, which was prevented 
by the selective A2AR antagonists, SCH 58261 (50 nM) or ZM 241385 (50 
nM). (c) Impact of the A2AR agonist, CGS 21680 (30 nM) on cell viability.  
The treatment of control cells (CTR +Dox) with the A2AR agonist, lead to a 
similar decrease in cell death as observed in aSyn overexpressing cells (CTR 
-Dox); this increase in cell death was prevented in both conditions upon 
a 
b 
c 
d 
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treatment with the NMDAR antagonist, APV (50 µM). (d) Impact of the A1R 
selective antagonist, DPCPX (50 nM) on cell viability. The treatment with the 
DPCPX induced a similar decrease in cell viability either in CTR +Dox or 
aSyn overexpressing cells (CTR -Dox). Cell viability is presented as the ratio 
between the number of living cells and the number of total cells counted. P < 
0.01. All values are mean ± SEM.  
 
To rule out any possible contribution of the more abundant 
adenosine receptor, A1R, to the aSyn-induced effects, we selectively 
blocked this receptor (DPCPX; 50 nM).  
DPCPX alone (50 nM) reduced cell viability by 20%, as expected 
(Valadas et al., 2012). A1R are not involved in aSyn induced toxicity since 
this reduction was similar in either Dox+ or Dox- cells (Fig. 2.4d). 
Moreover, the effect of A2AR activation by CGS 21680 is independent of 
A1R, being maintained even under A1R blockade (+Dox plus 
DPCPX+CGS). Finally, the increase in cell viability achieved by A2AR 
blockade (ZM 241385) in Dox- cells is still present even under A1R 
blockade (Fig. 2.4d). 
 
A2AR blockade does not affect aSyn oligomerization 
We next evaluated whether A2AR affected the initial events of aSyn 
aggregation, by monitoring the ability of aSyn to oligomerize, using a 
stable cell model of aSyn dimerization/oligomerization based on BiFC 
(Outeiro et al., 2008) (Fig. 2.5a). We found that aSyn formed oligomers in 
H4 control cells (CTR; Fig. 2.5c) and no significant differences in the 
oligomerization pattern was detected upon A2AR modulation, as assessed 
by Venus fluorophore reconstitution (Fig. 2.5b, c). This lack of effect does 
not stem from a reduced dynamic range, as we have previously validated 
the reversibility of the system in response to multiple conditions (Outeiro 
et al., 2008; Zondler et al., 2014).  
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Figure 2.5. A2AR modulators do not change aSyn dimerization in living 
cells using Bimolecular Fluorescence Complementation (BiFC) assay. (a) 
Schematic representation of the BiFC assay. aSyn BiFC constructs in an anti-
parallel orientation. (b) Quantification of the mean fluorescence intensity of 
cells showing no significant difference in cells treated with the A2AR 
antagonists ZM 241385 (50 nM) or SCH 58261 (50 nM) nor with the A2AR 
agonist CGS 21680 (30 nM). Results were normalized to control condition 
(CTR). All values are mean ± SEM of 5 independent experiments. (c) 
Representative images of H4 cells with different treatments. Scale bar: 50 µm. 
 
A2AR blockade decreases aSyn aggregation 
Finally, we asked whether A2AR affected latter steps in the process of aSyn 
aggregation. For this, we used an established model of aSyn inclusion 
formation in human neuroglioma H4 cells (Lázaro et al., 2014; McLean et 
c 
b a 
The Role of A2AR on aSyn Toxicity 
78 
al., 2001) that also express A2AR (Fig. 2.6c, d). We found that a 24-h 
treatment with the A2AR antagonist ZM 241385 (50 nM) significantly 
reduced the percentage of cells displaying aSyn inclusions (aSyn 
inclusionsCTR = 100.0 ± 2.9%; aSyn inclusionsZM 241385 = 81.8 ± 5.9%, n = 
3-4; P < 0.05; Fig. 2.6a, b). In contrast, activation of A2AR with CGS 
21680 (30 nM) increased the percentage of cells containing aSyn 
inclusions (aSyn inclusionsCGS 21680 = 117.3 ± 1.5%, n = 3; P < 0.05 vs. 
aSyn inclusions CTR; Fig. 2.6a, b). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. A2AR blockade decreases aSyn aggregation in a SynT-
Synphilin-1 neuroglioma cell model. (a) Representative images of H4 cells 
in (i) control conditions (CTR), (ii) incubated for 24 h with ZM 241385 (50 
nM) or (iii) CGS 21680 (30 nM). Scale bar: 50 µm. (b) ZM 241385 
significantly reduced the % of cells containing aSyn inclusions whereas CGS 
21680 increased the % of cells with inclusions, compared with control cells. 
Results are expressed as the percentage of the total number of transfected 
cells. P < 0.05. All values are mean ± SEM of 3 independent experiments. (c) 
qPCR products of A2AR (245 bp) in H4 cells, β-actin (233 bp) was used as 
housekeeping control and RT-minus control yielded no appreciable bands in 
the expected band size for the primers used. (d) Western blot showing A2AR 
expression in H4 cells. 
a b 
c 
d 
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Discussion 
We have gathered evidence indicating that A2AR play an important role in 
modulating the deleterious effects of aSyn. Here, we show, for the first 
time, that selective A2AR antagonists are able to rescue both exogenous 
and intracellular aSyn-mediated cyto- and neurotoxicity. Furthermore, 
pharmacological and genetic inactivation of A2AR fully prevents the aSyn-
mediated toxic effects on synaptic function. This neuroprotective effect 
afforded by A2AR inhibition is due to the reestablishment of glutamate 
NMDAR signaling. Finally, we found that A2AR antagonists are also able 
to decrease the number of aSyn aggregates, which might explain their 
protective effects on aSyn-associated synaptic dysfunction and neuronal 
death.  
aSyn aggregation and progressive neuronal cell death are the 
neuropathological hallmarks of several neurodegenerative disorders 
known as synucleinopathies (Marques and Outeiro, 2012). However, the 
precise molecular mechanisms underlying the process of aSyn aggregation 
and the exact nature of the toxic species produced during aggregation 
remain unclear. aSyn is a soluble protein expressed ubiquitously in the 
CNS, including the cerebral cortex, hippocampus, amygdala, and olfactory 
bulb (Abeliovich et al., 2000; Maroteaux and Scheller, 1991). Under 
pathological conditions, this protein exhibits a propensity to misfold and 
aggregate, first into small oligomeric species that are rich in β-sheet 
structure, and then into higher molecular weight insoluble fibrils (Lashuel 
et al., 2012; Spillantini et al., 1998). As reported for amyloid-beta (Aβ) 
plaques in AD, soluble oligomeric species are thought to constitute the 
most neurotoxic species (Emadi et al., 2009; Glabe and Kayed, 2006; 
Irvine et al., 2008; Kayed et al., 2003; Martin et al., 2012; Outeiro et al., 
2008). Consistently, we observed that mature extracellular aSyn oligomers 
have the ability to induce synaptic impairment through an NMDAR-
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dependent mechanism (Diógenes et al., 2012). We now report that 
exposure to aSyn oligomers causes damage in primary cortical cultures, 
ultimately leading to neuronal death. In contrast, aSyn monomers have no 
effect. 
An imbalance in adenosine levels in the brain together with an 
abnormal function and increased A2AR levels, which facilitates 
excitotoxicity and consequent neuronal death, has been reported in 
multiple conditions such as ischemia, stress, epilepsy, AD and PD (Batalha 
et al., 2013; Cunha et al., 2006; Latini and Pedata, 2001; Lopes et al., 
1999a; Rebola et al., 2005b; Varani et al., 2010; Villar-Menéndez et al., 
2014). Based on this idea, A2AR antagonists started emerging as promising 
candidates in modulating the demise of different psychiatric and 
neurological disorders, including PD. In fact, it was demonstrated that 
consumption of caffeine, a non-specific A2AR antagonist, reduces the risk 
of developing PD (Ascherio et al., 2001). Indeed, polymorphisms in the 
human A2AR gene (ADORA2A) are linked to a reduced risk of Parkinson’s 
disease (Popat et al., 2011). The specific blockade of these receptors was 
shown to be protective in several Parkinson’s disease models (Aguiar et 
al., 2006; Chen et al., 2001a; Ikeda et al., 2002; Kachroo et al., 2010; Xu 
et al., 2010); including in aSyn-mediated neurotoxicity (Kachroo and 
Schwarzschild, 2012). The crossing of A2AR KO with hm
2-aSyn mice 
resulted in reduced neuronal loss, suggesting the potential involvement of 
A2AR on aSyn-associated toxicity. However, in this report, the impact of 
A2AR on aSyn oligomerization or aggregation was not determined 
(Kachroo and Schwarzschild, 2012). 
In order to clarify the molecular basis of A2AR-mediated protection 
against aSyn toxicity, we now evaluated the A2AR effect in multiple 
models of aSyn aggregation and toxicity. Our data demonstrate that the 
selective blockade or deletion of A2AR prevents both synaptic plasticity 
impairment and neuronal death induced by extracellular aSyn oligomers. 
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The ability to respond to theta-burst stimulation, when exposed to aSyn 
mature oligomers, is restored either in hippocampal slices from A2AR KO 
mice or, WT slices in the presence of a specific A2AR antagonist. As we 
have previously reported, aSyn oligomers promote an increase in basal 
synaptic transmission both by the activation of NMDAR and by the 
insertion of Ca2+- permeable AMPA receptors in the postsynaptic 
membrane (Diógenes et al., 2012), which leads to synapse saturation and 
consequent LTP impairment. Since Ca2+- permeable AMPA receptors are 
crucial for LTP maintenance (Plant et al., 2006), the complete rescue of 
LTP impairment by A2AR antagonist suggests a reestablishment of this 
AMPA impaired trafficking. In fact, it has been described that A2AR have 
the ability to modulate the membrane levels of Ca2+-permeable AMPA 
receptors (Dias et al., 2012), which can explain the observed effects. 
Furthermore, we show that the basal overactivation of NMDAR caused by 
aSyn oligomers is also prevented by A2AR blockade since NMDAR basal 
contribution is no longer observed. However, while the glutamatergic 
transmission is restored, the effects of aSyn on basal synaptic transmission 
were not rescued by A2AR blockade or in A2AR KO mice, as reflected in 
the unmodified steeper I/O curve. A2AR do not only affect glutamatergic 
transmission but can also directly enhance inhibitory GABAergic 
transmission, leading to disinhibition of pyramidal cells (Rombo et al., 
2014). A possible explanation for the lack of effect of A2AR blockade on 
the I/O curve might be due to a resulting overall excitation, caused by a 
decrease in the inhibitory GABAergic tonus.  
In addition to these effects in early synaptic dysfunction, A2AR 
antagonists were also effective in preventing subsequent neuronal death in 
neuronal cultures exposed to aSyn oligomers. Our observations are 
consistent with previous reports showing that pharmacologic or genetic 
modulation of A2AR can prevent neurotoxicity and the extent of neuronal 
damage in neurons affected by ischemia, hypoxia, stress or Aβ exposure 
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(Canas et al., 2009; Cunha, 2005; Valadas et al., 2012). To further detail 
the mechanism of A2AR action on aSyn-induced toxicity, we used an 
established SH-SY5Y cell model of endogenous aSyn accumulation 
(Vekrellis et al., 2009). Cells overexpressing aSyn for 12 DIV show 
increased cell death that is rescued by selective A2AR antagonists. 
Furthermore, if we activate A2AR in control cells (+Dox), we mimic the 
cytotoxic effects induced by aSyn accumulation (-Dox), supporting the 
idea of the involvement of A2AR overactivation on aSyn-induced cell 
death. Together these data raise the hypothesis that aSyn accumulation is 
leading to a toxic overactivation of A2AR. This can result either from, 
overexpression of A2AR in these conditions or, alternatively, to an increase 
of the endogenous ligand adenosine. The fact that overexpression of aSyn 
does not alter A2AR levels favors the latter hypothesis. Under physiological 
conditions, adenosine is tonically activating the abundant A1R and 
producing synaptic inhibition (Dittman and Regehr, 1996; Dunwiddie and 
Diao, 1994; Takahashi et al., 1995). However, in this situation, A1R do not 
seem to contribute to aSyn-induced toxicity, since when we blocked the 
receptors, we could not see any differences in cell viability upon aSyn 
accumulation. This is in accordance with different sources of adenosine 
activating A1R and A2AR (Cunha, 2008). 
Together, our results suggest that aSyn-induced cell death is 
associated with an increase in A2AR activation that mediates NMDAR 
overactivation which is a prominent synaptic event leading to 
excitotoxicity (Besancon et al., 2008). In fact, A2AR are known to increase 
NMDAR function in the hippocampus (Rebola et al., 2008), namely 
promoting Ca2+ entry through NMDAR, by (PKA)-dependent regulation 
(Higley and Sabatini, 2010). Interestingly, the same mechanisms as Ca2+ 
entry dysfunction (Martin et al., 2012) and NMDAR  activation (Diógenes 
et al., 2012) are involved in aSyn-associated neurotoxicity. This suggests 
that A2AR blockade is probably counteracting these aSyn-associated 
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effects, which then translates into the prevention of synaptic dysfunction 
and cell death. While non-neuronal A2AR have been implicated in 
neurotoxin-based PD mechanisms (such as MPTP or 6-OHDA) (Yu et al., 
2008), forebrain neuronal A2AR are critical for the control of cortico-
striatal synaptic activity. Our data reinforce the notion that counteracting 
neuronal A2AR activation has benefits, specifically against aSyn-induced 
synaptic deficits.  
Furthermore, dysfunction in Ca2+ has also been shown to increase 
aSyn propensity to form aggregates (Rcom-H’cheo-Gauthier et al., 2014) 
which are known to be associated with PD-related neurotoxicity (Conway 
et al., 2000; Karpinar et al., 2009). Based on these findings, we 
hypothesized that the observed protective effects of A2AR blockade could 
be due to the modulation of aSyn aggregation process, as also observed to 
occur for the formation of mutated ataxin-3 aggregates (Gonçalves et al., 
2013). To this end, we used two cell-based models mimicking different 
steps of the aSyn aggregation process namely dimerization/ 
oligomerization and inclusions formation (McLean et al., 2001, 2002; 
Outeiro et al., 2008). We did not detect significant differences in the 
oligomerization pattern using the BiFC assay, upon treatment with A2AR 
modulators. Since this assay does not distinguish between dimers, trimers 
and higher molecular weight aSyn oligomers (Outeiro et al., 2008), we 
cannot discard the hypothesis that A2AR modulators might interfere with 
the later stages of aggregation. Indeed, A2AR blockade decreases the 
number of aSyn inclusions in a cell model of aSyn inclusion formation, 
while their activation enhances inclusion formation. It has been reported 
that the activation of NMDAR can downregulate the ubiquitin proteasome 
system (Caldeira et al., 2013), which may consequently lead to the 
accumulation of proteins that are prone to aggregation, like aSyn. There 
are reports suggesting that A2AR can directly bind and modulate the 
activity of ubiquitin proteasome system (Chiang et al., 2009; Milojevic et 
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al., 2006). The observed changes are not associated with A2AR affecting 
directly the levels of aSyn, in accordance with previous observations from 
Kachroo and Schwarzschild et al (2012). In that study, the authors did not 
assess changes in the aggregation pattern. Here, we now report for the first 
time, that the A2AR blockade reduces the percentage of cells containing 
inclusions, using a very sensitive model that allows more accurate 
quantifications. Our results suggest that A2AR modulation does not 
interfere with the initial events leading to the formation of oligomeric 
species but, instead, may interfere with the latter stages of the aSyn 
aggregation process.  
Currently, there are multiple specific A2AR antagonists, including 
caffeine, progressing through phase II and III clinical trials for the 
symptomatic treatment of PD (Barkhoudarian and Schwarzschild, 2011). 
Thus, this class of agents is well positioned for clinical testing of their 
neuroprotective potential. The present findings strengthen the rationale for 
disease modification trials of A2AR antagonism and complement 
epidemiological data on caffeine links to a reduced risk of PD, and 
substantially broaden the potential use of A2AR as therapeutic targets in 
synucleinopathies.  
Overall, our results highlight the interplay between toxic and 
protective influences of A2AR on aSyn aggregation and associated synaptic 
toxicity and neurodegeneration, raising the possibility that adenosine A2AR 
antagonists produce their well-documented neuroprotective effects in PD 
models by preventing aSyn-inclusion formation and consequent associated 
toxicity. Furthermore, we now show that this rescue of aSyn-associated 
toxicity is being mediated via NMDAR, which are known to be involved 
in proteasome clearance system. Moreover, we also demonstrate that both 
intracellular overexpression of aSyn and extracellular addition of 
oligomeric aSyn increases cell death, suggesting that aSyn may induce 
similar toxic effects irrespective of being generated intra- or extracellulary 
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and more importantly A2AR antagonists are able to completely rescue these 
aSyn-associated toxic events. 
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Materials and Methods 
Animals 
Animal procedures were performed in accordance with the guidelines of 
the European Community guidelines (Directive 2010/63/EU), Portuguese 
law on animal care (1005/92) and approved by the Instituto de Medicina 
Molecular Internal Committee and the Portuguese Animal Ethics 
Committee (Direcção Geral de Veterinária). Environmental conditions 
were kept constant: food and water ad libitum, 21 ± 0.5°C, 60 ± 10% 
relative humidity, 12-h light/dark cycles. All animals were killed by 
decapitation after anesthesia under halothane atmosphere. Male Wistar rats 
(8–12 weeks old) purchased from Harlan Interfauna Iberica, SL. Global 
A2AR KO mice with a C57Bl/6-background were generated by a standard 
replacement-type vector constructed to inactivate the A2AR (Chen et al., 
1999). Congenic global A2AR KO mice were made by backcrossing KO 
on mixed (129-Steel x C57BL/6) genetic background to C57BL/6 mice for 
13–15 generations. Heterozygous cross-breeding was used to generate WT 
and global KO mice. Male KO and WT mice with matched age (8-12 
weeks old, male) were used for electrophysiological experiments.  
 
Purification and Oligomerization of Recombinant aSyn  
aSyn was prepared as previously (Diógenes et al., 2012; Vicente Miranda 
et al., 2013). Monomeric aSyn was readily used or stored at -80°C until 
further use. Oligomerization was induced by the continuous shaking of 
monomeric aSyn (140 µM) for 6 days at 37°C in a thermomixer 
(Eppendorf) at 900 rpm. Samples were ultracentrifuged to remove 
fibrillary aSyn. The supernatant containing monomeric and oligomeric 
aSyn was centrifuged in Amicon filter unit with Ultracel membrane 
NMWL of 30 kDa (Millipore). The retained fraction, containing aSyn 
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oligomers (> 30 kDa) was readily used or stored at -80°C until further use. 
The concentration of aSyn was determined using its molar extinction 
coefficient at 280 nm (i.e. Ɛ280=5960 L/mol/cm).  
 
SDS-PAGE 
The composition of different aSyn species, monomers, and oligomers, was 
evaluated by SDS-PAGE. Five micrograms of each aSyn sample was 
separated by SDS-PAGE using a Tetra Cell (Bio-Rad) on a precast 4–15% 
polyacrylamide gel (Bio-Rad) using standard procedures. Proteins were 
transferred to a nitrocellulose membrane (Bio-Rad) using the Mini Tans-
Blot system (Bio-Rad). 
Prestained standard proteins were also loaded on the gel. 
Membrane was blocked for 1 h at room temperature (RT) with blocking 
solution (5% bovine serum albumin in 50 mM Tris, 150 mM NaCl, 0.1% 
and Tween 20, pH 7.5). The membrane was incubated overnight at 4°C 
with the mouse anti-aSyn primary antibody (1:1000; BD transduction lab) 
diluted in blocking solution. Membrane was washed and incubated for 1 h 
at RT with anti-mouse-horseradish peroxide (HRP)-conjugated secondary 
antibody (1:10000, Invitrogen) diluted in blocking solution. Detection 
procedures were performed according to ECL system (Millipore) using a 
chemidoc system (Bio-Rad). 
 
Rat Primary Neuronal Cultures  
Hippocampal neurons were cultured from 18 days Sprague Dawley rat 
(Harlan, Barcelona, Spain) embryos as previously described (Valadas et 
al., 2012). Briefly, embryos were collected in Hank’s Balanced Salt 
Solution (1 mM Ca2+ and 1 mM Mg2+) and rapidly decapitated. Meninges 
and white matter were removed and whole cortices (hippocampi and 
attached cortex) were incubated for 15 min in Hank’s Balanced Salt 
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Solution and 0.025% trypsin. Cells were centrifuged three times and 
washed with Hank’s Balanced Salt Solution (10% fetal bovine serum) and 
finally resuspended in Neurobasal medium. Cells were plated on poly-D-
lysine-coated coverslips in 24-well plates at a density of 8 x 104 cells/well. 
Neurons were grown for 10 days at 37°C in a 5% CO2 humidified 
atmosphere in Neurobasal medium with 2% B-27 supplement, 25 μM 
glutamate, 0.5 mM glutamine, and 2 U/mL penicillin/streptomycin, in the 
absence of any positive selection for neurons. Cells with 9 or 10 DIV were 
treated with extracellular aSyn species (500 nM) for 24 h or 90 min, 
respectively. 
 
Electrophysiological fEPSPs Recordings 
The experiments were performed in acute transverse hippocampal slices 
from male Wistar rats (8–12 weeks old) and in A2AR KO and WT mice. 
After decapitation, the brain was rapidly removed, and the hippocampi 
were dissected free in ice-cold artificial CSF or Krebs solution composed 
of (mM): NaCl 124; KCl 3; NaH2PO4 1.25; NaHCO3 26; MgSO4 1; CaCl2 
2; and D-glucose 10, previously gassed with 95% O2 and 5% CO2, pH 7.4. 
Slices (400 m thick) were obtained with a McEwan tissue chopper and 
were incubated with or without extracellular aSyn oligomers (500 nM) for 
90 min at RT in gassed artificial CSF. Incubation with SCH 58261 (50 nM) 
started 20 min prior to aSyn oligomers incubation and was kept throughout 
the 90 min of aSyn incubation (Fig. 2.2a). Following this incubation 
period, slices were superfused with artificial CSF (3 mL/min) at 32ºC and 
fEPSPs were recorded as previously (Diógenes et al., 2012) in the stratum 
radiatum of the CA1 area. We first carried out input–output (I/O) curves 
and then LTP was induced by a theta-burst protocol (10 trains with four 
pulses each at 100 Hz, separated by 200 ms). 
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SH-SY5Y Cells Inducibly Overexpressing Wild Type aSyn 
Stable SH-SY5Y cell lines inducibly expressing human WT aSyn (a kind 
gift from Prof. Kostas Vekrellis, Athens, Greece) were generated as 
previously described (Vekrellis et al., 2009). Cells were cultured in RPMI 
1640® medium (Life Technologies) supplemented with 10% fetal bovine 
serum, penicillin (100 U/mL) and streptomycin (100 mg/mL). SH-SY5Y 
cells were maintained in 250 μg/mL G418 and 50 μg/mL hygromycin B. 
aSyn expression was switched off by the addition of doxycycline (Dox) (2 
μg/mL). Stock cultures were kept in the presence of Dox. Overexpressing 
aSyn cells were maintained for 12 DIV in the absence of Dox. For 
propidium iodide (PI) and Syto-13 uptake assay cells were plated onto 12-
well plates (3.8 cm2) at a density of 6 x 104 cells/well, 24 h before drug 
exposure. For Western blot analysis, the cells were seeded into 6 well 
plates at a density of 15 x 104 cells/well.  
 
H4 Cells Stably Expressing VN-Syn/Syn-VC 
For the aSyn dimerization model, human H4 neuroglioma cells stably 
expressing two aSyn BiFC constructs were used (Outeiro et al., 2008).  
This assay is based on the reconstitution of functional fluorescent proteins 
promoted by the interaction between, at least, two aSyn molecules, that 
enables the direct visualization of aSyn dimeric/oligomeric species 
formation. The two BiFC constructs used were generated by fusing half of 
the fluorescent Venus protein with aSyn in the N-terminal and the other 
half fused with aSyn in the C-terminal. 
Cells were maintained in OPTI-MEM® (Life Technologies) 
supplemented with 10% fetal bovine serum, penicillin (100 U/mL) and 
streptomycin (100 mg/mL) in a humidified atmosphere of 5% of CO2 in 
air at 37°C. Cells were plated onto 12-well plates and 24 h before 
treatment. 24 h after drug treatment, cells were washed with phosphate 
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buffer saline (PBS: NaCl 137 mM, KCl 2.7 mM, KH2PO4 1.8 mM and 
Na2HPO4 10 mM, pH 7.4) and fixed with 4% paraformaldehyde (PFA) for 
10 min at RT, followed by a 10 min incubation with Hoescht 33258 dye (1 
mg/mL, Life Technologies-Invitrogen, Carlsbad, CA, USA) at RT. Cells 
were then washed and maintained in PBS and imaged on an Olympus 
IX81-ZDC microscope system (Olympus Germany, Hamburg, Germany) 
using the 20x objective and maintaining the same exposure time for Venus 
and Hoechst channels for each condition. Quantification of the number of 
cells and average Venus fluorescence intensity was performed using an in-
house developed macro for ImageJ (http://imagej.nih.gov/ij/). Briefly, 
single cell nuclei were identified using the Hoechst channel by 
thresholding and particle analysis and the corresponding regions of interest 
(ROIs) were then used to measure the average intensity in the Venus 
channel. The number of cells with aSyn dimers was determined by 
counting the ROIs where the average fluorescent intensity was higher than 
a given threshold. Values of each condition were then averaged, and 
statistical analysis was performed. 
 
Human Neuroglioma H4 Cells 
Human neuroglioma H4 cells were maintained in OPTI-MEM® (Life 
Technologies) supplemented with 10% fetal bovine serum, penicillin (100 
U/mL) and streptomycin (100 mg/mL) in a humidified atmosphere of 5% 
of CO2 in air at 37 °C. Cells were plated in 12-well plates 24 h prior to 
transfection. Cells were transfected with equimolar amounts of the 
plasmids encoding the human WT aSyn with a C-terminal tag 
corresponding to a truncated fragment of EGFP (referred to as SynT) and 
synphilin-1 as previously (Lázaro et al., 2014). 24 h after transfection, cells 
were incubated for 24 h with different A2AR modulators and, after this 
period, cells were subjected to immunocytochemistry for studying aSyn 
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inclusions. Transfected cells were identified and classified into two 
groups: cells without inclusions and cells with one or more inclusions. 
Results were expressed as the percentage of the total number of transfected 
cells. 
 
Immunocytochemistry 
48 h after transfection, H4 cells were washed with PBS and fixed with 4% 
PFA for 10 min at RT, followed by a permeabilization step with 0.5% 
Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) for 20 min at RT. 
After blocking in 1.5% normal goat serum (PAA, Cölbe, Germany)/DPBS 
for 1 h, cells were incubated with mouse anti-aSyn primary antibody 
(1:1000, BD Transduction Laboratory, New Jersey, USA) primary 
antibody overnight at 4ºC. After a 30 min washing with PBS, cells were 
incubated with the secondary antibody Alexa Fluor 488 donkey anti-
mouse IgG (Life Technologies- Invitrogen, Carlsbad, CA, USA) for 2 h at 
RT. Finally, cells were stained with Hoechst 33258 (1 mg/mL, Life 
Technologies-Invitrogen, Carlsbad, CA, USA) (1:5000 in DPBS) for 10 
min, and maintained in PBS for epifluorescence microscopy. 
 
PI and Syto-13 Uptake Assay  
This protocol was used either in primary cortical cultures or SH-SY5Y 
cells and performed as previously described (Valadas et al., 2012). Briefly, 
cells were washed with Krebs-HEPES (NaCl 117 mM, KCl 3 mM, glucose 
10 mM, NaHCO3 26 mM, Na2HPO4 1.25 mM, HEPES 10 mM, CaCl2 2 
mM, MgCl2 1 mM), incubated with Syto-13 (4 μM) and PI (5 μg/mL) for 
3 min at RT and directly observed using an Axiovert 200 fluorescence 
microscope. An average of 1400 cells was counted per condition in each 
experiment. Syto-13 labels with green fluorescence (emits preferentially 
at 509 nm when excited at 488 nm) both RNA and DNA in living cells. PI 
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labels with red fluorescence (absorbing preferentially at 535 nm and 
emitting at 617 nm) cells that lost plasma membrane integrity. Cell 
viability was presented as the ratio between the number of living cells and 
the total number of cells. 
 
Real-Time qPCR 
Total RNA from H4 and SH-SY5Y cells was extracted using the RNAspin 
Mini RNA isolation kit (GE Healthcare, Buckinghamshire, UK). Briefly, 
cell cultures were washed with PBS, scraped, collected in lysis buffer and 
processed according to the manufacturer’s instructions. RNA was 
quantified with the NanoDrop 2000 (Thermo scientific, Wilmington, DE, 
USA). Total RNA (2 g) was reverse-transcribed using random primers 
and SuperScript™ First-Strand Synthesis System for RT-PCR (Invitrogen, 
Life technologies, Carlsbad, CA, USA) and negative controls were made 
without reverse transcriptase. qPCR was carried out with Power SYBR 
Green PCR Master mix (Applied Biosystems, Warrington, UK), using 8 
ng/μL of total cDNA and 0.2 μM of each primer, performed in a Rotor-
Gene 6000 Real Time Rotary Analyzer (Corbett Research, Cambridge, 
UK). The thermal cycler conditions were 10 min at 95°C, 40 cycles of a 
two-step PCR, 95°C for 15 s followed by 60°C for 25 s with a final thermal 
ramp from 72 to 95ºC.  The primers used in qPCR include: forward 5′-
AACCTGCAGAACGTCAC-3′ and reverse 5′-
GTCACCAAGCCATTGTACCG-3′ for human A2AR (Invitrogen, HPLC 
purified, product size 245 bp) and forward 5′-
GGACTTCGAGCAAGAGATGG-3′ and reverse 5′-
AGCACTGTGTTGGCGTACAG-3′ for human β-actin (Invitrogen, 
HPLC purified, product size 233 bp). The qPCR products were analyzed 
by electrophoresis on a 2% agarose gel containing Greensafe Premium 
Nucleic Acid Gel Stain (Nzytech, Portugal). 
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Co-immunoprecipitation (Co-IP) 
Briefly, WT rat hippocampal slices were homogenized in IP buffer (NP40 
1%, SDS 0.1%, Tris-HCl 50 mM, NaCl 150 mM, sodium deoxycholate 
0,5%, EDTA 1 mM, protease inhibitors - Complete, EDTA-free Protease 
Inhibitor cocktail tablets; Roche, Manheim, Germany). Protein extracts 
were incubated with protein G PLUS-Agarose (Santa Cruz Biotechnology, 
Heidelberg, Germany) for 1 h at 4°C to eliminate non-specific binding. 
After incubation, the pre-cleared supernatants containing 1 mg protein 
were incubated with anti-PSD-95 antibody (1:50; Cell Signaling 
Technology) or IgG (for negative control; Santa Cruz Biotechnology, 
Heidelberg, Germany) overnight at 4°C under rotation. The day after, 
lysates were incubated with protein G PLUS-Agarose for 3 h with rotation 
at 4ºC. Beads were washed three times with IP buffer and resuspended in 
1.5x sample buffer pH (Tris 359 mM pH 6.8, glycerol 30%, sodium 
dodecyl sulfate 10%, dithiothreitol 600 mM, and bromophenol blue 
0.012%). Bound proteins eluted from the immune complexes were 
denatured by heating to 95°C for 5 min and used for Western blot analysis. 
Western blots were performed with anti-NMDAR2B (1:1000; Cell 
Signaling technology), anti-NMDAR1 (1:500; BD PharmingenTM) and 
anti-PSD-95 (1:1000; Cell Signaling Technology) (see Western Blotting). 
 
Western Blotting 
SH-SY5Y cells were washed with cold PBS and then mechanically 
scrapped in radioimmunoprecipitation assay buffer pH 8.0 (RIPA buffer: 
NaCl 150 mM, Tris-base 50 mM, EDTA 1 mM, Nonidet P40 1%, sodium 
dodecyl sulfate 0.1%, proteases inhibitors - Complete, EDTA-free 
Protease Inhibitor cocktail tablets; Roche, Manheim, Germany). Cells 
were centrifuged at 16000 x g during 10 min at 4°C and the pellet, 
including cell debris, was discarded and the supernatant used for Western 
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blot. After protein quantification using BioRad DC Protein Assay kit, 
lysates were denatured with 5x sample buffer pH 6.8 (Tris 359 mM pH 
6.8, glycerol 30%, sodium dodecyl sulfate 10%, dithiothreitol 600 mM, 
and bromophenol blue 0.012%) and heated at 95°C for 5 min and further 
processed as before (Valadas et al., 2012). Samples and the pre-stained 
molecular weight marker (BIO-RAD) were separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; 15% gel) under 
reducing conditions and electro-transferred to polyvinylidene difluoride 
membranes (0.45 μm, Immobilon) using standard procedures. Thereafter, 
nonspecific binding was blocked with 3% bovine serum albumin (fatty 
acid-free) in Tris-buffered saline (pH 7.6) containing 0.1% Tween 20 
(TBS-T) for 1 h at RT. Membranes were then incubated overnight at 4°C 
with the corresponding primary antibody, namely mouse anti-aSyn 
(1:1000; BD transduction lab, Franklin Lakes, NJ, USA), mouse anti-
adenosine A2AR (1:1000; Millipore), rabbit anti-α-tubulin (1:5000; 
Abcam, UK), mouse anti-GAPDH (1:1000; Ambion), rabbit anti-PSD-95 
(1:1000; Cell Signaling), rabbit anti-NMDAR2B (1:1000; Cell Signaling), 
mouse anti-NMDAR1 (1:500; BD PharmingenTM) diluted in blocking 
solution.  After three washing periods of 10 min with TBS-T, membranes 
were incubated with horseradish peroxidase (HRP) conjugated anti-mouse 
or anti-rabbit secondary antibodies (1:10000; Santa Cruz Biotechnology, 
Heidelberg, Germany) (in 5% non-fat dry milk) for 1 h at RT. After 40 min 
of washing with TBS-T, chemiluminescent detection was performed with 
ECL western blotting detection reagent (GE Healthcare) using X-Ray 
films (Fujifilm, Dusseldorf, Germany). Densitometric quantification was 
determined using Image-J software and normalized to the corresponding 
α-tubulin band density.  
 
 
 
A2AR modulate aSyn aggregation and toxicity 
95 
Drugs 
5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-
triazolo[1,5-c] pyrimidine (SCH 58261; Tocris Cookson, UK) and 4-(2-
[7-amino)]-2-(2-furyl{1,2,4}-triazolo{2,3-a{1,3,5}triazin-5-yl-
aminoethyl)phenol} (ZM 241385; Tocris Cookson, UK) were prepared as 
5 mM stock solutions in dimethylsulfoxide (DMSO). 2-[p-(2-
Carboxyethyl)-phenylethylamino]-5´-N-ethylcarboxamidoadenosine 
(CGS 21680; Tocris Cookson, UK) was prepared as a 12 μM stock solution 
in DMSO. N6-Cyclopentyladenosine (CPA; Tocris) was prepared as a 5 
mM stock solution in DMSO. 1,3-Dipropyl-8-cyclopentyladenosine 
(DPCPX; Tocris Cookson, UK) was prepared as a 5 mM stock solution in 
99% DMSO and 1% NaOH 1 M. DL-2-Amino-5-phosphonopentanoic 
acid (APV; Abcam, UK) was prepared as a 100 mM stock solution in 
NaOH 100 mM. All aliquots were kept frozen at -20°C until use. 
 
Statistics 
The values presented are mean ± SEM of n independent experiments. To 
test the significance of the differences between two conditions a Student´s 
t test was used. In statistical tests between three or more conditions, a one-
way ANOVA, followed by a Bonferroni’s multiple comparison post-hoc 
test was used. Values of P < 0.05 were considered statistically significant. 
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Supplementary information 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Characterization of aSyn and A2AR levels in 
Tet-inducible SH-SY5Y cells. (a) qPCR products showing expression of 
A2AR (245 bp) in SH-SY5Y cells. β-actin (233 bp) was used as a housekeeping 
control. RT-minus yielded no appreciable bands in the expected band size for 
the primers used. (b) Representative Western blot and averages of three 
independent experiments showing aSyn levels in the presence (+) or absence 
(-) of doxycycline (Dox). In the absence of Dox, cells begin expressing aSyn 
transgene at 6 DIV, this expression increases until 12 DIV, when maximal 
expression is observed. GAPDH was used as a loading control. (c) qPCR 
showing no change in A2AR mRNA expression levels upon aSyn 
overexpression. (d) Western blot showing no change in A2AR protein levels 
upon aSyn overexpression. (e) Representative Western blot of four 
independent experiments to evaluate aSyn levels after treatment with SCH 
58261 (50 nM), ZM 241385 (50 nM) or CGS 21680 (30 nM). aSyn protein 
levels remained unchanged in all conditions. α-tubulin was used as a loading 
control.
a 
b 
c 
d 
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Abstract 
Synucleinopathies, such as Parkinson’s disease (PD) and dementia with 
Lewy bodies (DLB), are neurodegenerative disorders characterized by the 
accumulation of alpha-synuclein (aSyn) in intracellular inclusions known 
as Lewy bodies (LB). LBs accumulate throughout the brain as the disease 
progresses, but the precise significance of these inclusions in disease 
pathogenesis is still unclear. Currently, prefibrillar, soluble aSyn 
oligomers, rather than larger inclusions, are considered early and key 
intermediates in the disease-related synaptic dysfunction that is common 
to various synucleinopathies. Here, we identified the cellular prion protein 
(PrPC) as a key mediator of aSyn-associated synaptic impairment. The 
aSyn-associated impairment of long-term potentiation (LTP) was blocked 
in Prnp null mice (Prnp-/-) and rescued upon PrPC blockade. We show that 
extracellular aSyn oligomers form a complex with PrPC at the post-
synaptic density, inducing the phosphorylation of intracellular Fyn kinase 
via metabotropic glutamate receptor 5 (mGluR5). aSyn engagement of 
PrPC/Fyn activates NMDA receptor (NMDAR) and alters Ca2+ 
homeostasis. In vivo blockade of mGluR5-evoked phosphorylation of 
NMDAR in aSyn transgenic (Tg) mice, using the adenosine A2A receptor 
(A2AR) antagonist KW-6002, rescued synaptic and cognitive deficits, 
supporting the hypothesis that a receptor-mediated mechanism, 
independent of pore formation and membrane leakage, is sufficient to 
trigger early synaptic damage induced by extracellular aSyn. 
 
Keywords: α-Synuclein, cellular prion protein, NMDA receptors, 
metabotropic glutamate 5 receptor, Fyn kinase, synucleinopathies, 
Parkinson’s disease, dementia with Lewy bodies, long term potentiation. 
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Introduction 
The abnormal accumulation of aggregated aSyn in LBs is a common 
neuropathological hallmark of synucleinopathies such as PD and DLB 
(Lee et al., 2014; Yang and Yu, 2016). LBs can be detected throughout the 
brain and are frequently observed in the hippocampus and related brain 
regions. Synucleinopathies are also characterized by progressive neuronal 
dysfunction and, eventually, death of affected neuronal populations (Braak 
and Del Tredici, 2008). In addition to the characteristic motor symptoms 
of PD, cognitive disturbances also represent an important clinical feature 
of the disease, and occur not only in advanced stages of the disease, but 
also in early and even pre-motor phases (Braak et al., 2005; Caviness et 
al., 2011; Goldman et al., 2014; Kao et al., 2009; Lee et al., 2014; Yang 
and Yu, 2016).  
Recent studies suggest that aSyn oligomers are the most toxic 
species and that they can be released from neuronal cells, contributing to 
the major pathological features of synucleinopathies (Lee et al., 2014; 
Marques and Outeiro, 2012). In fact, extracellular aSyn oligomers, but not 
monomers or fibers, impair hippocampal LTP - the molecular paradigm 
involved in learning and memory (Diógenes et al., 2012; Ferreira et al., 
2015) - through the activation of NMDAR. This synaptic dysfunction 
precedes neuronal death, leading to significant changes in resting 
membrane potential or in input resistance values (Diógenes et al., 2012; 
Ferreira et al., 2015). 
Recently PrPC was reported to act as a receptor for neurotoxic Aβ 
oligomers, which share structural and functional similarities with aSyn 
oligomers (Biasini et al., 2012). PrPC was additionally suggested to 
mediate synaptic dysfunction, memory deficits, and neurodegeneration of 
several β-sheet-rich conformers (Gimbel et al., 2010; Laurén et al., 2009; 
Resenberger et al., 2011), acting via NMDAR (Larson et al., 2012; Um et 
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al., 2012). Furthermore, we have previously demonstrated that aSyn 
oligomers can form complexes with NMDAR at the postsynaptic density 
(Ferreira et al., 2015), where PrPC is known to be present (Um et al., 2012).  
Here, we found that aSyn interacts physically with PrPC to mediate 
Ca2+ dysregulation and synaptic dysfunction, through a mechanism 
involving Fyn phosphorylation and consequent NMDAR2B activation, via 
mGluR5. Moreover, we found that synaptic and cognitive deficits 
associated with aSyn overexpression in a Tg mouse model of 
synucleinopathy are reverted upon blockade of mGluR5-evoked 
phosphorylation of Src kinases and of the toxic activation of NMDAR2B. 
Overall, our study sheds light into the early pathophysiological 
mechanisms preceding aSyn-mediated neurodegeneration and implicates 
PrPC as a molecular target in synucleinopathies. 
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Results 
aSyn oligomers impair long-term potentiation through a 
PrPC-dependent mechanism 
We previously demonstrated that extracellular aSyn oligomers impair LTP 
in rodent hippocampal slices via a mechanism dependent on NMDAR 
(Diógenes et al., 2012; Ferreira et al., 2015). PrPC is known to be involved 
in NMDAR signaling and, therefore, we hypothesized that PrPC could 
mediate the detrimental effects of aSyn oligomers on synaptic plasticity. 
For this, we compared synaptic function of hippocampal dorsal slices from 
WT versus Prnp null mice (Prnp-/-) in the presence of extracellular aSyn 
oligomers (characterized by AFM and SDS-PAGE) (Supplementary Fig. 
3.1a), as previously described (Diógenes et al., 2012; Ferreira et al., 2015). 
Synaptic function was assessed by electrophysiological recordings of field 
excitatory postsynaptic potentials (fEPSPs) in the Schaffer collaterals/CA1 
pyramid glutamatergic synapses (Fig. 3.1a). As we previously reported 
(Diógenes et al., 2012; Ferreira et al., 2015), soluble aSyn oligomers 
significantly decreased the LTP magnitude in hippocampal slices of WT 
animals (aSyn olig, 500 nM, 90 min; P < 0.001; Fig. 3.1b, c and 
Supplementary Fig. 3.1c, d), whereas neither aSyn monomers nor fibrils 
affected LTP magnitude (P > 0.05; Supplementary Fig. 3.1b, c). 
Strikingly, in slices from Prnp-/- animals, which display normal LTP when 
compared to WT animals (P > 0.05; Fig. 3.1c, d and Supplementary Fig. 
3.1d) (Curtis et al., 2003; Laurén et al., 2009; Lledo et al., 1996), treatment 
with aSyn oligomers did not affect LTP (P > 0.05; Fig. 3.1d and 
Supplementary Fig. 3.1d). 
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Figure 3.1. PrPC mediates synaptic impairment induced by 
extracellular aSyn oligomers. (a) Top panel: Schematic representation 
of the simplified circuitry of the hippocampus. DG: Dentate Gyrus; MF: 
Mossy Fibers; SC: Schaffer Collaterals; PF: Perforant Pathway; CA3: 
Cornu Ammonis 3; CA1: Cornu Ammonis 1. A recording electrode and 
two independent stimulation pathways (S0 and S1), allowing two 
protocols in the same slice, are placed in the CA1 dendritic area. Bottom 
panel: a representative field Excitatory Post Synaptic Potential (fEPSP). 
(1) Stimulus artifact; (2) Fiber volley; (3) fEPSP slope. (b) Schematic 
representation of hippocampal slices incubation protocol. (c) Changes 
in fEPSP slope induced by theta-burst stimulation recorded from WT 
mice hippocampal slices pre-incubated with extracellular aSyn 
oligomers (aSyn olig, 90 min, 500 nM, n = 10) or in control conditions 
(CTR, n = 7) (means ± s.e.m., P < 0.001, one-way ANOVA followed 
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by a Bonferroni’s Multiple Comparison Test). The top panels show 
representative traces prior (1) and after (2) LTP induction. (d) Changes 
in fEPSP slope were recorded from slices of mice lacking PrP (Prnp-/-) 
pre-incubated with extracellular aSyn oligomers (n = 6) or in control 
conditions (n = 6) (means ± s.e.m., P > 0.05, one-way ANOVA 
followed by a Bonferroni’s Multiple Comparison Test) obtained by the 
same method as in c. (e) Left panel: Changes in fEPSP slope were 
recorded by the same method as in a, from hippocampal slices pre-
incubated with aSyn oligomers alone (n = 6), in the presence of the 
6D11 antibody against PrPC (6D11, 110 min, 100 nM, n = 4) together 
with the aSyn oligomers or in control conditions (n = 4). Right panel: 
Plot of the LTP magnitude represented on the left panel plus the LTP 
magnitude of WT hippocampal slices in the presence of 
immunoglobulin G (IgG, 110 min, 100 nM, n = 4) or the anti-PrPC 
antibodies, 8B4 (110 min, 10 µM, n = 4) or C-20 (110 min, 10 µM, n = 
4) together with aSyn oligomers (change in fEPSP slope at 50–60 min 
after theta-burst stimulation, compared to baseline) (means ± s.e.m., P 
< 0.001, one-way ANOVA followed by a Bonferroni’s Multiple 
Comparison Test). Top panels: Schematic representation of 
hippocampal slices incubation protocol and representative traces prior 
(1) and after (2) LTP induction. (f) Schematic diagram of PrP 
representing the binding sites of 8B4, 6D11 and C-20 anti- PrPC 
antibodies. (g) Schematic representation of WT hippocampal synapses 
exposed to aSyn oligomers alone (left panel) or in the presence of the 
anti-PrPC antibody 6D11. 6D11 PrPC blockade prevents NMDAR 
overactivation and subunit modification, basal synaptic 
hyperexcitability, and LTP impairment induced the extracellular aSyn 
oligomers. 
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In order to evaluate whether PrPC was also involved in baseline 
synaptic efficiency, I/O curves were recorded in slices from WT or Prnp-
/- animals in the presence or absence of aSyn oligomers. WT slices pre-
incubated with aSyn oligomers displayed max slope values higher than 
control slices (P < 0.001; Supplementary Fig. 3.1e). This increase in basal 
excitability was not observed in Prnp-/- slices in the presence of aSyn 
oligomers, which displayed fEPSP slope values that were similar to those 
in control slices when stimulated with the same intensity (P > 0.05; 
Supplementary Fig. 3.1f). 
Thus, we concluded that PrPC is essential for the aSyn oligomer-
mediated inhibition of hippocampal LTP. 
 
PrPC 93-109 amino acid region is required for aSyn 
oligomer-mediated inhibition of LTP 
The absence of sensitivity to aSyn in Prnp-/- slices regarding basal 
excitability and LTP, suggests that PrPC may act as a key mediator for 
aSyn synaptic toxicity. 
To investigate the region(s) of PrPC that mediated the aSyn effects, 
we targeted three regions in the protein, using different antibodies against 
PrPC: 6D11 (epitope targeting the region 93-109 of PrPC; 100 nM), 8B4 
(epitope targeting the N-terminus of PrPC; 10 µg) and C-20 (epitope 
targeting the C-terminus of PrPC; 10 µg) (Fig. 3.1f). In slices pre-treated 
with 6D11 anti-PrPC antibody, the effect of aSyn oligomers on LTP was 
blocked (P < 0.001; Fig. 3.1e). In contrast, pre-treatment with 8B4 or C-
20 had no effect (P > 0.05; Fig. 3.1e and Supplementary Fig. 3.1h). This 
suggests that the 93-109 segment of PrPC is the crucial region for aSyn-
induced toxic effects. Accordingly, the 6D11 anti-PrPC antibody also 
prevented the effect of aSyn oligomers on the I/O curve (P > 0.05; 
Supplementary Fig. 3.1g). Presynaptic short-term plasticity was not 
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altered by aSyn oligomers nor by the 6D11 antibody under these 
conditions, as evaluated by paired-pulse facilitation (PPF) (P > 0.05; 
Supplementary Fig. 3.1i). We also confirmed that 6D11 alone did not 
affect LTP, nor did IgG modify the aSyn-mediated reduction of LTP (Fig. 
3.1e, bar graph). 
Thus, PrPC deletion or blockade at the 93-109 segment prevents 
aSyn oligomer-induced impairments both in LTP and basal synaptic 
transmission, suggesting that PrPC mediates this synaptic dysfunction in a 
6D11-sensitive manner (Fig. 3.1g).  
 
PrPC modulates aSyn-mediated synaptic impairment 
through the activation of Src Tyr-kinases and NMDAR2B 
The function of PrPC relates to the modulation of phosphorylation 
cascades, in particular, the one governed by Fyn (Linden et al., 2008; 
Sorgato and Bertoli, 2009; Wulf et al., 2017), a member of the Src Tyr-
kinase family (SFK) that is highly expressed in neurons (Um and 
Strittmatter, 2013). Moreover, both Fyn and PrPC localize in lipid rafts, 
and clustering of PrPC activates Fyn in cell lines (Mouillet-Richard et al., 
2007; Pantera et al., 2009; Williamson et al., 2007). Fyn was also reported 
to co-localize with PrPC at the postsynaptic density (PSD), where it plays 
a critical role in cognition and LTP by mediating NMDAR 
phosphorylation and, consequently, excitotoxicity (Grant et al., 1992; 
Nakada et al., 2011; Suzuki and Okumura-Noji, 1995; Weilinger et al., 
2016). As such, the tyrosine kinase Fyn is a candidate mediator of signal 
transduction from an aSyn/PrPC interaction. We assessed the involvement 
of Fyn in aSyn-associated synaptic deficits. For this we treated rat 
hippocampal slices with aSyn oligomers alone or in the presence of a 
selective SFK inhibitor, 1-Naphtlyl PP1 (PP1, 30 µM, 110 min; Fig. 3.2a), 
and induced LTP as before. As expected, the LTP magnitude was 
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significantly reduced in slices pre-incubated with aSyn oligomers (P < 
0.01; Fig. 3.2a and Supplementary Fig. 3.2a). When Fyn was blocked by 
PP1, the LTP magnitude was reestablished to control values (P < 0.01; Fig. 
3.2a and Supplementary Fig. 3.2a). PP1 alone did not affect the LTP 
magnitude (P > 0.05; Supplementary Fig. 3.2a). The aSyn-induced shift 
in I/O curve was also lost when Fyn activation was inhibited by PP1 
(Supplementary Fig. 3.2b).  
Next, we hypothesized that PrPC/Fyn activation converged to 
activate NMDAR (Nakazawa et al., 2001; Salter and Kalia, 2004). To test 
this, we evaluated the effect of the NMDAR antagonist APV (50 μM) on 
basal synaptic transmission. APV did not modify the fEPSP slope in 
control WT slices (P > 0.05; Fig. 3.2b and Supplementary Fig. 3.2c). In 
contrast, the acute application of APV induced a progressive reduction of 
the fEPSP in aSyn oligomer-treated WT slices (P < 0.001; Fig. 3.2b and 
Supplementary Fig. 3.2c), indicating a basal activation of NMDAR 
caused by aSyn (Diógenes et al., 2012; Ferreira et al., 2015). Inhibition of 
Fyn by PP1 prevented this effect (P < 0.01; Fig. 3.2b and Supplementary 
Fig. 3.2c). This loss of aSyn effect was also observed in slices from Prnp-
/- mice, compared to their WT littermates (Fig. 3.2c and Supplementary 
Fig. 3.2d, e). We showed previously that exposure to aSyn is associated 
with an increase in NMDAR subunit 2B (NMDAR2B) levels (Ferreira et 
al., 2015). We now found that, in Prnp-/- mice, aSyn oligomers lost the 
ability to alter NMDAR2B levels, whereas the levels of NMDAR subunit 
1 (NMDAR1) were not altered by aSyn in WT or Prnp-/- mice 
(Supplementary Fig. 3.2f). 
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Figure 3.2. PrPC dependent-toxic effects of aSyn oligomers are mediated 
by Src family-kinases. (a) Top panel: schematic representation of 
hippocampal slices incubation protocol. Bottom panels: Representative traces 
prior (1) and after (2) LTP induction and changes in fEPSP slope in 
hippocampal slices from WT rat in control conditions (CTR, n = 4), and pre-
incubated with aSyn oligomers alone (aSyn olig, 90 min, 500 nM, n = 6) or in 
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the presence of the Src-family inhibitor, 1-naphthyl PP1 (PP1, 110 min, 30 
µM; PP1 + aSyn olig, n = 3; means ± s.e.m., P < 0.01, one-way ANOVA 
followed by a Bonferroni’s Multiple Comparison Test). (b) Effect of the 
NMDAR antagonist APV (50 µM, 30 min) superfusion on basal fEPSP slope 
from control WT hippocampal slices in the same conditions as in a (means ± 
s.e.m., P < 0.01, one-way ANOVA followed by a Bonferroni’s Multiple 
Comparison Test). (c) Effect of APV superfusion on basal fEPSP slope in 
Prnp-/- hippocampal slices in the same conditions as in b (P > 0.05).  (d) 
Schematic representation of primary neuronal cultures incubation protocol. (e) 
Representative immunoblots and quantification of the phospho-Src levels, 
normalized to Fyn immunoreactivity, in WT and Prnp-/- primary neuronal 
cultures in control conditions (n = 6), and treated with aSyn oligomers alone 
(n = 5) or in the presence of the 6D11, C-20, 8B4 antibodies against PrPC (n 
= 3-4) or the selective mGluR5 antagonist (MPEP, n = 4; means ± s.e.m., P < 
0.001, one-way ANOVA followed by a Bonferroni’s Multiple Comparison 
Test). (f) Representative immunoblots and quantification of the phospho-
NMDAR2B levels, normalized to NMDAR immunoreactivity, in the same 
conditions as in e plus in the presence of 1-naphthyl-PP1 (n = 3; means ± 
s.e.m., P < 0.001, one-way ANOVA followed by a Bonferroni’s Multiple 
Comparison Test). (g) Representative western blot of 3 independent 
experiments showing immunoprecipitation of PSD-95 in WT hippocampal 
control slices and slices pre-incubated with aSyn oligomers. Membranes were 
immunoblotted with anti-NMDAR2B, anti-Fyn, anti-PrP and anti-PSD-95 
antibodies. (h) Representative western blot of 3 independent experiments 
showing immunoprecipitation of aSyn and PrP, in aSyn Tg, Prnp-/-, and WT 
hippocampal slices in control conditions and pre-incubated with aSyn 
oligomers. Membranes were immunoblotted with anti-NMDAR2B, anti-Fyn, 
anti-PrPC and anti-aSyn antibodies. IgG was used as a negative control (Neg 
CTR). (i) Immunohistochemistry of WT and Prnp-/- primary neuronal cultures 
(representative image of n = 3). aSyn is labelled in green, PrPC is labelled in 
red, and cell nuclei are stained with Hoechst in blue (scale bar: 15 μm). At the 
bottom, a 63x magnification image (scale bar: 5 μm). Colocalization is 
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indicated by arrows and was assessed by Mander’s overlap coefficient method 
using ZEN Software (Zeiss). PrPC-bound aSyn was detected in WT neuronal 
cultures pre-treated with aSyn oligomers for 5 min (Mander’s overlap 
coefficient = 0.70), compared to control conditions, where no colocalization 
was observed (Mander’s overlap coefficient = 0). No surface binding of aSyn 
oligomers was detected in Prnp-/- cultures (Mander’s overlap coefficient = 0).  
 
We then evaluated Fyn activation by quantifying Src 
phosphorylation levels. We exposed primary neuronal cultures (12 DIV) 
to aSyn oligomers for different time periods. At this stage, neurons were 
fully mature, as confirmed by morphological analysis and MAP2 staining 
(Supplementary Fig. 3.3a). We detected a maximal level of phospho-Src 
after a 5-min exposure, with no alterations in Fyn (Supplementary Fig. 
3.3c, d). This was coincident with a significant increase in aSyn levels 
(Supplementary Fig. 3.3b). We asked whether PrPC was required for the 
observed aSyn-induced Src activation, but we could not detect any effect 
of aSyn on Src activation in neuronal cultures from Prnp-/- mice (P > 0.05; 
Fig. 3.2e). Additionally, we found that the 6D11-PrPC antibody prevented 
Src activation by aSyn (P < 0.001; Fig. 3.2d, e), whereas neither 8B4 nor 
C-20 antibodies prevented Src phosphorylation. These effects on Src 
activation were not due to alterations in PrPC levels since similar levels of 
PrPC were detectable after aSyn exposure for different time periods 
(Supplementary Fig. 3.3e).  
NMDAR plays a key role in synaptic plasticity and in aSyn-
induced LTP impairment (Diógenes et al., 2012).  Intracellular segments 
of NMDAR2A and NMDAR2B subunits are phosphorylated on tyrosine 
residues by SFK (Salter and Kalia, 2004).  Of these, Y1472 of NMDAR2B 
is a major phosphorylation site of Fyn kinase (Nakazawa et al., 2001). We 
examined total and phosphorylated levels of Y1472 NMDAR2B in 
neuronal cultures exposed to aSyn oligomers for different time periods. At 
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5 min of exposure, an increase in the levels of phospho-NMDAR2B was 
already detected, with no changes in the total levels of NMDAR2B 
(Supplementary Fig. 3.3f, g). This increase was blocked by the 6D11 
anti-PrPC and the Fyn inhibitor (PP1, 30 µM, 25 min; P < 0.05; Fig. 3.2f), 
but was not affected by 8B4 or C-20 anti-PrPC antibodies. In agreement, 
aSyn oligomers failed to induce further NMDAR2B phosphorylation in 
neuronal cultures from Prnp-/- mice (Fig. 3.2f). Thus, aSyn requires PrPC, 
in particular, the 93-109 region, in order to induce Fyn activation and 
subsequent NMDAR2B phosphorylation, which may underlie the LTP 
impairments observed in the presence of aSyn oligomers. 
 
aSyn physically interacts with PrPC to form a complex with 
NMDAR2B and Fyn kinase at the postsynaptic membrane 
In our previous studies reported in Chapter II, we demonstrated a 
postsynaptic action of aSyn oligomers in hippocampal synapses, where 
aSyn forms a complex with NMDAR2B (Ferreira et al., 2015). Proteomic 
analyses revealed PrPC is a component of the postsynaptic density (PSD) 
(Collins et al., 2006). Consistently, PrPC co-fractionates with PSD-95 and 
Fyn kinase, and is involved in Fyn activation in cell lines and in animal 
models (Mouillet-Richard et al., 2007; Pantera et al., 2009; Williamson et 
al., 2007).  
To test whether aSyn interacted with PrPC, we first showed that the 
PrPC/Fyn/NMDAR2B complex is increased after exposure to aSyn 
oligomers, by co-immunoprecipitation (co-IP) of PSD-95 (Fig. 3.2g). 
Next, by pulling down PrPC we detected Fyn, NMDAR2B, and aSyn in the 
same complex in WT, but not in Prnp-/- slices, both in CTR or aSyn 
exposed slices (Fig. 3.2h). This was further validated by the reverse co-IP, 
where we pulled down aSyn and detected NMDAR2B, Fyn, and PrPC (Fig. 
3.2h). As expected, a non-interacting protein, α-tubulin, was only detected 
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in the pre-IP lysates, with no detectable signal in neither aSyn nor PrPC 
IPs, further confirming the specificity of aSyn-PrPC association.  In all 
these conditions, co-IP with IgG (negative control) did not yield any bands 
(Fig. 3.2h). In addition, we detected PrPC-bound aSyn in WT neuronal 
cultures pre-treated with aSyn oligomers (Fig. 3.2i). In control conditions, 
no co-localization was observed. Moreover, we did not detect any surface 
binding of aSyn oligomers in Prnp-/- cultures (Fig. 3.2i). 
To confirm the aSyn-PrPC interaction in vivo, we used Tg mice 
expressing human WT aSyn under control of Thy1 promoter (Thy1-aSyn 
mice), which display significant levels of aSyn in the hippocampus prior 
to nigrostriatal modifications (Chesselet et al., 2012; Magen et al., 2012). 
When we immunoprecipitated either PrPC or aSyn from the hippocampus 
of aSyn Tg mice, we detected the counterpart of the aSyn-PrPC complex 
(Fig. 3.2h). Moreover, we found that the PrPC levels followed the increase 
in aSyn in the hippocampus (Supplementary Fig. 3.5a, e), as reported 
before for Aβ oligomers (Caetano et al., 2011).  
Taken together, our data confirm an association of aSyn with PrPC 
and the formation of a PrPC-Fyn-NMDAR2B protein complex at the post-
synaptic density. 
 
aSyn oligomers impair calcium homeostasis through a 
PrPC-dependent mechanism 
Phosphorylation of NMDAR2B mediates alterations in NMDAR-induced 
calcium levels. To investigate the involvement of calcium signaling 
disruption as a consequence of aSyn oligomer-mediated NMDAR 
hyperactivation we measured variations in intracellular calcium 
concentrations ([Ca2+]i) in primary neuronal cultures. Changes in [Ca2+]i 
were detected by Ca2+ imaging using fura 2-acetoxymethyl ester (Fura 
2AM) (Fig. 3.3a).  
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Figure 3.3. aSyn oligomers, but not monomers, increase intracellular Ca2+ 
levels in primary neuronal cultures in a PrPC/NMDAR2B-dependent 
mechanism. (a) Representative images of Ca2+ imaging. Bright regions 
indicate the location of cytoplasm and organelles, where the concentration of 
Ca2+ is higher than in the dark regions indicating the intercellular medium, 
where diffusion processes take place. Right image corresponds to the ratio 
between the radiation emitted at 510 nm, when cells are excited at 340 nm, 
over emission upon excitation at 380 nm (F340/F380). (b, c) Graphs showing 
a 55 min time course of Ca2+-dependent fluorescence recorded and averaged 
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from FURA-2 AM WT neurons in response to aSyn monomers (aSyn mon, 
20min, 500 nM), oligomers (aSyn olig, 20 min, 500 nM), and oligomers in the 
presence of selective NMDAR2B antagonist, Ifenprodil (40 min, 3 µM) or in 
the presence of the 6D11 (40 min, 100 nM), 8B4 (40 min, 10 µM),  or C-20 
(40 min, 10 µM) antibodies against PrP. (d) WT representative images of the 
different conditions showed in b, c. (e) Prnp-/- representative images and 
graphs showing a 55 min time course of Ca2+-dependent fluorescence 
recorded and averaged from FURA-2 AM Prnp-/- neurons before and after 
exposure to aSyn oligomers (20 min, 500 nM). Cells were challenged with 
ionomycin (15 min, 2 µM) at the conclusion of each experiment. Each point 
represents the means ± s.e.m. of 340/380 nm readings of 20-25 responsive 
cells per experimental condition from 3 independent cultures. P < 0.001, one-
way ANOVA followed by a Bonferroni’s Multiple Comparison Test.  
 
Application of oligomeric forms of aSyn rapidly elevated 
intracellular Ca2+ levels (Supplementary Video 1), whereas equivalent 
amounts of aSyn monomers evoked no detectable changes in fluorescence 
(P < 0.001; Fig. 3.3b, d). This aSyn oligomer-evoked increase in [Ca2+]i 
was prevented by the 6D11 PrP antibody (P < 0.001; Fig. 3.3c, d), but not 
by either C-20 or 8B4 antibodies (Fig. 3.3c, d). None of the antibodies 
alone affected calcium levels (Fig. 3.3c, d). When the specific NMDAR2B 
subunit was blocked by ifenprodil (3 µM), the effect of aSyn oligomers on 
[Ca2+]i was also suppressed (P < 0.001; Fig. 3.3b, d). More importantly, 
in primary neuronal cultures of Prnp-/- mice, aSyn oligomers failed to 
induce any increase in intracellular Ca2+ levels (Fig. 3.3e and 
Supplementary Video 2), showing that the aSyn-mediated calcium 
deregulation depends on PrPC/NMDAR2B-mediated signaling.  
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mGluR5 mediates aSyn/PrPC synaptic dysfunction 
Although PrPC and SFK are enriched in the postsynaptic density (PSD) 
(Collins et al., 2006; Um et al., 2012), the connection of aSyn/PrPC to SFK 
cannot be direct, since PrPC is anchored via glycolipid to the plasma 
membrane, whereas SFK kinases are cytoplasmic (Salter and Kalia, 2004). 
Previous studies reported metabotropic glutamate receptor 5 (mGluR5) as 
a mediator of Fyn activation promoted by PrPC (Um and Strittmatter, 
2013). We hypothesized that mGluR5, a PSD transmembrane protein 
(Emes et al., 2008; Um et al., 2013), could mediate aSyn/PrPC signaling 
leading to impaired neuronal function. First, we treated primary cultures 
with the selective mGluR5 antagonist MPEP (5 µM), prior to a 5 min 
exposure to aSyn oligomers.  Blockade of mGluR5 prevented both Fyn 
and NMDAR2B activation, measured by Src and NMDAR2B 
phosphorylation levels. To investigate the functional role of this mGluR5-
mediated phosphorylation of NR2B subunit, we treated rat hippocampal 
slices with aSyn oligomers in the presence of MPEP (5 µM, 110 min; Fig. 
3.4a) and induced LTP in Schaffer collaterals/CA1 pyramid glutamatergic 
synapses by theta-burst stimulation. Interestingly, mGluR5 blockade by 
MPEP prevented LTP impairment induced by aSyn oligomers alone (P < 
0.001; Fig. 3.4b and Supplementary Fig. 3.4a). MPEP alone did not 
affect the LTP magnitude (P > 0.05; Supplementary Fig. 3.4a). 
Furthermore, when mGluR5 was activated by the selective agonist DHPG 
(10 µM, 110 min; Fig. 3.4c), the protective effect of the anti-PrPC antibody 
6D11 against aSyn-induced LTP impairment, was no longer detectable (P 
< 0.001; Fig. 3.4d and Supplementary Fig. 3.4c). DHPG alone did not 
change the effects of aSyn on LTP (P > 0.05; Supplementary Fig. 3.4c). 
Taken together, these data suggest that mGluR5 acts downstream of PrPC 
and probably serves as a bridge between PrPC and SFK/NMDAR2B to 
impair synaptic function.  
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Figure 3.4. PrPC blockade rescues LTP impairment induced by 
extracellular aSyn oligomers through a mechanism dependent on 
mGluR5. (a) Schematic representation of hippocampal slices incubation 
protocol used in b. (b) Changes in fEPSP slope induced by theta-burst 
stimulation recorded from WT hippocampal slices in control conditions (CTR, 
n = 4), pre-incubated with extracellular aSyn oligomers alone (aSyn olig, 90 
min, 500 nM, n = 6) or in the presence of the mGluR5-selective antagonist 
MPEP (110 min, 5 µM; MPEP + aSyn olig, n = 4; means ± s.e.m., P < 0.001, 
one-way ANOVA followed by a Bonferroni’s Multiple Comparison Test). 
The left panels show representative traces prior (1) and after (2) LTP 
induction. (c) Schematic representation of hippocampal slices incubation 
protocol used in d. (d) Changes in fEPSP slope induced by theta-burst 
stimulation recorded from WT hippocampal slices in control conditions (n = 
4), pre-incubated with extracellular aSyn oligomers together with the 6D11 
antibody (110 min, 100 nM; 6D11 + aSyn olig, n = 4) and in the presence of 
the mGluR5-selective agonist DHPG (110 min, 10 µM; 6D11 + DHPG + aSyn 
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olig, n = 4; means ± s.e.m., P < 0.001, one-way ANOVA followed by a 
Bonferroni’s Multiple Comparison Test). The left panels show representative 
traces prior (1) and after (2) LTP induction.  
 
Blockade of mGluR5-evoked tyrosine phosphorylation of 
NMDAR2B reverses memory deficits in a Tg mouse model 
of PD 
Phosphorylation of the NMDAR2B-Y1472 residue by Fyn kinase is under 
tight regulation of mGluR5 via adenosine A2A receptors (A2AR) (Fig. 3.7). 
Blockade of A2AR effectively inhibits NMDAR2B phosphorylation 
evoked by mGluR5 (Sarantis et al., 2015) and prevents LTP impairment 
and NMDAR overactivation mediated by aSyn in vitro as discussed in 
Chapter II (Ferreira et al., 2015). Accordingly, we observed that A2AR 
blockade prevented aSyn-mediated Src kinase phosphorylation in primary 
cultures (Fig. 3.6h). Furthermore, blocking A2AR (SCH-58261, 50 nM) in 
hippocampal slices protected against aSyn-mediated LTP impairments 
(Supplementary Fig. 3.4b), and this protective effect was lost if mGluR5 
were activated, reinforcing a common signaling pathway for the effects 
observed (P > 0.05; Supplementary Fig. 3.4b, c).  
To provide in vivo evidence for this mechanism, we assessed the 
effect of an A2AR blocker (KW-6002, also known as istradefylline) 
(Batalha et al., 2013, 2016; Coelho et al., 2014), particularly suited for 
chronic administration based on its bioavailability and brain penetration 
(Yang et al., 2007), to rescue memory and synaptic impairments in aSyn 
Tg mice (Thy1-aSyn). These animals express human aSyn in the whole 
hippocampus (Supplementary Fig. 3.5a), with an enrichment in cell 
bodies and axons of pyramidal neurons, in comparison to WT mice, in 
which the mouse aSyn mainly co-localizes with the presynaptic marker, 
SNAP25 (Supplementary Fig. 3.5b). Five-month-old aSyn Tg mice and 
their WT littermates were treated for one month with KW-6002, delivered 
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in the drinking water, at a dose known to be effective in vivo (3 mg/Kg/day) 
(Batalha et al., 2013; Coelho et al., 2014), (as depicted in Fig. 3.5a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. In vivo treatment of Thy1-aSyn (aSyn Tg) mice with KW-6002 
rescues aSyn-associated cognitive deficits. (a) Schematic representation of 
the groups of animals used and the corresponding oral pharmacological 
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treatment (vehicle or KW-6002). (b) Spatial memory performance was 
assessed by the Y-Maze test. Schematic representation of the Y-maze test (top 
panel). Representative traces (left panel) and quantification of the time spent 
in novel arm (N) versus the other arm (O) in the different groups of animals 
represented in a (n = 8-12; means ± s.e.m., P < 0.05, two-way ANOVA 
followed by a Tukey post-hoc comparison test). (c) Quantification of the 
number of transitions between arms observed in each group (n = 8-12; means 
± s.e.m., P > 0.05, two-way ANOVA followed by a Tukey post-hoc 
comparison test). (d) Quantification of the average swimming speed during 
Morris water maze (MWM) probe test (n = 6-11; means ± s.e.m., P > 0.05, 
two-way ANOVA followed by a Tukey post-hoc comparison test). 
Hippocampal-dependent memory performance was assessed by the MWM 
test, in which acquisition (e) and retention (f) were evaluated (n = 6-11; means 
± s.e.m., P < 0.05, two-way ANOVA followed by a Tukey post-hoc 
comparison test). (g) Representative immunoblots and quantification of aSyn 
levels in the hippocampus of WT and aSyn Tg mice treated with vehicle (n = 
5 and 4) or KW-6002 (n = 5 and 7) (means ± s.e.m., P < 0.001, two-way 
ANOVA followed by a Tukey post-hoc comparison test). α-Tubulin was used 
as a loading control. 
 
Hippocampal-dependent memory was assessed by the Morris 
Water Maze (MWM) test, in which memory acquisition and retention were 
evaluated. Chronic blockade of A2AR completely reverted the learning and 
memory deficits induced by aSyn overexpression. During the acquisition 
phase, treatment of aSyn Tg with KW-6002 restored learning (P < 0.001; 
Fig. 3.5e), when compared to animals treated with vehicle, which 
exhibited a slower learning performance to find the hidden platform, 
showing deficits at day 3, 4 and 5 (P < 0.001; Fig. 3.5e). Furthermore, 
KW-6002 treatment reestablished the retention ability of aSyn Tg mice, as 
observed in the probe test, measured by the time spent in the target 
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quadrant compared to the other quadrants (Fig. 3.5f). No changes were 
observed in the overall swimming speed among groups (Fig. 3.5d). 
Short-term reference memory was assessed in a spontaneous 
novelty-based spatial preference Y-maze test. aSyn Tg mice performed 
worse than WT mice, revealing no preference for the novel arm (P < 0.05; 
Fig. 3.5b). Importantly, KW-6002 restored memory impairments in aSyn 
Tg animals, as observed by the increased time spent in the novel arm (P < 
0.05; Fig. 3.5b). No changes were observed in the number of transitions 
between arms (P > 0.05; Fig. 3.5c), discarding significant motor 
impairments as described, since at this early stage these aSyn Tg mice 
exhibit mostly cognitive and memory deficits, prior to nigrostriatal 
pathology (Chesselet et al., 2012).  This correlated with the absence of 
significant dopaminergic neuronal loss, evaluated by tyrosine hydroxylase 
(TH) levels (Supplementary Fig. 3.5c, d). Furthermore, we did not detect 
any influence of the treatment with KW-6002 on the levels of aSyn in the 
hippocampus (P > 0.05; Fig. 3.5g). 
Treatment with KW-6002 also rescued LTP deficits induced by 
aSyn overexpression, without affecting LTP magnitude in WT animals (P 
< 0.05; Fig. 3.6a, b). Moreover, the treatment also rescued the I/O 
alterations observed in aSyn Tg mice, without changing the I/O curve in 
WT mice (P < 0.001; Fig. 3.6c). No changes were observed in the 
magnitude of long-term depression (LTD) or in PPF across genotypes or 
treatment (P > 0.05; Fig. 3.6d, e, f). 
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Figure 3.6. aSyn-associated synaptic and NMDA receptor dysfunction are 
rescued by KW-6002 in vivo treatment. (a) Changes in the fEPSP slope 
upon LTP induced by theta-burst stimulation from hippocampal slices. (b) 
LTP magnitude after theta-burst stimulation (change in fEPSP slope at 50–60 
min) (n = 4-5; means ± s.e.m., P < 0.05, two-way ANOVA followed by a 
Tukey post-hoc comparison test). (c) Input/output (I/O) curves corresponding 
to fEPSP slope evoked by different stimulation intensities (60–300 µA) (n = 
3-5; means ± s.e.m., P < 0.001, F-test). (d) Changes in fEPSP slope upon LTD 
induction (theta-burst stimulation) obtained for WT and Thy1-aSyn (aSyn Tg) 
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mice treated with vehicle or KW-6002. (e) LTD magnitude after theta-burst 
stimulation (change in fEPSP slope at 50–60 min) (n = 3-4; means ± s.e.m., P 
> 0.05, two-way ANOVA followed by a Tukey post-hoc comparison test). (f) 
PPF plotted against different interpulse intervals in WT and aSyn Tg mice 
treated with vehicle or KW-6002 (n = 3; means ± s.e.m., P > 0.05, two-way 
ANOVA followed by a Tukey post-hoc comparison test). (g) Representative 
immunoblot and quantification of NMDA receptor subunit 2B (NMDAR2B) 
and NMDA receptor subunit 1 (NMDAR1) levels in WT and aSyn Tg mice 
hippocampus in the same conditions as shown in a (n =4-8; means ± s.e.m., P 
< 0.01, two-way ANOVA followed by a Tukey post-hoc comparison test). 
GAPDH was used as a loading control. (h) Representative immunoblots and 
quantification of the phospho-Src levels, normalized to Fyn 
immunoreactivity, in WT and Prnp-/- primary neuronal cultures in control 
conditions (CTR, n = 3), and treated with aSyn oligomers alone (aSyn olig, n 
= 3) or in the presence of the SCH-58261 (SCH, 50 nM, n = 3) (means ± 
s.e.m., P < 0.05, one-way ANOVA followed by a Bonferroni’s Multiple 
Comparison Test). 
 
Finally, we found that the aSyn Tg mice had increased levels of 
NMDAR2B in the hippocampus when compared to WT littermates. 
Selectively blocking mGluR5-Fyn signaling with KW-6002 treatment 
restored the levels of NMDAR2B in the aSyn Tg animals (Fig. 3.6g), 
providing evidence that this pathway regulates the aSyn-mediated effects 
in vivo (Fig. 3.7). 
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Figure 3.7. Summary diagram of the mechanism by each aSyn oligomers 
induce an aberrant PrPC-mGluR5-NMDAR2B signaling at the post-
synaptic density. aSyn oligomers physically interact with PrPC (1) to activate 
mGluR5 (2) (Di Scala et al., 2016a). This leads to the phosphorylation and 
activation of the Src kinase Fyn (3) followed by the phosphorylation of 
NMDAR2B (Y1472) (4) (Yang et al., 2007) and robust increase in 
intracellular Ca2+ (5). Adenosine A2AR are required for the mGluR5-induced 
NMDAR2B phosphorylation (6) (Urrea et al., 2017).  
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Discussion 
The main finding of this chapter is that aSyn oligomeric species interact 
with PrPC through mGluR5, activating SFK kinases and, subsequently, 
NMDAR2B. We discovered a physical interaction between aSyn, PrPC, 
NMDAR2B and Fyn kinase in the post synaptic density (PSD) of the 
hippocampus, supporting a role of this interaction in the 
pathophysiological effects induced by aSyn. Furthermore, we show for the 
first time that genetic or antibody-mediated inactivation of PrPC prevent 
the toxic effects of aSyn on synaptic function. This protective effect 
afforded by PrPC inhibition is due to prevention of aberrant 
SFK/NMDAR2B signaling triggered by mGluR5, and the reestablishment 
of intracellular Ca2+ homeostasis. Finally, we confirmed the importance of 
this mechanism in vivo, in a mouse model of synucleinopathies based on 
the overexpression of human aSyn, by rescuing synaptic and cognitive 
deficits upon A2AR blockade and consequently inhibition of mGluR5-
evoked phosphorylation of NMDAR. Together, these data support the 
hypothesis that a receptor-mediated mechanism, independent of pore 
formation and membrane leakage, is sufficient to trigger early synaptic 
damage induced by extracellular aSyn, which could occur both as part of 
the normal biology of the protein or during the spreading of pathology in 
PD and other synucleinopathies. 
aSyn aggregation, synaptic dysfunction and consequent neuronal 
cell loss are key neuropathological hallmarks of synucleinopathies, but the 
precise molecular mechanisms and nature of the toxic species produced 
during aggregation remained unclear (Schulz-Schaeffer, 2010). 
Nevertheless, extracellular soluble aSyn oligomers are attracting much 
attention because of their potential role in disease pathogenesis and 
progression (Kayed et al., 2003; Lee et al., 2014; Outeiro et al., 2008). In 
fact, it is now widely accepted that aSyn is secreted and propagates 
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between neurons in a prion-like manner (Marques and Outeiro, 2012; 
Martin et al., 2012). Therefore, different aSyn species (monomer, 
oligomers, or fibrils) are predicted to gain access to the extracellular space 
and act postsynaptically, to impair neuronal communication and plasticity. 
Consistent with this hypothesis, we have previously shown that 
extracellular aSyn oligomers impair LTP, via NMDAR activation, before 
the occurrence of any neuronal death or changes in membrane conductance 
(Diógenes et al., 2012; Ferreira et al., 2015). Recent findings demonstrate 
that the cellular form of PrP (PrPC) can act as a cell surface binding partner 
for β-sheet-rich protein aggregates, namely soluble oligomeric protein 
species (Beraldo et al., 2016; Caetano et al., 2011; Laurén et al., 2009; 
Resenberger et al., 2011). Moreover, PrPC is involved in age-dependent 
behavioral abnormalities (Schmitz et al., 2014), memory impairment in 
animal models of neurodegeneration (Gimbel et al., 2010), and mediates 
Ca2+ influx via NMDAR (Khosravani et al., 2008). These observations 
suggest that PrPC might act as a mediator of the synaptotoxic effects 
triggered by aSyn oligomers. We now establish a previously 
undocumented link between aSyn and PrPC, whereby extracellular aSyn 
oligomers disturb Ca2+ homeostasis, impacting on synaptic plasticity. 
These toxic effects depend on PrPC since LTP and calcium impairments 
are lost in Prnp null mice or by blocking PrPC with an antibody. In 
addition, our data suggest that the amino acid region 93-109 of PrPC is 
involved in mediating the toxic effects of aSyn. Whether the reported 
interaction also affects the spreading of aSyn in the brain (Urrea et al., 
2017), still needs to be investigated. 
It has been suggested that the putative receptor function of PrPC 
relates to the modulation of phosphorylation cascades, in particular that 
governed by Fyn (Linden et al., 2008; Sorgato and Bertoli, 2009), a 
member of the Src Tyr-kinase (SFK) family, which highly expressed in 
neurons (Um and Strittmatter, 2013). Through this pathway, PrPC is 
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thought to play a key role in the regulation of several cellular processes, 
ranging from embryogenesis to neuroprotective signaling (Wulf et al., 
2017). In fact, under physiological conditions, PrPC depresses Fyn activity 
and, consequently, attenuates Ca2+ influx via NMDAR (Khosravani et al., 
2008). Our findings are in line with these results by demonstrating that the 
interaction of PrPC with extracellular aSyn oligomers leads to SFK 
phosphorylation and, consequently, to NMDAR hyper-activation followed 
by a rise in postsynaptic Ca2+ levels. Moreover, either Fyn or PrPC 
inhibition, completely prevent aSyn-mediated synaptic deficits. This toxic 
Fyn signaling cascade can be attributed to the relief of the PrPC constitutive 
block of Fyn or, alternatively, to aberrant Fyn activation, as previously 
proposed for Aβ oligomers (Larson et al., 2012; Um et al., 2012). Our 
results support the latter, since Prnp-/- mice do not display LTP 
impairments even in the presence of aSyn oligomers, suggesting that no 
significant constitutive SFK inhibition occurred. Moreover, Fyn-mediated 
intracellular Ca2+ flux can occur via store-operated Ca2+ entry (SOCE) (De 
Mario et al., 2015) or via NMDAR (Khosravani et al., 2008). We 
demonstrate that the PrPC-dependent effect on Ca2+ influx arises via 
NMDAR2B rather than SOCE, since NMDAR2B blockade rescued Ca2+ 
increase and both PrPC and SFK blockade prevented NMDAR2B 
phosphorylation, induced by aSyn.  
aSyn/PrPC and SFK cannot interact directly, given that PrPC is 
extracellularly anchored to the plasma membrane, whereas SFK is 
cytosolic. Our data identifies mGluR5 as the protein linking PrPC and SFK 
on opposite sides of the plasma membrane. Previous studies demonstrated 
that mGluR5 mediates Fyn activation promoted by PrPC (Um and 
Strittmatter, 2013). Consistently, when we blocked mGluR5 activation we 
prevented aSyn-induced NMDAR2B phosphorylation and synaptic 
impairment. Conversely, we bypassed the PrPC blockade of the aSyn 
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effects by activating mGluR5 directly, suggesting mGluR5 acts 
downstream of aSyn/PrPC and upstream of Fyn/NMDAR2B activation. 
Interestingly, the identification of the mGluR5-Fyn-NMDAR2B 
pathway as a mediator of the aSyn-PrPC signaling uncovers new targets for 
therapeutic intervention. However, blocking directly Fyn kinase, PrPC or 
NMDAR interferes with basal neuronal function and impairs memory, 
even in WT mice, as these proteins are crucial components of the 
postsynaptic density (Khosravani et al., 2008).  Accordingly, Prnp-/- 
exhibit deficits in hippocampal-dependent spatial learning, alterations in 
hippocampal physiology (Criado et al., 2005), synaptic alterations 
(Collinge et al., 1994; Curtis et al., 2003), social recognition memory 
deficits, impaired motor coordination, and activity (Katamine et al., 1998; 
Schmitz et al., 2014). Thus, this deleterious phenotype of the Prnp-/- mice 
may occlude any attempt to rescue in vivo aSyn-induced toxicity in a Prnp 
null background. Likewise, a failure to rescue this particular aSyn 
phenotype by using a Fyn kinase inhibitor, PrPC antibody, or NMDAR 
antagonists in vivo would prove inconclusive, since their constitutive 
activity is essential for synaptic function. Another alternative for rescuing 
memory and synaptic impairments in vivo, would be to interfere with 
mGluR5. mGluR5 are key players in cognitive and synaptic plasticity 
processes, and their direct antagonism impairs LTP and memory in vivo 
(Um et al., 2013). Yet, their functional interaction with adenosine A2AR, 
which regulate mGluR5-mediated effects via NMDAR2B phosphorylation 
(Sarantis et al., 2015; Tebano et al., 2005), provides a suitable alternative 
for regulating aberrant mGluR5 signaling without disrupting its 
constitutive activity. A similar approach was used to determine the 
involvement of PrPC in synaptic impairment driven by Aβ oligomers (Um 
et al., 2013). 
We now demonstrate the ability of an A2AR antagonist (KW-6002) 
to rescue synaptic and cognitive deficits in aSyn-transgenic mice, 
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providing the crucial evidence that the toxic effects of aSyn are indeed 
modulated by downstream effectors of PrPC (mGluR5/Fyn), as we 
described in vitro. KW-6002, also known as istradefyline, is approved in 
Japan for the adjunctive treatment of motor deficits in PD (Dungo and 
Deeks, 2013) and was shown to be particularly suited to target the CNS, 
based on its bioavailability, half-life, and brain penetration in animal 
studies (Yang et al., 2007). 
Previous evidence that blockade of A2AR effectively inhibits 
NMDAR2B phosphorylation evoked by mGluR5 (Tebano et al., 2005) and 
prevents LTP impairment and NMDAR overactivation mediated by aSyn 
in vitro, as shown in chapter II of this thesis (Ferreira et al., 2015) further 
supports this crosstalk. More importantly, deletion of A2AR is protective 
against neuronal degeneration induced by a mutant human α-synuclein 
(hm(2)-αSYN) transgene, although the underlying mechanisms were 
unknown at the time (Kachroo and Schwarzschild, 2012). 
Our evidence that KW-6002 treatment normalizes NMDAR2B and 
PrPC levels in Thy1-aSyn mice, preventing Fyn phosphorylation while 
rescuing memory and LTP, is very relevant to support our hypothesis and 
the involvement of this pathway in vivo (Fig. 3.7). Also, the fact that aSyn 
was found to be increased in cerebrospinal fluid of prion disease patients 
reinforces the pathophysiological relevance of our findings (Kasai et al., 
2014). 
 Importantly, at the time of treatment, the aSyn transgenic mice used 
already displayed detectable cognitive deficits (Magen et al., 2012), 
suggesting that memory impairments elicited by aSyn overexpression are 
reversible and do not result from cell death. Indeed, aSyn mice only present 
neuronal loss later in life (Chesselet et al., 2012). In accordance, we show 
that aSyn oligomers activate SFK/NMDAR as early as 5 min after 
exposure, while neuronal death occurs only after 24 h of exposure, as 
demonstrated in chapter II results (Ferreira et al., 2015). These data support 
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the hypothesis that a receptor-mediated mechanism, independent of pore 
formation and membrane leakage (Di Scala et al., 2016b), is sufficient to 
trigger early synaptic damage induced by extracellular aSyn. Furthermore, 
we identified novel key players in the signaling cascade triggered by aSyn, 
suggesting PrPC signaling may play a role in early stages of PD and DLB.  
In total, our findings provide novel options for therapeutic 
intervention aimed at neutralizing the downstream effects taking place at 
synapses, rather than relying solely on the disease-causing agent.  Thus, 
this strategy may prove more effective at preventing or delaying the onset 
of synucleinopathy-associated memory deficits. 
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Materials and Methods 
Animals 
Animal procedures were performed in accordance with the European 
Community guidelines (Directive 2010/63/EU), Portuguese law on animal 
care (DL 113/2013), and approved by the Instituto de Medicina Molecular 
Internal Committee and the Portuguese Animal Ethics Committee 
(Direcção Geral de Veterinária). Environmental conditions were kept 
constant: food and water ad libitum, 21 ± 0.5°C, 60 ± 10% relative 
humidity, 12 h light/dark cycles, 2 to 3 rats per cage or 3 to 4 mice per 
cage. Only male animals were used in all experiments. Mice were 
sacrificed by cervical dislocation and rats sacrificed by decapitation after 
anesthesia under halothane atmosphere. Male Sprague Dawley rat (SD; 
Harlan, Barcelona, Spain) with 8-12 weeks old were used for 
electrophysiological experiments. Tg mice overexpressing human aSyn 
under the Thy-1 promoter were generated on a mixed C57BL/6-DBA/2 
background as described previously (Rockenstein et al., 2002). Animals 
were maintained on this background by breeding mutant females with type 
(WT) with C57BL/6-DBA/2 males. Offspring were genotyped with 
polymerase chain reaction (PCR) amplification analysis of tail DNA (40 
cycles, 60°C annealing temperature). The sequences of primers used were: 
Thy-1-F: 5’-CTG GAA GAT ATG CCT GTG GA-3’, Thy-1-R: 5’-GAG 
GAA GGA CCT CGA GGA AT-3’ (Invitrogen). Male Tg Thy1-aSyn 
mice and their WT littermates with matched age (6-8 month old) were used 
for behavioral experiments. Prion protei knockout mice (designated Prnp-
/-, or Zurich I) homozygous for the disrupted Prnp gene, were produced on 
a mixed C57BL/6J x 129/Sv background as previously described (Büeler 
et al., 1992). Male Prnp-/- mice and their WT littermates with matched ages 
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(6-8 month old) were used for electrophysiological and molecular biology 
experiments. 
 
Oral administration of the drug 
KW-6002 (istradefylline; Tocris Bioscience), a selective adenosine A2AR 
antagonist (Yang et al., 2007), was orally administered, diluted in the 
drinking water, being continuously available, as before (Batalha et al., 
2013; Coelho et al., 2014). The weight of the animals and the volume 
intake were assessed twice a week and the concentration of the solution 
was adjusted so that the drug intake was maintained at 3 mg/kg per day. 
Animals were divided into four groups: WT mice drinking vehicle 
(0.025% methylcellulose) or drinking KW-6002 (3 mg/kg per day, 0.025% 
methylcellulose), and aSyn Tg mice drinking vehicle or KW-6002 at the 
same concentration (Fig. 3.5a). The treatment started at 5 months old, one 
month until behavior assessment started. The KW-6002 administration 
was kept until sacrifice. 
 
Behavioral assessments 
Mice were first handled for 5 days prior to behavioral tests. Mazes were 
cleaned with a 70% ethanol solution between each animal. Animals were 
randomized, and the experimenter blinded to genotype for the duration of 
behavioral testing. All behavioral tests were performed during the light 
phase between 8 a.m. and 6 p.m. in a sound attenuated room. 
Y-maze behavioral assessment. Short-term reference memory was 
assessed in a spontaneous novelty-based spatial preference Y-maze test. 
The Y-maze was performed in a two-trial recognition test in a Y-shaped 
maze with 3 arms (each with 15 cm length x 5 cm wide x 12 cm height), 
angled at 120º and with opaque walls. Different cues were placed on the 
surrounding walls. Allocation of arms was counterbalanced within each 
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group. During the first trial (learning trial), mice were placed at the end of 
the “start” arm and were allowed to explore the maze for 10 min with only 
two arms opened (“start” and “other” arm). Access to the third arm of the 
maze (“novel” arm) was blocked by an opaque door. The mouse was then 
removed from the maze and returned to its home cage. After 1 h, the animal 
was placed again in the “start” arm of the maze, the door of the “novel” 
arm was removed, and the mouse was allowed to explore the maze for 5 
min (test trial). Mice tracings were continuously monitored by an 
automated tracking system (Smart 2.5, PanLab, Barcelona). Preference for 
the novel arm is considered a measure of short-term reference memory. To 
exclude the possible confounding effect of alterations of locomotor 
activity, we used the frequency of entrance into the arms (number of 
transitions) as an indirect indicator of the general locomotor activity. The 
animal’s behavior was performed by an observer blind to the treatment 
conditions and genotype. 
Morris water maze (MWM). Spatial memory ability was evaluated 
in the MWM test (Morris et al., 1982). The test was performed over the 
course of six consecutive days and consisted of a five-day acquisition 
phase and a one-day probe test. The test was performed in a circular pool, 
with 100 cm in diameter, filled with water opacified with non-toxic white 
paint (Luxens) and kept at 24ºC. A round 8-cm in diameter platform was 
hidden 1 cm beneath the surface of the water at a fixed position. Four 
positions around the edge of the tank were used, dividing the tank into four 
quadrants: target quadrant (T, quadrant here the platform was hidden), left 
quadrant (L, quadrant on the left of the target quadrant), right quadrant (R, 
quadrant of the right of the target quadrant) and opposite quadrant (O, 
quadrant on the opposite side of the target quadrant). During the 
acquisition phase, each mouse was given four swimming trials per day (30-
min intertrial interval). A trial consisted of placing the mouse into the 
water facing the outer edge of the pool and allowing the mouse to explore 
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and reach for the hidden platform. If the animal reached the platform 
before 60 secs, it was allowed to remain there for 10 secs, if the animal 
failed to find the target before 60 secs, it was manually guided to the 
platform, where it was allowed to remain for 20 secs. After the end of each 
trial, mice were removed from the pool and placed back into their home 
cages beneath heat lamps in order to prevent temperature loss. On the 
probe test, the platform was removed, and animals were allowed to swim 
freely for 60 secs while recording the percentage of time spent in each 
quadrant. The latency to find the platform during the acquisition phase and 
the percentage of time in the platform quadrant in the probe test were 
recorded and analyzed using the Smart 2.5 tracking system (PanLab, 
Barcelona) and used to evaluate hippocampal-dependent memory. 
Swimming speed, measure of possible motor defects that could interfere 
with the ability to perform the task, was also registered. 
 
Histological procedures 
Mice were transcardially perfused with phosphate-buffered saline (PBS) 
followed by 4% paraformaldehyde in PBS (0.1 mol/L PBS, pH 7.4) under 
deep pentobarbital anesthesia. Brains were removed, post-fixed for 24 h in 
4% paraformaldehyde, embedded in paraffin and cut into coronal sections 
of 1.5 μm. For immunohistochemistry, slides were deparaffinized, 
rehydrated and antigen retrieval was performed by heating at 70ºC for 1 
hour in 0.01M Citrate Buffer pH 6. Slices were incubated with primary 
antibodies specific for aSyn (1:200, mouse monoclonal IgG1, BD 
Biosciences, 610787) and SNAP25 (1:5000, rabbit polyclonal IgG, Sigma-
Aldrich, S9684) or PrPC (C-20, 1:50; goat polyclonal IgG, Santa Cruz 
Technology, #sc-7693) overnight at room temperature and washed with 
PBS before being incubated overnight at room temperature with secondary 
antibodies (Alexa Fluor 568 donkey anti-mouse and Alexa Fluor 488 
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donkey anti-rabbit or anti-goat, 1:400, Invitrogen). After washing, slices 
were incubated with Hoechst (Hoechst 33342, Thermo Scientific; 12 
μg/ml final concentration), washed once and mounted in Dako Fluorescent 
Mounting Medium (Dako). Z-stack images at 63x magnification were 
acquired with a Zeiss LSM 880 Confocal Microscope and compositional 
images of hippocampal formation were produced by tile stitching of 
images at 10x magnification acquired using Zeiss Cell Observer Widefield 
Fluorescence Microscope. For tyrosine hydroxylase (TH) 
immunohistochemistry, coronal sections of 4 μm were used. Slices were 
then deparaffinized, rehydrated and antigen retrieval was performed by 
heating at 70ºC for 1 hour in 0.01M Citrate Buffer pH 6. Slices were 
incubated with primary antibody specific for TH (1:750, rabbit polyclonal 
IgG, abcam, ab112). Quantification of the TH staining intensity was 
performed using the NDP view Software (Hamamatsu Photonics, France).  
 
Electrophysiological fEPSPs recordings 
The experiments were performed in acute transverse hippocampal slices 
from male SD rats (8–12 weeks old), in Prnp-/- mice, and in Thy1-aSyn 
(aSyn Tg) mice and their respective WT littermates. The experimenter was 
blind to genotype and/or treatment. After decapitation, the brain was 
rapidly removed, and the hippocampi were dissected free in ice-cold 
artificial CSF, known also as Krebs solution, which is composed of (mM): 
NaCl 124; KCl 3; NaH2PO4 1.25; NaHCO3 26; MgSO4 1; CaCl2 2; and D-
glucose 10, previously gassed with 95% O2 and 5% CO2, pH 7.4. Slices 
(400 μm thick) were obtained with a McEwan tissue chopper and were 
pre-incubated with or without extracellular aSyn oligomers (500 nM) for 
90 min at RT in gassed artificial CSF. Treatment with the different drugs 
started 20 min prior to aSyn oligomers pre-incubation and was kept 
throughout the 90 min of aSyn pre-incubation (Fig. 3.1b, 3.2a, 3.4a, c). 
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The range of concentration and time-course chosen for aSyn incubation 
was based on previous data in which we tested and optimized for obtaining 
the max effect without compromising the slice viability crucial for the 
electrophysiology recordings (Diógenes et al., 2012). In a set of 
preliminary experiments, we tested 10–50 nM aSyn in fEPSPs but did not 
detect significant changes. Following this incubation period, slices were 
then washed, placed in the recording chamber and superfused with 
artificial CSF (3 mL/min) at 32°C. fEPSPs were recorded in the stratum 
radiatum of the CA1 area (Fig. 3.1a), as previously described (Diógenes 
et al., 2012). An input-output (I/O) protocol was performed to determine 
the synaptic response parameters for each slice. The Schaffer collaterals 
were stimulated (stimulus rate of 1 pulse per 30 sec) at a range of stimulus 
intensities. The stimulus strength was increased until the maximum 
population spike amplitude was reached. The I/O curve was plotted as the 
relationship of fEPSP slope versus stimulus intensity, which provides a 
measure of synaptic efficiency. The max slope values were obtained by 
extrapolation upon nonlinear fitting of the I/O curve and an F-test was used 
to determine differences between the parameters. Short-term synaptic 
plasticity at the dendritic synapses was assessed by measuring paired-pulse 
facilitation (PPF) using a standard paired-pulse stimulation protocol 
applied to the Schaffer collaterals. Paired-pulse interval of 200 ms was 
used at a test stimulus intensity that elicited a fEPSP equal to 50% of the 
maximal fEPSP amplitude, as determined from I/O protocols. Three 
paired-pulse responses were averaged in each slice. Long-term plasticity 
was evaluated by a long-term potentiation (LTP) and a long-term 
depression (LTD) protocol. LTP was induced by a theta-burst stimulation 
protocol (TBS, 10 trains with 4 pulses each at 100 Hz, separated by 200 
ms) applied to the Schaffer collaterals at the test stimulus intensity (50% 
half-maximal fEPSP). Long-term depression (LTD) was induced using a 
low frequency stimulation protocol (LFS, 3 trains with 10 min interval of 
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2 Hz, 1200 pulses) as previously described (Laurent et al., 2014). The 
specificity of these effects was previously validated by testing the same 
concentration of insulin oligomers, which caused no significant changes in 
LTP magnitude (Diógenes et al., 2012). Stimulation, data acquisition and 
analysis were performed using the electrophysiology software program 
WinLTP program or pClamp (Molecular Devices). 
 
Primary neuronal cultures 
Hippocampal neurons were cultured from 18 days Sprague Dawley rat 
(Harlan, Barcelona, Spain) and Prnp-/- mice embryos as previously 
described (Pedersen et al., 2002; Valadas et al., 2012). Briefly, embryos 
were collected in Hank’s Balanced Salt Solution (HBSS, Corning) and 
rapidly decapitated. Meninges were removed, and whole cortices 
(hippocampi and attached cortex) were dissociated and incubated for 15 
minutes in HBSS with 0.025% trypsin. Cells were washed once with 
HBSS with 30% Fetal Bovine Serum (FBS), centrifuged three times, re-
suspended in Neurobasal Medium (Gibco – Life Technologies) 
supplemented with 2% B-27 supplement, 25 μM Glutamate, 0.5 mM 
glutamine, and 2 U/ml Penicillin/Streptomycin, gently dissociated and 
filtered through a 70μm strainer (VWR). Cells were plated on poly-D-
lysine-coated plates and grown for 10 days at 37°C in a 5% CO2-
humidified atmosphere in the previously described supplemented 
Neurobasal medium, in the absence of any positive selection for neurons. 
Medium was not replaced, and cultures were treated with aSyn species 
(500 nM) and drugs at day 12. 
 
Ca2+ imaging 
Primary neuronal cultures from WT and Prnp-/- mice were plated at a 
density of 20 x 103 cells per well in glass bottom microwell chambers 
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previously coated with poly-D-lysine. At the 12-16 DIV neurons were 
loaded with Fura-2 AM (5 µM, in external physiological solution with the 
following composition in mM: NaCl 125, KCl 3, NaH2PO4 1.25, CaCl2 2, 
MgSO4 2, D-(+)-glucose 10 and HEPES 10; pH 7.4 adjusted with NaOH) 
and incubated at 37ºC for 1 h. Cells were then placed on a heated chamber 
installed in an inverted microscope with epifluorescent optics and 
equipped with a high speed multiple excitation fluorimetric system 
(Lambda DG4, with a 175W Xenon arc lamp). Data was recorded by a 
CDD camera. Fura-2 AM leaded neurons were sequentially excited both 
at 340 nm and 380 nm, for 250 ms at each wavelength, and the emission 
fluorescence was recorded at 510 nm. Experiments were performed on 
cells with a baseline fluorescence ratio around 0.5, which corresponds 
approximately to a [Ca2+]i of about 100 nM, considered the normal [Ca2+]i 
(Barhoumi et al., 2010; Knot, 2005). Cells with a baseline fluorescence 
ratio above 1 were discarded from the experiment. Experiments were 
performed at 37ºC in a 5% CO2-humidified atmosphere. Drugs, anti-PrP
C 
antibodies and aSyn species were applied directly to the cells medium. All 
cells were challenged with ionomycin (an effective Ca2+ ionophore) at the 
end of the experiment and only those that responded were included, 
confirming neuronal viability. Image data were recorded and analyzed 
using the MetaFluor software (Universal Imaging, West Chester, PA, 
USA). 
 
Immunocytochemistry 
Primary neuronal cultures with 12 DIV were fixed for 10 minutes with 4% 
Paraformaldehyde diluted in Phosphate Buffer Saline (PBS). After 
washing with PBS, cells were permeabilized for 10 minutes with 0.05% 
Triton-X in PBS, blocked for 30 minutes with 10% FBS in PBS and 
incubated overnight at 4°C with the mature neuronal marker, rabbit anti-
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MAP-2 (microtubule-associated protein 2; abcam ab32454; 1:200 
dilution), and the astrocytic and the immature neuronal marker, mouse 
anti-GFAP antibody (glial fibrillary acidic protein; Millipore MAB360; 
1:250 dilution) or, with the primary antibodies specific for aSyn (1:50, 
rabbit polyclonal IgG, Cell Signaling Technology, #2628S) and PrPC 
(1:50; Santa Cruz Technology, #sc-7693), diluted in PBS with 0.05% 
Tween-20 (PBS-T) and 4% FBS. After washing with PBS-T, cells were 
incubated for 1 hour with Alexa Fluor 488 donkey anti-rabbit and Alexa 
Fluor 568 donkey anti-mouse or anti-goat antibodies (Invitrogen) diluted 
1:400 in PBS-T with 4% FBS. In order to label cell nucleus, after washing 
with PBS-T, coverslips were incubated for 5 minutes with Hoechst 
(Hoechst 33342, Thermo Scientific; 12μg/ml final concentration) and 
washed for 30 minutes with PBS -T. After a final washing step with PBS, 
coverslips were mounted with Dako Fluorescent Mounting Medium 
(Dako) and let to dry for 24h at room temperature, protected from light 
exposure. Cells were observed with a Zeiss Cell Observer Widefield 
Fluorescence Microscope and a Zeiss LSM 880 Confocal Microscope. For 
culture characterization purposes, fifteen arbitrary photographs were 
acquired at 20x magnification and different cell subsets were counted and 
analyzed using Image-J software (NIH, Bethesda, MD, USA). 
Approximately, 50% of cells were mature neurons (MAP-2 positive cells) 
and 30% were GFAP positive cells. The remaining cells were microglia, 
as confirmed by nuclei identification based on their morphological 
characteristics (Garman, 2011). 
 
Purification and oligomerization of recombinant aSyn 
aSyn was prepared as previously (Diógenes et al., 2012; Vicente Miranda 
et al., 2013). Monomeric aSyn was readily used or stored at −80°C until 
further use. Oligomerization was induced by continuous shaking of 
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monomeric aSyn (140 µM) for 6 days at 37°C in a thermomixer 
(Eppendorf) at 900 rpm. Samples were ultracentrifuged to obtain fibrillary 
aSyn. The supernatant containing monomeric and oligomeric aSyn was 
centrifuged in Amicon filter unit with Ultracel membrane NMWL of 30 
kDa (Millipore). The fibrillary aSyn (>180 kDa) and the retained fraction 
containing aSyn oligomers (> 30 kDa) was readily used or stored at −80°C 
in small aliquots to avoid freeze/thaw cycles until further use. The 
concentration of aSyn was determined using its molar extinction 
coefficient at 280 nm (i.e., ɛ280 = 5960 L/mol/cm). The composition of 
different aSyn species, monomers, oligomers and fibrils was evaluated by 
SDS–PAGE (Supplementary Fig. 3.1a). Five micrograms of each aSyn 
sample was separated by SDS–PAGE using a Tetra Cell (Bio-Rad) in a 
precast 4–15% polyacrylamide gel (Bio-Rad), using standard procedures. 
To ensure consistency and stability of the effects of the oligomer 
preparation, each batch was pre-screened for toxicity using LTP as readout 
prior to any further testing.  
 
Co-immunoprecipitation (Co-IP) 
Briefly, WT rat hippocampal slices were homogenized in IP buffer (NP40 
1%, SDS 0.1%, Tris–HCl 50 mM, NaCl 150 mM, sodium deoxycholate 
0,5%, EDTA 1 mM, protease inhibitors - Complete, EDTA-free Protease 
Inhibitor cocktail tablets; Roche) (pre-IP lysates, see in Supplementary 
Material). Protein extracts were incubated with protein G PLUS-Agarose 
(Santa Cruz, Biotechnology) for 1 h at 4°C to eliminate nonspecific 
binding. After incubation, the precleared supernatants containing 1 mg of 
protein were incubated with anti-PSD-95 antibody (1:50; Cell Signaling 
Technology, #D27E11), anti-PrP C-20 (1:50; Santa Cruz Technology, #sc-
7693), anti-aSyn (1:50; Cell Signaling Technology, #4179), anti-α-tubulin 
(1:50, Abcam, #ab52866), or IgG (for negative control; Santa Cruz 
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Biotechnology) overnight at 4°C under rotation. The day after, lysates 
were incubated with protein G PLUS-Agarose for 3 h with rotation at 4°C. 
Beads were washed 3 times with IP buffer and resuspended in 1.5× sample 
buffer pH (Tris 70 mM pH 6.8, glycerol 6%, sodium dodecyl sulfate 2%, 
dithiothreitol 120 mM, and bromophenol blue 0.0024%). Pre-IP lysates 
and bound proteins eluted from the immune complexes were denatured by 
heating to 95°C for 5 min and used for western blot analysis. 
 
Western Blotting 
Neuronal cells were washed with cold PBS and then mechanically 
scrapped in radioimmunoprecipitation assay buffer pH 8.0 (RIPA buffer: 
NaCl 150 mM, Tris-base 50 mM, EDTA 1 mM, Nonidet P40 1%, sodium 
dodecyl sulfate 0.1%, proteases inhibitors - Complete, EDTA-free 
Protease Inhibitor cocktail tablets; Roche). Hippocampus from Thy1-aSyn 
(aSyn Tg) and WT mice were homogenized in the same buffer by 
sonication. After protein quantification using BioRad DC Protein Assay 
kit, lysates were denatured with 5x sample buffer pH 6.8, as above and 
heated at 95°C for 5 min and further processed as before (Valadas et al., 
2012). Samples and the prestained molecular weight marker (BIO-RAD) 
were separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS–PAGE; 15% gel) under reducing conditions and 
electro-transferred to polyvinylidene difluoride membranes (0.45 µm, GE 
Healthcare Life Sciences) using standard procedures. Thereafter, 
nonspecific binding was blocked with 3% bovine serum albumin (fatty 
acid free) in Tris-buffered saline (pH 7.6) containing 0.1% Tween 20 
(TBS-T) for 1 h at RT. Membranes were then incubated overnight at 4°C 
with the corresponding primary antibody, namely mouse anti-aSyn 
(1:1000; BD Biosciences, #610787), rabbit anti-aSyn (1:1000; Cell 
Signaling Technology, #4179), rabbit anti-α-tubulin (1:5000; Abcam, 
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#ab52866), mouse anti-GAPDH (6C5; 1:1000; ThermoFisher Scientific, 
#AM4300), rabbit anti-PSD-95 (1:1000; Cell Signaling Technology, 
#2507), rabbit anti-NMDA receptor subunit 2B (D15B3; 1:1000; Cell 
Signaling Technology, #4212), rabbit anti-phospho-NMDA receptor 
subunit 2B (Tyr1472; 1:1000; Cell Signaling Technology, #4208), mouse 
anti-NMDA receptor subunit 1 (1:500; BD Biosciences, #556308), rabbit 
anti-Fyn kinase (H-80; 1:1000; Santa Cruz Biotechnology, #sc-28791), 
rabbit anti-phospho-Src (Tyr416; 1:100; Cell Signaling, #2101), mouse 
anti-PrP 6D11 (6D11; 1:1000; BioLegend, #SIG-39810), goat anti-PrP C-
20 (C-20; 1:500; Santa Cruz Biotechnology, #sc-7693) and/or mouse anti-
tyrosine hydroxylase (TH; 1:200; abcam, #ab112) diluted in blocking 
solution. After 3 washing periods of 10 min with TBS-T, membranes were 
incubated with horseradish peroxidase (HRP) - conjugated anti-mouse, 
anti-rabbit or anti-goat secondary antibodies (1:10 000; Santa Cruz 
Biotechnology) (in 5% nonfat dry milk) for 1 h at RT. After 40 min of 
washing with TBS-T, chemiluminescent detection was performed with 
ECL western blotting detection reagent (GE Healthcare Life Sciences) 
using X-Ray films (Fujifilm). Densitometric quantification was 
determined using Image-J software and normalized to the corresponding 
control band density.  
 
Drugs and PrPC antibodies 
The mGluR5-selective agonist, (S)-3,5-Dihydroxyphenylglycine (DHPG), 
and the ionophore Ionomycin were purchased from Sigma-Aldrich. The 
A2AR-selective antagonists, (E)-8-(2-(3,4-dimethoxyphenyl)-vinyl)-1,3-
diethyl-7-methyl-3,7-dihydropurine-2,6-dione (KW-6002, istradefylline), 
and 5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-
triazolo[1,5c]pyrimidine (SCH-58261) plus the mGluR5-selective 
antagonist, 2-Methyl-6-(phenylethynyl)pyridine (MPEP), were purchased 
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from Tocris Bioscience. The Src-family inhibitor 1-(1,1-Dimethylethyl)-
3-(1-naphthalenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1-Naphthyl 
PP1), the selective NMDAR antagonist,  DL-2-Amino-5-
phosphonopentanoic acid (APV), and the selective NMDAR subunit 
NR2B, Ifenprodil, were purchased from Abcam.  
The following anti-PrP antibodies were used: 6D11 (mouse 
monoclonal; epitope targeting between amino acids 93 and 109; 
BioLegend, #SIG-39810), C-20 (goat polyclonal; epitope targeting the C 
terminus; Santa Cruz Biotechnology, #sc-7693), and 8B4 (mouse 
monoclonal; Santa Cruz Biotechnology, epitope targeting the N-terminus, 
#sc-47729). 
 
Statistical analysis 
All statistical analyses were performed with GraphPad Prism software. 
Values are presented as dot blots with individual values plus bar, with 
mean ± s.e.m. in figure legends. Statistical analyses were designed using 
the assumption of normal distribution and similar variance among groups, 
as previously tested. Statistical comparisons included two-sided unpaired 
t test, one or two-way ANOVA followed by a Bonferroni’s, Dunnett’s or 
Tukey’s multiple comparison post hoc tests as specified in the figure 
legends. P-values of < 0.05 were considered statistically significant. The 
sample size was determined based on preliminary results or similar 
experiments carried-out in the past. Power Analysis was performed using 
G-power in order to estimate the number of animals required, for a signal-
to-noise ratio of 1.4 and 80% to 90% power assuming a 5% significance 
level. 
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Supplementary information 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3.1. Characterization of the aSyn species and 
biological effects. (a) SDS–PAGE separation of the different aSyn species. 
Monomers (aSyn mon) migrate with monomeric molecular weight (15 kDa) 
whereas aSyn oligomers (aSyn olig), and fibrils (aSyn fib) display SDS-
resistant high-molecular weight species. (b) Changes in fEPSP slope induced 
by theta-burst stimulation recorded from WT rat hippocampal slices pre-
incubated with extracellular aSyn monomers (90 min, 500 nM, n = 4), fibrils 
(90 min, 500 nM, n = 3) or in control conditions (CTR, n = 4). (c) Plot of the 
LTP magnitude represented in b (change in fEPSP slope at 50–60 min after 
theta-burst stimulation, compared to baseline) (means ± s.e.m., P < 0.01, one-
way ANOVA followed by a Bonferroni’s Multiple Comparison Test). (d) Plot 
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of the LTP magnitude obtained from WT and Prnp-/- hippocampal slices pre-
incubated with extracellular aSyn oligomers (n = 10, 6) or in control 
conditions (n = 7, 6) (means ± s.e.m., P < 0.001, one-way ANOVA followed 
by a Bonferroni’s Multiple Comparison Test). (e) Input/Output (I/O) curves 
corresponding to fEPSP slope evoked by various stimulation intensities (10 – 
120 µA) from WT hippocampal slices pre-incubated with or without aSyn 
oligomers (n = 5, 7; means ± s.e.m., P < 0.001, F-test). (f) I/O curves from 
Prnp-/- hippocampal slices pre-incubated with (n = 4) or without (n = 4) aSyn 
oligomers obtained by the same method as in e (means ± s.e.m., P > 0.05, F-
test). (g) I/O curves obtained by the same method as in e, from hippocampal 
slices CTR (n = 6), pre-incubated with aSyn oligomers alone (n = 7) or in the 
presence of the anti-PrP 6D11 antibody (6D11 + aSyn olig, 110 min, 100 nM, 
n = 4) (means ± s.e.m., P < 0.01, F-test). (h) Changes in fEPSP slope, obtained 
by the same methods as in b, from WT hippocampal slices in control 
conditions (n = 4) and in the presence of aSyn oligomers alone (n = 6) or 
together with the anti-PrP antibodies, 8B4 (8B4 + aSyn, 110 min, 10 µg, n = 
4) or C-20 (C-20 + aSyn olig, 110 min, 10 µg, n = 4) (means ± s.e.m., P < 
0.001, one-way ANOVA followed by a Bonferroni’s Multiple Comparison 
Test). (i) Paired Pulse Facilitation (PPF) plotted against 200 ms interpulse 
intervals in WT slices submitted to the same conditions as in g (n = 3-5; means 
± s.e.m., P > 0.05, one-way ANOVA followed by a Bonferroni’s Multiple 
Comparison Test). 
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Supplementary Figure 3.2. Src pharmacological blockade prevents aSyn 
oligomer-induced synaptic impairment. (a) Plot of the LTP magnitude 
(change in fEPSP slope at 50–60 min after theta-burst stimulation, compared 
to baseline) from control WT hippocampal slices (CTR, n = 4), slices pre-
incubated with the Src antagonist 1-naphthyl-PP1 (PP1, 110 min, 30 µM, n = 
3) and slices pre-incubated with extracellular aSyn oligomers alone (aSyn 
olig, 90 min, 500 nM, n = 6) or in the presence of PP1 (PP1 + aSyn olig, n = 
3) (means ± s.e.m., P < 0.01, one-way ANOVA followed by a Bonferroni’s 
Multiple Comparison Test). (b) I/O curves corresponding to fEPSP slope 
evoked by various stimulation intensities (10 – 120 µA) from control WT 
hippocampal slices (CTR, n = 5) and slices pre-incubated with extracellular 
aSyn oligomers alone (n = 5) or in the presence of PP1 (n = 4) (means ± s.e.m., 
P < 0.001, F-test). (c) Quantification of the effects of the NMDAR antagonist 
APV (50 μM, 30 min) perfusion on basal fEPSP slope from control WT 
hippocampal slices (n = 5), and slices pre-incubated with extracellular aSyn 
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oligomers alone (n = 4) or in the presence of PP1 (PP1 + aSyn olig, n = 4) 
(change in slope between baseline and the last 10 min of APV application) 
(means ± s.e.m., P < 0.01, one-way ANOVA followed by a Bonferroni’s 
Multiple Comparison Test). (d) Effect of APV (50 μM, 30 min) perfusion on 
basal fEPSP slope in WT hippocampal slices in control conditions (n = 3) or 
in the presence of aSyn oligomers (n = 4). (e) Quantification of the APV 
perfusion effects on basal fEPSP slope (change in slope between baseline and 
the last 10 min of APV application) from WT and Prnp-/- hippocampal control 
slices (CTR) or slices pre-incubated with aSyn oligomers (n = 3-4; means ± 
s.e.m., P < 0.001). (f) Representative immunoblot and quantification of 
NMDAR subunit 2B (NMDAR2B) and NMDAR subunit 1 (NMDAR1) levels 
in hippocampal slices from WT and Prnp-/- mice in the same conditions as in 
d (n = 4; means ± s.e.m., P < 0.001, one-way ANOVA followed by a 
Bonferroni’s Multiple Comparison Test). GAPDH was used as a loading 
control.  
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Supplementary Figure 3.3. Extracellular aSyn oligomers induce 
phosphorylation of SFK kinases and NR2B subunit of NMDAR. (a) 
Representative image of primary cultures from WT animals at 12 DIV. 
Mature neurons are labeled with green fluorescence with MAP-2 
antibody, astrocytes, in red, are probed with anti-GFAP antibody, and 
cell nucleus are labeled with Hoechst 33342, in blue fluorescence. Z-
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stack images were acquired using a confocal microscope at 40x 
magnification and converted into maximum intensity projections. At 
the bottom a schematic representation of the aSyn incubation 
protocol used. (b, c) Representative immunoblots and quantification 
of the aSyn and Fyn levels in neuronal cultures incubated with 
extracellular aSyn oligomers over time (n = 4-5, n = 4; P < 0.01, P > 0.05, 
one-way ANOVA followed by a Dunnett’s Multiple Comparison Test). 
GAPDH was used as a loading control. (d) Representative immunoblots 
and quantification of the SFK kinases phosphorylation levels, 
normalized to Fyn immunoreactivity, in primary neuronal cultures 
incubated with extracellular aSyn oligomers over time (n = 3-10; P < 
0.01, one-way ANOVA followed by a Dunnett’s Multiple Comparison 
Test). (e, f) Representative immunoblots and quantification of the PrPC 
and NMDAR2B levels in neuronal cultures incubated with extracellular 
aSyn oligomers over time (n = 6, n = 4; P > 0.05, one-way ANOVA 
followed by a Dunnett’s Multiple Comparison Test). GAPDH was used 
as a loading control. GAPDH was used as a loading control. (g) 
Representative immunoblots and quantification of NMDAR subunit 
NR2B phosphorylation levels, normalized to NMDAR 
immunoreactivity, in neuronal cultures incubated with extracellular 
aSyn oligomers over time. (n = 3-7; P < 0.05, one-way ANOVA followed 
by a Dunnett’s Multiple Comparison Test). (h) Quantitative analysis of 
IP:aSyn and IP:PrPC (n = 3; means ± s.e.m., P < 0.05, two-sided unpaired 
t test). (i) Immunohistochemistry in 1.5 μm hippocampal sections from 
WT and aSyn Tg mice. aSyn is labelled in red and PrPC is labelled in 
green (scale bar: 25 μm). At the bottom, details from the 63x 
magnification images are presented (scale bar: 5 μm).  
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Supplementary Figure 3.4. mGluR5 mediated aSyn/PrPC long-term 
potentiation impairment. (a) Plot of the LTP magnitude (change in fEPSP 
slope at 50–60 min after theta-burst stimulation, compared to baseline) from 
control WT hippocampal slices (CTR, n = 4), slices pre-incubated with the 
mGluR5 antagonist MPEP (110 min, 5 µM, n = 3) and slices pre-incubated 
with extracellular aSyn oligomers alone (aSyn olig, 90 min, 500 nM, n = 6) or 
in the presence of MPEP (MPEP + aSyn olig, n = 4) (means ± s.e.m., P < 0.05, 
one-way ANOVA followed by a Bonferroni’s Multiple Comparison Test). (b) 
Changes in fEPSP slope induced by theta-burst stimulation recorded from WT 
rat hippocampal slices pre-incubated with extracellular aSyn oligomers alone 
(aSyn mon, 90 min, 500 nM, n = 6), in the presence of the selective A2AR 
antagonist SCH-58261 (110 min, 50 nM, SCH + aSyn olig, n = 3) and in the 
presence of SCH-58261 together with the mGluR5 agonist DHPG (110 min, 
10 µM; SCH + DHPG + aSyn olig, n = 4). (c) Plot of the LTP magnitude 
represented in b and in Fig. 3.4d (change in fEPSP slope at 50–60 min after 
theta-burst stimulation, compared to baseline) (means ± s.e.m., P < 0.01, one-
way ANOVA followed by a Bonferroni’s Multiple Comparison Test). 
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Supplementary Figure 3.5. Characterization of Thy1-aSyn (aSyn Tg) 
overexpressing mice. (a) Representative western blot of independent 
experiments to evaluate aSyn levels in the hippocampus (HIP) and striatum 
(STR) of WT and aSyn Tg mice. GAPDH was used as a loading control. At 
the bottom quantification of aSyn immunoreactivity in relation to WT (n = 2-
5; means ± s.e.m., P < 0.05, two-sided unpaired t test). (b) Top panels: 
compositional images of fluorescence immunohistochemistry of WT and 
aSyn Tg mice hippocampus (scale bar: 500 μm). aSyn is identified in red 
fluorescence and cell nuclei are stained with Hoechst in blue fluorescence. 
Bottom panels: maximum intensity projection images of z-stack taken at 63x 
magnification in the CA1 area of hippocampus (scale bar: 25 μm). At the right, 
details from the 63x magnification images are presented (scale bar: 5μm). 
aSyn is identified in red fluorescence and SNAP25 is labeled in green. (c) 
Representative western blot of independent experiments to evaluate TH levels 
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in the striatum of WT and aSyn Tg mice. GAPDH was used as a loading 
control. At the bottom the respective quantification of TH immunoreactivity 
in relation to WT (n = 4; means ± s.e.m., P > 0.05, two-sided unpaired t test). 
(d) Representative images of TH immunohistochemistry of WT and aSyn Tg 
mice coronal brain sections. At the bottom the respective quantification of TH 
immunoreactivity in relation to WT (n = 3-4; means ± s.e.m., P > 0.05, two-
sided unpaired t test). (e) Representative western blot of 3 independent 
experiments to evaluate PrP levels in the hippocampus of WT, aSyn Tg, and       
Prnp-/- mice. GAPDH was used as a loading control. At the bottom the 
respective quantification of PrP immunoreactivity in relation to WT (n = 5-6; 
means ± s.e.m., P < 0.05, two-sided unpaired t test). 
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General Discussion and Concluding Remarks 
Increasing life expectancy will inevitably lead to an increase in the 
incidence of neurodegenerative disorders such as PD, constituting an 
increasing social and economic burden (Dorsey et al., 2007). At the same 
time, current dopaminergic therapies of PD, while effective in the initial 
motor symptoms, are accompanied by a loss of drug efficacy, the onset of 
motor complications, a lack of effect on NMS, and a failure to modify 
disease progression. As so, new treatments targeting beyond the damage 
dopaminergic system that are able to tackle disabling non-motor symptoms 
such as cognitive impairments, and are effective in both the early and late 
stages of PD, are urgently required. 
Based on this, A2AR antagonists are now being recognized as 
important targets for the treatment of PD. The interest of A2AR was further 
emphasised by their prominent role in aSyn-mediated neurotoxicity since 
aSyn-induced damage to striatal neurons was clearly reduced in A2AR KO 
mice (Kachroo and Schwarzschild, 2012). Although the involvement of 
A2AR have been investigated extensively in PD-related motor deficits and 
associated brain areas, less is known about the role of this receptors in 
synaptic dysfunction, cognitive deficits and the underlying molecular 
mechanisms involved. 
The work developed during my PhD and reported in the present 
dissertation, aimed at clarifying the pathological mechanisms driven by 
aSyn and the involvement of A2AR on this toxicity and to reveal the 
importance of this interaction in the light of synaptic functioning and early 
cognitive deficits, in order to obtain data supporting the potential 
therapeutic actions of A2AR in PD and other synucleinopathies. 
Current clinical studies seem to indicate that neuronal aSyn 
accumulation, followed by synaptic impairments, underlie the onset of PD 
motor symptoms and neuronal death. This suggests that the loss of synaptic 
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function, and not the neurodegeneration, constitutes a crucial 
neuropathological event in the brain of PD patients (Bellucci et al., 2016). 
On the other hand, A2AR are now recognized as having a prominent role 
in controlling synaptic plasticity at glutamatergic synapses, via NMDAR 
activation (Cunha et al., 2008). In accordance with this view, the results 
here reported show that aSyn-synaptic impairments are rescued in A2AR 
KO mice or upon A2AR blockade. This synaptic protection afforded by 
A2AR inhibition is due to the reestablishment of glutamate NMDAR 
overactivation. These observations are consistent with previous reports 
showing that pharmacologic or genetic modulation of A2AR can prevent 
neurotoxicity and the extent of neuronal damage in neurons affected by 
ischemia, hypoxia, stress, or β-amyloid exposure (Batalha et al., 2013; 
Canas et al., 2009; Cunha, 2005; Valadas et al., 2012).  
In addition to the effects on early synaptic dysfunction, A2AR 
antagonists were also effective in preventing subsequent neuronal death in 
neuronal cultures exposed to aSyn oligomers, and not monomers of fibrils, 
supporting the idea that soluble oligomeric species constitute the most 
neurotoxic species (Lashuel et al., 2012). Moreover, we showed that 
activation of A2AR per si, triggered the same toxic effect as the aSyn. This 
raises the hypothesis that aSyn is leading to a toxic overactivation of A2AR. 
In fact, a recent study showed that aSyn instigates aberrant A2AR signaling 
(Hu et al., 2016). This can result either from, overexpression of A2AR in 
these conditions or, alternatively, to an increase overactivation of the 
receptor. The fact that the overexpression of aSyn did not alter A2AR levels 
favours the latter hypothesis.  
aSyn aggregation, synaptic dysfunction and consequent neuronal 
cell loss are key neuropathological hallmarks of synucleinopathies, but the 
precise molecular mechanisms through which A2AR contributes to a 
NMDAR-mediated aSyn synaptic dysfunction remains unknown. 
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Recently the cellular form of PrP, a membrane-anchored neuronal 
glycoprotein whose normal function is uncertain, was identified as a cell 
surface binding partner for β-sheet-rich protein aggregates prompting their 
toxic effects. This, together with the fact that PrPC is involved in age-
dependent behavioral abnormalities, memory impairment, and mediates 
Ca2+ influx via NMDAR raised the hypothesis that PrPC could also act as 
a mediator of aSyn synaptotoxic effects. We now establish a previously 
undocumented link between aSyn and PrPC, whereby extracellular aSyn 
interacts with the amino acid region 93-109 of PrPC forming a complex at 
the post-synaptic density that mediates disruption of Ca2+ signaling and 
consequently synaptic plasticity, via mGluR5-Fyn-NMDAR2B activation. 
Either blocking or deleting PrPC prevents the toxic activation of this 
signaling pathway by aSyn oligomers and, consequently, reestablishes 
Ca2+ homeostasis and synaptic plasticity. 
The identification of this downstream mGluR5 pathway linking 
aSyn-PrPC to Fyn-NMDAR and synaptic toxicity also sheds light on the 
mechanisms by which A2AR are able to rescue NMDAR-dependent 
synaptic impairment. In fact, A2AR and mGluR5 co-localize and 
functionally interact at glutamatergic hippocampal synapses. Specifically, 
A2AR exert both a facilitatory and a permissive role on mGluR5-mediated 
effects, namely on phosphorylation of NMDAR2B (Try1472) (Sarantis et 
al., 2015; Tebano et al., 2005, 2006). Our results come in line with this 
studies since, A2AR blockade is able to prevent aSyn-mediated Fyn 
phosphorylation which directly phosphorylates NMDAR2B at tyrosine 
1472, the same phosphorylation site regulated by aSyn. 
Importantly, we now report, for the first time, that the in vivo 
selective blockade of A2AR (KW-6002) rescues both cognitive and 
synaptic impairments observed in aSyn Tg mice, providing the crucial 
evidence that the toxic effects of aSyn are indeed modulated by 
downstream effectors of PrPC (mGluR5/Fyn), as we described in vitro. 
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KW-6002, also known as istradefylline, is approved in Japan for the 
adjunctive treatment of motor deficits in PD and was shown to be 
particularly suited to target the CNS, based on its bioavailability, half-life, 
and brain penetration in animal studies. 
Additionally, it is important to mention that A2AR blockade per si 
was able to normalize NMDAR2B and PrPC levels, whose expression are 
increased in aSyn tg animals. This suggests that A2AR blockade could not 
only impacting on mGluR5 downstream pathways but also be able to 
directly interfere with PrPC. But it still remains to be directly shown that 
the beneficial effects of blocking A2AR in aSyn-induced toxicity, are 
hampered or not by manipulation of PrPC. 
Another significant finding of our studies is that A2AR are able to 
interfere with the latter stages of aSyn aggregation process, since 
blockade/activation of A2AR leads, respectively, to a decrease/increase of 
cells containing aSyn aggregates. This can be either due to an alteration of 
aggregates formation or a modification in the proper aggregation 
clearance. Intracellular Ca2+  transient increase has been shown to induce 
cytoplasmic aSyn aggregates (Rcom-H’cheo-Gauthier et al., 2014). 
Having this in mind and knowing that A2AR blockade rescues NMDAR 
overactivation and consequently Ca2+ dysfunction, we might propose that 
the reestablishment of the mGluR5-NMDAR signaling, inhibits aSyn 
aggregation by Ca2+ buffering, supporting the first hypothesis.  
While Ca2+ dysfunction contribute to aSyn aggregate formation, 
components of the proteostasis network dictate the fate of protein 
aggregates. Both alterations in the two major degradation systems, the 
ubiquitin-proteasome system (UPS) or the autophagy-lysosomal pathway 
(ALP) have been linked NMDAR activation and aSyn pathology (Caldeira 
et al., 2013; Ebrahimi-Fakhari et al., 2011). Furthermore, there are also 
reports suggesting that A2AR can directly bind and modulate the activity 
of UPS (Milojevic et al. 2006; Chiang et al. 2009), supporting the second 
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hypothesis. Taken together these suggests that blocking A2AR, and 
consequently establishing NMDAR-Ca2+ dysfunction, might prevent both 
aSyn aggregation formation and aSyn aggregates accumulation, by 
rescuing UPS and ALP dysfunction. Although we cannot exclude the 
involvement of downstream mediators of aSyn toxicity. 
Moreover, these data strongly suggest that the recently reported 
ability of caffeine, a nonselective adenosine receptor antagonist, to 
interfere with aSyn aggregation might be due to its actions on A2AR 
(Kardani and Roy, 2015). Again, whether these effects are due to the 
attenuation of UPS and ALP dysfunction or to downstream mediators of 
aSyn toxicity remains to be clarified. 
Overall, our study sheds light into the early pathophysiological 
mechanisms preceding aSyn-mediated neurodegeneration, and implicates 
A2AR and PrP
C as key molecular target in PD and other synucleinopathies 
(Fig. 4.1). Furthermore, the ability of the in vivo A2AR blockade to restore 
synaptic impairments and cognitive deficits in aSyn Tg mice, in parallel to 
studies linking A2AR to cognitive function and neurodegeneration, 
provides an additional mechanistic support to encourage testing the 
therapeutic efficacy of A2AR antagonists in early PD patients.  
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Fig. 4.1 Schematic representation of aSyn pathological 
mechanisms mediated by A2AR. In pathological conditions where 
aSyn levels are exacerbated and aSyn aggregation occur, there is an 
impairment of the Fyn-NMDAR signaling and as a consequence, there 
a toxic increase in intracellular Ca2+ levels, which in turn mediate 
synaptic dysfunction, associated with cognitive deficits, and 
eventually, at latter phases, neuronal death. This is accompanied by 
an activation of PrPC and A2AR, both contributing to a toxic Fyn-
NMDAR signaling via mGLuR5, explaining the rational of blocking 
A2AR to prevent synaptic toxicity and neurodegeneration. When A2AR 
are blocked, Fyn-NMDAR2B signaling is reestablished, resulting in 
restored hippocampal function, memory performance and synaptic 
plasticity. One the other hand, A2AR blockade is also able to restore 
PrPC level and interfere with aSyn aggregation. 
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